17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL mediated gene transfer of endostatin in vivo results in high level 
17 NULL NULL NULL adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor 
9 of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases . NULL NULL 
18 in vivo results in high level of transgene expression and inhibition of tumor growth and metastases . NULL NULL NULL NULL 
0 results in high level of transgene expression and inhibition of tumor growth and metastases . NULL NULL NULL NULL NULL NULL 
4 in high level of transgene expression and inhibition of tumor growth and metastases . NULL NULL NULL NULL NULL NULL NULL 
14 level of transgene expression and inhibition of tumor growth and metastases . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of angiogenesis has been shown to be an effective strategy 
3 NULL NULL NULL NULL NULL NULL NULL NULL inhibition of angiogenesis has been shown to be an effective strategy in cancer 
0 NULL inhibition of angiogenesis has been shown to be an effective strategy in cancer therapy in mice . NULL NULL NULL 
19 has been shown to be an effective strategy in cancer therapy in mice . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL however , its widespread application has been hampered by difficulties in the large-scale production of 
0 widespread application has been hampered by difficulties in the large-scale production of the antiangiogenic proteins . NULL NULL NULL NULL NULL 
3 been hampered by difficulties in the large-scale production of the angiogenic proteins . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL this limitation may be resolved by in vivo delivery and expression of the antiangiogenic genes . NULL NULL NULL 
0 this limitation may be resolved by in vivo delivery and expression of the antiangiogenic genes . NULL NULL NULL NULL NULL 
3 be resolved by in vivo delivery and expression of the angiogenic genes . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL we have constructed a recombinant adenovirus that expresses murine endostatin that is biologically 
0 a recombinant adenovirus that expresses murine endostatin that is biologically active both in vitro , as determined in endothelial cell proliferation 
1 active both in vitro , as determined in endothelial cell proliferation assays , and in vivo , by suppression of angiogenesis 
18 endothelial cell proliferation assays , and in vivo , by suppression of angiogenesis induced by vascular endothelial growth factor 165 . 
3 proliferation assays , and in vivo , by suppression of angiogenesis induced by vascular endothelial growth factor 165 . NULL NULL 
17 assays , and in vivo , by suppression of angiogenesis induced by vascular endothelial growth factor 165 . NULL NULL NULL 
0 vivo , by suppression of angiogenesis induced by vascular endothelial growth factor 165 . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL persistent high serum levels of endostatin ( 605-1740 ng/ml ; mean , 936 ng/ml 
19 ; mean , 936 ng/ml ) were achieved after systemic administration of the vector to nude mice , which resulted in 
17 systemic administration of the vector to nude mice , which resulted in significant reduction of the growth rates and the volumes 
0 of the vector to nude mice , which resulted in significant reduction of the growth rates and the volumes of jc 
18 the vector to nude mice , which resulted in significant reduction of the growth rates and the volumes of jc breast 
4 nude mice , which resulted in significant reduction of the growth rates and the volumes of jc breast carcinoma and lewis 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , the endostatin vector treatment completely prevented the formation of 
19 NULL NULL NULL NULL in addition , the endostatin vector treatment completely prevented the formation of pulmonary micrometastases in lewis lung 
18 NULL NULL in addition , the endostatin vector treatment completely prevented the formation of pulmonary micrometastases in lewis lung carcinoma ( 
2 in addition , the endostatin vector treatment completely prevented the formation of pulmonary micrometastases in lewis lung carcinoma ( p = 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL immunohistochemical staining of the tumors demonstrated a decreased number of blood 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL immunohistochemical staining of the tumors demonstrated a decreased number of blood vessels 
18 NULL NULL NULL immunohistochemical staining of the tumors demonstrated a decreased number of blood vessels in the treatment group versus the 
0 tumors demonstrated a decreased number of blood vessels in the treatment group versus the controls . NULL NULL NULL NULL NULL 
0 number of blood vessels in the treatment group versus the controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL in conclusion , the present study clearly demonstrates the potential of vector-mediated antiangiogenic gene therapy 
0 NULL in conclusion , the present study clearly demonstrates the potential of vector-mediated antiangiogenic gene therapy as a component in cancer 
0 conclusion , the present study clearly demonstrates the potential of mediated antiangiogenic gene therapy as a component in cancer therapy . 
3 , the present study clearly demonstrates the potential of vector-mediated angiogenic gene therapy as a component in cancer therapy . NULL 
0 present study clearly demonstrates the potential of vector-mediated antiangiogenic gene therapy as a component in cancer therapy . NULL NULL NULL 
19 of vector-mediated antiangiogenic gene therapy as a component in cancer therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 unspecified mesodermal cells differentiates into primitive endothelial cells , which migrate to and occupy positions within the stereotypical blueprint of the 
2 NULL NULL once in position , these cells coalesce and form cords , which lumenize and become ensheathed by supporting pericytes 
0 and form cords , which lumenize and become ensheathed by supporting pericytes and smooth muscle cells . NULL NULL NULL NULL 
0 is extensively remodeled in some places , and expanded by sprouting in others . NULL NULL NULL NULL NULL NULL NULL 
0 , quail/chick , and frog have uncovered a number of signals that guide these complex processes but many gaps still exist 
0 have uncovered a number of signals that guide these complex processes but many gaps still exist in our understanding of the 
0 NULL NULL NULL NULL NULL NULL because many questions will require in vivo studies to be properly addressed , the zebrafish 
0 genetic methods , should prove invaluable in identifying new molecules involved in blood vessel development and integrating pathways that influence embryonic 
2 prove invaluable in identifying new molecules involved in blood vessel development and integrating pathways that influence embryonic blood vessel formation . 
0 identifying new molecules involved in blood vessel development and integrating pathways that influence embryonic blood vessel formation . NULL NULL NULL 
0 molecules involved in blood vessel development and integrating pathways that influence embryonic blood vessel formation . NULL NULL NULL NULL NULL 
2 vessel development and integrating pathways that influence embryonic blood vessel formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL a small peptide derived from flt-1 ( vegfr-1 ) functions as an angiogenic inhibitor 
0 NULL a small peptide derived from flt-1 ( vegfr-1 ) functions as an angiogenic inhibitor . NULL NULL NULL NULL NULL 
3 peptide derived from flt-1 ( vegfr-1 ) functions as an angiogenic inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL 
18 derived from flt-1 ( vegfr-1 ) functions as an angiogenic inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) is an angiogenic stimulator which functions 
3 NULL vascular endothelial growth factor ( vegf ) is an angiogenic stimulator which functions through two endothelial specific tyrosine kinase receptors 
16 growth factor ( vegf ) is an angiogenic stimulator which functions through two endothelial specific tyrosine kinase receptors , flt-1 and 
0 this work , we show that an 11-amino acid peptide derived from the second immunoglobulin-like domain of flt-1 functions as an 
0 acid peptide derived from the second immunoglobulin-like domain of flt-1 functions as an angiogenic inhibitor in chick chorioallantoic membrane and inhibited 
3 from the second immunoglobulin-like domain of flt-1 functions as an angiogenic inhibitor in chick chorioallantoic membrane and inhibited vegf-induced vascular permeability 
18 the second immunoglobulin-like domain of flt-1 functions as an angiogenic inhibitor in chick chorioallantoic membrane and inhibited vegf-induced vascular permeability in 
0 functions as an angiogenic inhibitor in chick chorioallantoic membrane and inhibited vegf-induced vascular permeability in miles ' assay without binding to 
0 as an angiogenic inhibitor in chick chorioallantoic membrane and inhibited induced vascular permeability in miles ' assay without binding to vegf 
15 and inhibited vegf-induced vascular permeability in miles ' assay without binding to vegf directly . NULL NULL NULL NULL NULL NULL 
0 magnetic resonance analyses indicate that this peptide forms a stable extended structure in solution , presumably beta-sheet structure and is most 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL our results suggest that this small peptide functions as an angiogenic inhibitor 
0 NULL NULL NULL our results suggest that this small peptide functions as an angiogenic inhibitor by inhibiting vegf function through a 
3 our results suggest that this small peptide functions as an angiogenic inhibitor by inhibiting vegf function through a non-vegf binding mechanism 
0 results suggest that this small peptide functions as an angiogenic inhibitor by inhibiting vegf function through a non-vegf binding mechanism . 
18 that this small peptide functions as an angiogenic inhibitor by inhibiting vegf function through a non-vegf binding mechanism . NULL NULL 
0 small peptide functions as an angiogenic inhibitor by inhibiting vegf function through a non-vegf binding mechanism . NULL NULL NULL NULL 
15 an angiogenic inhibitor by inhibiting vegf function through a non-vegf binding mechanism . NULL NULL NULL NULL NULL NULL NULL NULL 
0 angiogenic inhibitor by inhibiting vegf function through a non-vegf binding mechanism . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL coexpression of vascular endothelial growth factor and p53 protein in squamous 
0 NULL NULL NULL NULL NULL NULL coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the 
0 NULL NULL coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the esophagus . NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL objective : p53 plays a role in tumor angiogenesis , and vascular endothelial growth 
16 NULL NULL NULL NULL NULL objective : p53 plays a role in tumor angiogenesis , and vascular endothelial growth factor ( 
0 NULL NULL NULL objective : p53 plays a role in tumor angiogenesis , and vascular endothelial growth factor ( vegf ) 
3 NULL NULL objective : p53 plays a role in tumor angiogenesis , and vascular endothelial growth factor ( vegf ) plays 
0 plays a role in tumor angiogenesis , and vascular endothelial growth factor ( vegf ) plays a key role in tumor 
16 angiogenesis , and vascular endothelial growth factor ( vegf ) plays a key role in tumor angiogenesis . NULL NULL NULL 
16 and vascular endothelial growth factor ( vegf ) plays a key role in tumor angiogenesis . NULL NULL NULL NULL NULL 
16 vascular endothelial growth factor ( vegf ) plays a key role in tumor angiogenesis . NULL NULL NULL NULL NULL NULL 
0 growth factor ( vegf ) plays a key role in tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 factor ( vegf ) plays a key role in tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the aim of the present study was to clarify how expression of p53 protein participates 
9 the aim of the present study was to clarify how expression of p53 protein participates in angiogenesis , and whether the 
0 the present study was to clarify how expression of p53 protein participates in angiogenesis , and whether the coexpression of vegf 
3 was to clarify how expression of p53 protein participates in angiogenesis , and whether the coexpression of vegf and p53 protein 
9 of p53 protein participates in angiogenesis , and whether the coexpression of vegf and p53 protein has a significance for angiogenesis 
0 angiogenesis , and whether the coexpression of vegf and p53 protein has a significance for angiogenesis and the clinicopathological features in 
3 coexpression of vegf and p53 protein has a significance for angiogenesis and the clinicopathological features in esophageal squamous cell carcinoma ( 
19 samples were taken from 60 patients with esophageal scc after surgery . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL the expression of vegf and p53 protein in these scc was examined 
0 NULL NULL NULL NULL the expression of vegf and p53 protein in these scc was examined immunohistochemically . NULL NULL NULL 
0 density ( mvd ) was determined by counting microvessels in tumor sections stained for factor viii-related antigen . NULL NULL NULL 
0 calculated , based on ki-67 antigen immunostaining , as a proliferative marker . NULL NULL NULL NULL NULL NULL NULL NULL 
0 ai ) was calculated , based on the terminal deoxynucleotidyl mediated deoxyuridine triphosphate biotin nick end labeling , to evaluate apoptosis 
0 transferase-mediated deoxyuridine triphosphate biotin nick end labeling , to evaluate apoptosis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : vegf expression was observed in 58.3 % , and 
9 NULL NULL NULL NULL NULL NULL NULL results : vegf expression was observed in 58.3 % , and p53 protein expression 
0 NULL NULL NULL NULL NULL results : vegf expression was observed in 58.3 % , and p53 protein expression was observed 
0 vegf expression was observed in 58.3 % , and p53 protein expression was observed in 61.7 % of the 60 patients 
9 expression was observed in 58.3 % , and p53 protein expression was observed in 61.7 % of the 60 patients . 
0 observed in 58.3 % , and p53 protein expression was observed in 61.7 % of the 60 patients . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL vegf and p53 protein were significantly coexpressed in 26 ( 43.4 % ) . 
9 NULL NULL NULL NULL vegf and p53 protein were significantly coexpressed in 26 ( 43.4 % ) . NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL histological venous invasion ( p less than 0.01 ) and distant metastasis ( 
0 venous invasion ( p less than 0.01 ) and distant metastasis ( p less than 0.05 ) were significantly correlated with 
0 p less than 0.05 ) were significantly correlated with p53 protein expression . NULL NULL NULL NULL NULL NULL NULL NULL 
9 less than 0.05 ) were significantly correlated with p53 protein expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL the two parameters were more frequently observed in the scc with vegf/p53 coexpression than in those without 
9 parameters were more frequently observed in the scc with vegf/p53 coexpression than in those without the coexpression . NULL NULL NULL 
9 the scc with vegf/p53 coexpression than in those without the coexpression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 p less than 0.001 ) in the scc with p53 protein expression than in the scc without it . NULL NULL 
9 less than 0.001 ) in the scc with p53 protein expression than in the scc without it . NULL NULL NULL 
9 and the ai was lower in the scc with vegf/p53 coexpression than in those without the coexpression . NULL NULL NULL 
9 the scc with vegf/p53 coexpression than in those without the coexpression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the 5-yr survival rate in patients with the coexpression was poorer than in 
9 NULL NULL the 5-yr survival rate in patients with the coexpression was poorer than in the other patients . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL conclusion : these results suggest that mutant p53 expression is associated with angiogenesis and 
9 NULL NULL conclusion : these results suggest that mutant p53 expression is associated with angiogenesis and distant metastasis in esophageal scc 
0 conclusion : these results suggest that mutant p53 expression is associated with angiogenesis and distant metastasis in esophageal scc , and 
3 these results suggest that mutant p53 expression is associated with angiogenesis and distant metastasis in esophageal scc , and that the 
0 that mutant p53 expression is associated with angiogenesis and distant metastasis in esophageal scc , and that the coexpression of p53 
9 and distant metastasis in esophageal scc , and that the coexpression of p53 and vegf may play an important role in 
16 , and that the coexpression of p53 and vegf may play an important role in angiogenesis , and have important clinical 
16 that the coexpression of p53 and vegf may play an important role in angiogenesis , and have important clinical significance . 
16 the coexpression of p53 and vegf may play an important role in angiogenesis , and have important clinical significance . NULL 
3 of p53 and vegf may play an important role in angiogenesis , and have important clinical significance . NULL NULL NULL 
0 may play an important role in angiogenesis , and have important clinical significance . NULL NULL NULL NULL NULL NULL NULL 
0 play an important role in angiogenesis , and have important clinical significance . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL troponin i inhibits capillary endothelial cell proliferation by interaction with the cell 's 
1 NULL NULL NULL NULL troponin i inhibits capillary endothelial cell proliferation by interaction with the cell 's bfgf receptor . NULL 
15 NULL NULL troponin i inhibits capillary endothelial cell proliferation by interaction with the cell 's bfgf receptor . NULL NULL NULL 
0 NULL NULL troponin i ( tni ) is a novel derived angiogenesis inhibitor , first demonstrated by moses et al. ( 
3 NULL troponin i ( tni ) is a novel cartilage-derived angiogenesis inhibitor , first demonstrated by moses et al. ( 1999 
0 troponin i ( tni ) is a novel cartilage-derived angiogenesis inhibitor , first demonstrated by moses et al. ( 1999 , 
18 NULL NULL NULL NULL NULL NULL usa 2645-2650 ) to inhibit endothelial cell proliferation and angiogenesis , both in vivo and 
1 NULL NULL NULL usa 2645-2650 ) to inhibit endothelial cell proliferation and angiogenesis , both in vivo and in vitro , 
3 NULL usa 2645-2650 ) to inhibit endothelial cell proliferation and angiogenesis , both in vivo and in vitro , and to 
18 , both in vivo and in vitro , and to inhibit metastasis of a wide variety of tumors in vivo . 
14 both in vivo and in vitro , and to inhibit metastasis of a wide variety of tumors in vivo . NULL 
0 NULL NULL NULL NULL NULL despite convincing evidence of its efficacy , little is known about the mechanism of action of 
0 evidence of its efficacy , little is known about the mechanism of action of tni as an anti-proliferative and anti-angiogenic agent 
0 its efficacy , little is known about the mechanism of action of tni as an anti-proliferative and anti-angiogenic agent . NULL 
0 known about the mechanism of action of tni as an proliferative and anti-angiogenic agent . NULL NULL NULL NULL NULL NULL 
3 the mechanism of action of tni as an anti-proliferative and angiogenic agent . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL in the current article we demonstrate that tni inhibits both bfgf-stimulated and basal levels of endothelial cell proliferation , 
17 in the current article we demonstrate that tni inhibits both stimulated and basal levels of endothelial cell proliferation , and we 
0 article we demonstrate that tni inhibits both bfgf-stimulated and basal levels of endothelial cell proliferation , and we hypothesize that this 
1 tni inhibits both bfgf-stimulated and basal levels of endothelial cell proliferation , and we hypothesize that this inhibition is occurring , 
18 of endothelial cell proliferation , and we hypothesize that this inhibition is occurring , at least in part , via an 
15 is occurring , at least in part , via an interaction of tni with the cell-surface bfgf receptor on capillary endothelial 
0 NULL NULL NULL NULL NULL NULL NULL NULL we further support this hypothesis by providing the first evidence that tni can 
16 this hypothesis by providing the first evidence that tni can act on nonendothelial as well as endothelial cells and by demonstrating 
18 as well as endothelial cells and by demonstrating that this inhibitory action is specific for the bfgf receptor on the target 
18 well as endothelial cells and by demonstrating that this inhibitory action is specific for the bfgf receptor on the target cells 
0 inhibitory action is specific for the bfgf receptor on the target cells . NULL NULL NULL NULL NULL NULL NULL NULL 
15 data suggest that tni may be competing with bfgf for interaction with the bfgf receptor on responsive cells . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome . 
3 a c-terminal fragment of collagen xviii , is an endogenous angiogenesis inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL 
0 c-terminal fragment of collagen xviii , is an endogenous angiogenesis inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL while endostatin is being investigated for its usefulness in treating solid tumors , its significance in hematologic malignancies is unknown 
0 methods : the authors evaluated plasma endostatin ( pe ) levels using an enzyme linked immunoassay in 71 patients with acute 
19 evaluated plasma endostatin ( pe ) levels using an enzyme linked immunoassay in 71 patients with acute myeloid leukemia ( aml 
0 syndrome ( mds ) , and correlated pe with various clinical parameters . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : there was no significant difference in the median pe 
0 NULL NULL NULL NULL NULL results : there was no significant difference in the median pe level between aml/mds patients and 
0 the median pe level between aml/mds patients and the normal controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 in multivariate analysis , pe was found to be a significant ( p = 0.03 ) predictor of overall survival ( 
0 a significant ( p = 0.03 ) predictor of overall survival ( os ) with adjustment of the other baseline covariates 
0 age , history of antecedent hematologic disorders , and the use of protective environments . NULL NULL NULL NULL NULL NULL 
0 low pe groups using the median pe level of normal controls as the cut-off . NULL NULL NULL NULL NULL NULL 
5 the authors found that patients in the high pe group survived for a significantly shorter time than those patients in the 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the mechanism underlying the association between high pe and poor clinical outcome 
0 NULL NULL NULL NULL NULL NULL the mechanism underlying the association between high pe and poor clinical outcome is unclear , 
0 the mechanism underlying the association between high pe and poor clinical outcome is unclear , although it may be related to 
0 it may be related to the possible pe reflection of tumor burden . NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL modulation of angiogenesis and progelatinase a by thrombin receptor mimetics and 
3 NULL NULL NULL NULL NULL NULL NULL NULL modulation of angiogenesis and progelatinase a by thrombin receptor mimetics and antagonists . 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL the angiogenic action of thrombin has been shown to be mediated by 
0 NULL NULL NULL NULL NULL NULL NULL NULL the angiogenic action of thrombin has been shown to be mediated by activation 
16 the angiogenic action of thrombin has been shown to be mediated by activation of the thrombin receptor . NULL NULL NULL 
17 action of thrombin has been shown to be mediated by activation of the thrombin receptor . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL in this report we studied the effects of sfllr , an agonist of the activated thrombin receptor 
17 studied the effects of sfllr , an agonist of the activated thrombin receptor and thrombin receptor peptide and non peptide antagonists 
3 receptor and thrombin receptor peptide and non peptide antagonists on angiogenesis in the chick chorioallantoic membrane ( cam ) system . 
0 NULL NULL NULL NULL NULL NULL NULL as antagonists were used the tripeptide fpr and non-peptide 1 , 4-disubstituted piperazine derivatives 
0 NULL NULL NULL the pentapeptide sfllr , like thrombin , caused a marked stimulation of angiogenesis in the cam . NULL 
17 the pentapeptide sfllr , like thrombin , caused a marked stimulation of angiogenesis in the cam . NULL NULL NULL NULL 
3 sfllr , like thrombin , caused a marked stimulation of angiogenesis in the cam . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL fpr and the piperazine derivatives caused suppression of angiogenesis and in combination with thrombin antagonized its 
18 NULL NULL NULL NULL fpr and the piperazine derivatives caused suppression of angiogenesis and in combination with thrombin antagonized its angiogenic 
3 NULL NULL fpr and the piperazine derivatives caused suppression of angiogenesis and in combination with thrombin antagonized its angiogenic effect . 
3 suppression of angiogenesis and in combination with thrombin antagonized its angiogenic effect . NULL NULL NULL NULL NULL NULL NULL NULL 
0 of angiogenesis and in combination with thrombin antagonized its angiogenic effect . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL thrombin and sfllr activated progelatinase a ( mmp-2 ) in the culture medium of 
0 and sfllr activated progelatinase a ( mmp-2 ) in the culture medium of human umbilical cord endothelial cells ( huvecs ) 
0 NULL NULL NULL NULL NULL NULL NULL NULL mmp-2 is involved in the early steps of angiogenesis leading to local dissolution 
3 NULL NULL mmp-2 is involved in the early steps of angiogenesis leading to local dissolution of basement membrane collagen and migration 
17 NULL mmp-2 is involved in the early steps of angiogenesis leading to local dissolution of basement membrane collagen and migration of 
11 involved in the early steps of angiogenesis leading to local dissolution of basement membrane collagen and migration of the activated endothelial 
14 angiogenesis leading to local dissolution of basement membrane collagen and migration of the activated endothelial cells . NULL NULL NULL NULL 
17 local dissolution of basement membrane collagen and migration of the activated endothelial cells . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL fpr and the piperazine derivatives inhibited the activation of this enzyme . NULL NULL NULL NULL 
17 NULL NULL NULL fpr and the piperazine derivatives inhibited the activation of this enzyme . NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL they also antagonised the effects of both thrombin and sfllr on mmp-2 activation . NULL 
17 antagonised the effects of both thrombin and sfllr on mmp-2 activation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results suggest that non-thrombogenic agonists or antagonists of the activated thrombin 
17 these results suggest that non-thrombogenic agonists or antagonists of the activated thrombin receptor can be used as modulators of angiogenesis . 
0 agonists or antagonists of the activated thrombin receptor can be used as modulators of angiogenesis . NULL NULL NULL NULL NULL 
3 the activated thrombin receptor can be used as modulators of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL vegf165 mediates formation of complexes containing vegfr-2 and neuropilin-1 that enhance vegf165-receptor 
15 NULL NULL NULL NULL NULL NULL NULL NULL vegf165 mediates formation of complexes containing vegfr-2 and neuropilin-1 that enhance vegf165-receptor binding 
17 vegf165 mediates formation of complexes containing vegfr-2 and neuropilin-1 that enhance vegf165-receptor binding . NULL NULL NULL NULL NULL NULL NULL 
15 formation of complexes containing vegfr-2 and neuropilin-1 that enhance vegf165-receptor binding . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL expression of nrp1 and ( vegfr-2 ) kdr on the surface 
17 kdr on the surface of endothelial cells ( ec ) enhances vegf165 binding to kdr and ec chemotaxis in response to 
15 the surface of endothelial cells ( ec ) enhances vegf165 binding to kdr and ec chemotaxis in response to vegf165 . 
14 ( ec ) enhances vegf165 binding to kdr and ec chemotaxis in response to vegf165 . NULL NULL NULL NULL NULL 
17 ) enhances vegf165 binding to kdr and ec chemotaxis in response to vegf165 . NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL overexpression of nrp1 by prostate tumor cells in vivo results in 
0 NULL NULL NULL NULL NULL overexpression of nrp1 by prostate tumor cells in vivo results in increased tumor angiogenesis and growth 
0 NULL overexpression of nrp1 by prostate tumor cells in vivo results in increased tumor angiogenesis and growth . NULL NULL NULL 
17 of nrp1 by prostate tumor cells in vivo results in increased tumor angiogenesis and growth . NULL NULL NULL NULL NULL 
0 nrp1 by prostate tumor cells in vivo results in increased tumor angiogenesis and growth . NULL NULL NULL NULL NULL NULL 
3 by prostate tumor cells in vivo results in increased tumor angiogenesis and growth . NULL NULL NULL NULL NULL NULL NULL 
4 tumor cells in vivo results in increased tumor angiogenesis and growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL we investigated the molecular mechanisms underlying mediated angiogenesis by analyzing the association of nrp1 and kdr . 
3 NULL NULL NULL we investigated the molecular mechanisms underlying nrp1-mediated angiogenesis by analyzing the association of nrp1 and kdr . NULL 
15 investigated the molecular mechanisms underlying nrp1-mediated angiogenesis by analyzing the association of nrp1 and kdr . NULL NULL NULL NULL NULL 
0 was immunoprecipitated from ec by anti-nrp1 antibodies only in the presence of vegf165 . NULL NULL NULL NULL NULL NULL NULL 
15 NULL NULL in contrast , vegf121 , which does not bind to nrp1 , did not support complex formation . NULL 
17 , which does not bind to nrp1 , did not support complex formation . NULL NULL NULL NULL NULL NULL NULL 
15 does not bind to nrp1 , did not support complex formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
15 complexes containing vegf165 , nrp1 , and kdr were also formed in an intercellular fashion by co-culture of ec expressing kdr 
19 and kdr were also formed in an intercellular fashion by culture of ec expressing kdr only , with cells expressing nrp1 
9 also formed in an intercellular fashion by co-culture of ec expressing kdr only , with cells expressing nrp1 only , for 
9 by co-culture of ec expressing kdr only , with cells expressing nrp1 only , for example , breast carcinoma cells . 
16 NULL NULL NULL NULL NULL NULL NULL NULL vegf165 also mediated the binding of a soluble nrp1 dimer to cells expressing 
15 NULL NULL NULL NULL NULL NULL vegf165 also mediated the binding of a soluble nrp1 dimer to cells expressing kdr only 
9 mediated the binding of a soluble nrp1 dimer to cells expressing kdr only , confirming the formation of such complexes . 
0 nrp1 dimer to cells expressing kdr only , confirming the formation of such complexes . NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL NULL furthermore , the formation of complexes containing kdr and nrp1 markedly increased 125i-vegf165 binding 
17 , the formation of complexes containing kdr and nrp1 markedly increased 125i-vegf165 binding to kdr . NULL NULL NULL NULL NULL 
15 formation of complexes containing kdr and nrp1 markedly increased 125i-vegf165 binding to kdr . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL our results suggest that formation of a ternary complex of vegf165 , 
15 NULL NULL NULL NULL NULL NULL our results suggest that formation of a ternary complex of vegf165 , kdr , and 
17 a ternary complex of vegf165 , kdr , and nrp1 potentiates vegf165 binding to kdr . NULL NULL NULL NULL NULL 
15 complex of vegf165 , kdr , and nrp1 potentiates vegf165 binding to kdr . NULL NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL NULL NULL these complexes are formed on the surface of ec and in a juxtacrine manner 
15 the surface of ec and in a juxtacrine manner via association of tumor cell nrp1 and ec kdr . NULL NULL 
0 of ec and in a juxtacrine manner via association of tumor cell nrp1 and ec kdr . NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL hypoxic induction of hif-1alpha and vegf expression in head and neck squamous 
9 NULL NULL NULL NULL hypoxic induction of hif-1alpha and vegf expression in head and neck squamous cell carcinoma lines is mediated 
16 expression in head and neck squamous cell carcinoma lines is mediated by stress activated protein kinases . NULL NULL NULL NULL 
0 and neck squamous cell carcinoma lines is mediated by stress activated protein kinases . NULL NULL NULL NULL NULL NULL NULL 
0 neck squamous cell carcinoma lines is mediated by stress activated protein kinases . NULL NULL NULL NULL NULL NULL NULL NULL 
4 solid tumors must establish a blood supply in order to proliferate and grow . NULL NULL NULL NULL NULL NULL NULL 
4 must establish a blood supply in order to proliferate and grow . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL cancer cells secrete soluble factors which can induce proliferation and migration of capillary endothelial cells . NULL NULL 
1 NULL NULL cancer cells secrete soluble factors which can induce proliferation and migration of capillary endothelial cells . NULL NULL NULL 
14 cancer cells secrete soluble factors which can induce proliferation and migration of capillary endothelial cells . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL among the most potent of the angiogenic factors is vascular endothelial growth factor ( vegf ) . 
0 the most potent of the angiogenic factors is vascular endothelial growth factor ( vegf ) . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL increased vegf expression by malignant tumors has been associated with high 
9 NULL NULL NULL NULL NULL NULL NULL NULL increased vegf expression by malignant tumors has been associated with high vascularity , 
0 NULL NULL NULL NULL NULL NULL increased vegf expression by malignant tumors has been associated with high vascularity , increased cancer 
16 NULL NULL increased vegf expression by malignant tumors has been associated with high vascularity , increased cancer cell growth , and 
17 by malignant tumors has been associated with high vascularity , increased cancer cell growth , and lymph node metastasis . NULL 
1 has been associated with high vascularity , increased cancer cell growth , and lymph node metastasis . NULL NULL NULL NULL 
14 vascularity , increased cancer cell growth , and lymph node metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL reduced oxygen tension has been shown to increase vegf production by 
17 NULL NULL NULL reduced oxygen tension has been shown to increase vegf production by induction of the transcription factor hypoxia inducible 
9 NULL reduced oxygen tension has been shown to increase vegf production by induction of the transcription factor hypoxia inducible factor 1 
17 oxygen tension has been shown to increase vegf production by induction of the transcription factor hypoxia inducible factor 1 alpha ( 
0 been shown to increase vegf production by induction of the transcription factor hypoxia inducible factor 1 alpha ( hif-1alpha ) . 
0 increase vegf production by induction of the transcription factor hypoxia inducible factor 1 alpha ( hif-1alpha ) . NULL NULL NULL 
0 NULL NULL NULL NULL NULL the mechanisms by which hypoxic tumor environments induce hif-1alpha and vegf expression are largely unknown . 
17 NULL NULL NULL the mechanisms by which hypoxic tumor environments induce hif-1alpha and vegf expression are largely unknown . NULL NULL 
9 mechanisms by which hypoxic tumor environments induce hif-1alpha and vegf expression are largely unknown . NULL NULL NULL NULL NULL NULL 
17 n terminal kinase ( jnk1 ) and p38 kinase are activated by a variety of stress stimuli . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL to determine if hypoxic activation of these stress activated protein kinases regulated hif-1alpha and vegf 
0 NULL NULL to determine if hypoxic activation of these stress activated protein kinases regulated hif-1alpha and vegf expression , we assayed 
0 NULL to determine if hypoxic activation of these stress activated protein kinases regulated hif-1alpha and vegf expression , we assayed jnk1 
16 determine if hypoxic activation of these stress activated protein kinases regulated hif-1alpha and vegf expression , we assayed jnk1 and p38 
9 of these stress activated protein kinases regulated hif-1alpha and vegf expression , we assayed jnk1 and p38 activity in squamous cell 
0 activated protein kinases regulated hif-1alpha and vegf expression , we assayed jnk1 and p38 activity in squamous cell carcinoma ( scc 
0 hif-1alpha and vegf expression , we assayed jnk1 and p38 activity in squamous cell carcinoma ( scc ) lines grown under 
0 p38 activity in squamous cell carcinoma ( scc ) lines grown under normoxic or hypoxic conditions . NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL hypoxia rapidly induced both jnk1 and p38 activity in these cells . NULL 
0 NULL NULL NULL hypoxia rapidly induced both jnk1 and p38 activity in these cells . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL this activation correlated with induction of hif-1alpha expression and dna binding activity 
17 NULL NULL NULL NULL NULL NULL this activation correlated with induction of hif-1alpha expression and dna binding activity which was blocked 
9 NULL NULL NULL this activation correlated with induction of hif-1alpha expression and dna binding activity which was blocked by the p38 
15 this activation correlated with induction of hif-1alpha expression and dna binding activity which was blocked by the p38 inhibitor sb203580 . 
0 activation correlated with induction of hif-1alpha expression and dna binding activity which was blocked by the p38 inhibitor sb203580 . NULL 
18 induction of hif-1alpha expression and dna binding activity which was blocked by the p38 inhibitor sb203580 . NULL NULL NULL NULL 
0 and dna binding activity which was blocked by the p38 inhibitor sb203580 . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL hypoxia also increased vegf production by scc lines , which was inhibited by 
9 NULL NULL NULL NULL NULL NULL hypoxia also increased vegf production by scc lines , which was inhibited by treatment with 
0 also increased vegf production by scc lines , which was inhibited by treatment with sb203580 . NULL NULL NULL NULL NULL 
19 vegf production by scc lines , which was inhibited by treatment with sb203580 . NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL overexpression of jnk1 or p38 was sufficient to induce hif-1alpha and 
0 NULL NULL NULL NULL overexpression of jnk1 or p38 was sufficient to induce hif-1alpha and vegf expression . NULL NULL NULL 
17 NULL NULL overexpression of jnk1 or p38 was sufficient to induce hif-1alpha and vegf expression . NULL NULL NULL NULL NULL 
9 jnk1 or p38 was sufficient to induce hif-1alpha and vegf expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results indicate that induction of sapks by hypoxia regulates hif-1alpha and 
17 NULL NULL NULL NULL NULL NULL these results indicate that induction of sapks by hypoxia regulates hif-1alpha and vegf expression in 
16 NULL these results indicate that induction of sapks by hypoxia regulates hif-1alpha and vegf expression in head and neck carcinoma cell 
9 that induction of sapks by hypoxia regulates hif-1alpha and vegf expression in head and neck carcinoma cell lines . NULL NULL 
0 this article is to explain radiologic patterns of benign and malignant breast lesions ( masses , microcalcifications ) based on histological 
0 NULL NULL NULL NULL NULL NULL the stromal fibrous reaction associated to infiltrating carcinomas is responsible of focal increased density , 
14 NULL NULL NULL NULL the stromal fibrous reaction associated to infiltrating carcinomas is responsible of focal increased density , and architectural 
0 NULL the stromal fibrous reaction associated to infiltrating carcinomas is responsible of focal increased density , and architectural distorsion , ultrasound 
0 fibrous reaction associated to infiltrating carcinomas is responsible of focal increased density , and architectural distorsion , ultrasound acoustic shadowing ; 
3 , and architectural distorsion , ultrasound acoustic shadowing ; abnormal angiogenesis can be detected by doppler , ct or mr imaging 
0 distorsion , ultrasound acoustic shadowing ; abnormal neoangiogenesis can be detected by doppler , ct or mr imaging . NULL NULL 
2 NULL NULL NULL invasive carcinomas without spiculated margins are poorly differentiated tumors . NULL NULL NULL NULL NULL NULL NULL NULL 
0 mammographic patterns of microcalcifications depend on their physiopathological process ( necrosis , secretion ) , and the shape of clusters ( 
0 of microcalcifications depend on their physiopathological process ( necrosis , secretion ) , and the shape of clusters ( round , 
0 physiopathological process ( necrosis , secretion ) , and the shape of clusters ( round , triangular ) typifies their anatomical 
0 homolog deleted on chromosome 10 ) was identified as a tumor suppressor gene on the long arm of chromosome 10 . 
18 deleted on chromosome 10 ) was identified as a tumor suppressor gene on the long arm of chromosome 10 . NULL 
0 NULL NULL NULL NULL NULL NULL NULL since then , important progress has been made with respect to the understanding of 
16 has been made with respect to the understanding of the role of the pten protein in the normal development of the 
0 respect to the understanding of the role of the pten protein in the normal development of the brain as well as 
2 of the role of the pten protein in the normal development of the brain as well as in the molecular pathogenesis 
0 development of the brain as well as in the molecular pathogenesis of human gliomas . NULL NULL NULL NULL NULL NULL 
0 review summarizes the current state of the art concerning the involvement of aberrant pten function in the development of different biologic 
16 the current state of the art concerning the involvement of aberrant pten function in the development of different biologic features of 
0 state of the art concerning the involvement of aberrant pten function in the development of different biologic features of malignant gliomas 
2 art concerning the involvement of aberrant pten function in the development of different biologic features of malignant gliomas , such as 
0 pten function in the development of different biologic features of malignant gliomas , such as loss of cell-cycle control and uncontrolled 
0 of different biologic features of malignant gliomas , such as loss of cell-cycle control and uncontrolled cell proliferation , escape from 
0 features of malignant gliomas , such as loss of cell-cycle control and uncontrolled cell proliferation , escape from apoptosis , brain 
1 , such as loss of cell-cycle control and uncontrolled cell proliferation , escape from apoptosis , brain invasion , and aberrant 
5 of cell-cycle control and uncontrolled cell proliferation , escape from apoptosis , brain invasion , and aberrant neoangiogenesis . NULL NULL 
14 and uncontrolled cell proliferation , escape from apoptosis , brain invasion , and aberrant neoangiogenesis . NULL NULL NULL NULL NULL 
16 proliferation , escape from apoptosis , brain invasion , and aberrant neoangiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 , escape from apoptosis , brain invasion , and aberrant angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL most of the tumor-suppressive properties of pten are dependent on its lipid phosphatase activity 
0 NULL NULL NULL NULL NULL NULL most of the tumor-suppressive properties of pten are dependent on its lipid phosphatase activity , 
16 NULL NULL most of the tumor-suppressive properties of pten are dependent on its lipid phosphatase activity , which inhibits the phosphatidylinositol-3'-kinase 
0 tumor-suppressive properties of pten are dependent on its lipid phosphatase activity , which inhibits the phosphatidylinositol-3'-kinase ( pi3k ) /akt signaling 
18 pten are dependent on its lipid phosphatase activity , which inhibits the phosphatidylinositol-3'-kinase ( pi3k ) /akt signaling pathway through dephosphorylation 
16 pten are dependent on its lipid phosphatase activity , which inhibits the phosphatidylinositol-3'-kinase ( pi3k ) /akt signaling pathway through dephosphorylation 
13 inhibits the phosphatidylinositol-3'-kinase ( pi3k ) /akt signaling pathway through dephosphorylation of phosphatidylinositol- ( 3 , 4 , 5 ) -triphosphate 
0 NULL NULL NULL NULL NULL NULL NULL NULL the additional function of pten as a dual-specificity protein phosphatase may also play 
0 NULL NULL the additional function of pten as a dual-specificity protein phosphatase may also play a role in glioma pathogenesis . 
16 function of pten as a dual-specificity protein phosphatase may also play a role in glioma pathogenesis . NULL NULL NULL NULL 
16 pten as a dual-specificity protein phosphatase may also play a role in glioma pathogenesis . NULL NULL NULL NULL NULL NULL 
0 dual-specificity protein phosphatase may also play a role in glioma pathogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL besides the wealth of data elucidating the functional roles of pten , recent studies suggest a diagnostic significance of 
16 , recent studies suggest a diagnostic significance of pten gene alterations as a molecular marker for poor prognosis in anaplastic astrocytomas 
19 NULL NULL NULL NULL furthermore , the possibility of selective targeting of pten mutant tumor cells by specific pharmacologic inhibitors of 
0 furthermore , the possibility of selective targeting of pten mutant tumor cells by specific pharmacologic inhibitors of members of the pten/pi3k/akt 
0 of the pten/pi3k/akt pathway opens up new perspectives for a targeted molecular therapy of malignant gliomas . NULL NULL NULL NULL 
19 pten/pi3k/akt pathway opens up new perspectives for a targeted molecular therapy of malignant gliomas . NULL NULL NULL NULL NULL NULL 
0 opens up new perspectives for a targeted molecular therapy of malignant gliomas . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL systemic regulation of distraction osteogenesis : a cascade of biochemical factors . 
0 NULL NULL NULL NULL NULL NULL NULL systemic regulation of distraction osteogenesis : a cascade of biochemical factors . NULL NULL 
0 NULL NULL NULL NULL NULL NULL systemic regulation of distraction osteogenesis : a cascade of biochemical factors . NULL NULL NULL 
0 NULL NULL NULL NULL this study investigates the systemic biochemical regulation of fracture healing in distraction osteogenesis compared with rigid osteotomy 
0 study investigates the systemic biochemical regulation of fracture healing in distraction osteogenesis compared with rigid osteotomy in a prospective in vivo 
0 investigates the systemic biochemical regulation of fracture healing in distraction osteogenesis compared with rigid osteotomy in a prospective in vivo study 
0 NULL NULL NULL NULL NULL NULL to further clarify the influence of mechanical strain on the regulation of bone formation , 
16 to further clarify the influence of mechanical strain on the regulation of bone formation , bone growth factors ( insulin-like growth 
2 the influence of mechanical strain on the regulation of bone formation , bone growth factors ( insulin-like growth factor [ igf 
0 mechanical strain on the regulation of bone formation , bone growth factors ( insulin-like growth factor [ igf ] i , 
0 regulation of bone formation , bone growth factors ( insulin-like growth factor [ igf ] i , igf binding protein [ 
0 ( insulin-like growth factor [ igf ] i , igf binding protein [ igfbp ] 3 , transforming growth factor [ 
0 insulin-like growth factor [ igf ] i , igf binding protein [ igfbp ] 3 , transforming growth factor [ tgf 
0 , igf binding protein [ igfbp ] 3 , transforming growth factor [ tgf ] beta1 , and basic fgf [ 
0 , and basic fgf [ bfgf ] ) , bone matrix degrading enzymes ( matrix-metalloproteinases [ mmps ] 1 , 2 
0 [ bfgf ] ) , bone matrix degrading enzymes ( matrix [ mmps ] 1 , 2 , and 3 ) 
0 ] 1 , 2 , and 3 ) , human growth hormone ( hgh ) , and bone formation markers ( 
0 , human growth hormone ( hgh ) , and bone formation markers ( alp , bone-specific alp [ bap ] , 
0 NULL NULL NULL NULL NULL NULL NULL NULL in the distraction group , a significant postoperative increase in mmp-1 , bfgf 
0 NULL NULL NULL NULL in the distraction group , a significant postoperative increase in mmp-1 , bfgf , alp , and 
17 NULL NULL in the distraction group , a significant postoperative increase in mmp-1 , bfgf , alp , and bap could 
0 mmp-1 , bfgf , alp , and bap could be observed during the lengthening and the consolidation period when compared with 
0 lengthening and the consolidation period when compared with the baseline levels . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL osteotomy fracture healing without the traction stimulus failed to induce a corresponding increase in these factors . NULL NULL NULL 
0 healing without the traction stimulus failed to induce a corresponding increase in these factors . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , comparison of both groups revealed a significantly higher increase 
17 addition , comparison of both groups revealed a significantly higher increase in tgf-beta1 , igf-i , igfbp-3 , and hgh in 
0 igfbp-3 , and hgh in the lengthening group during the distraction period , indicating key regulatory functions in mechanotransduction . NULL 
0 in the lengthening group during the distraction period , indicating key regulatory functions in mechanotransduction . NULL NULL NULL NULL NULL 
0 the lengthening group during the distraction period , indicating key regulatory functions in mechanotransduction . NULL NULL NULL NULL NULL NULL 
0 lengthening group during the distraction period , indicating key regulatory functions in mechanotransduction . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL the time courses of changes in mmp-1 , bone growth factors ( tgf-beta1 and bfgf 
0 NULL the time courses of changes in mmp-1 , bone growth factors ( tgf-beta1 and bfgf ) , and hgh , 
0 , correlated significantly during the lengthening phase , indicating common regulatory pathways for these factors in distraction osteogenesis . NULL NULL 
0 correlated significantly during the lengthening phase , indicating common regulatory pathways for these factors in distraction osteogenesis . NULL NULL NULL 
0 phase , indicating common regulatory pathways for these factors in distraction osteogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
0 , indicating common regulatory pathways for these factors in distraction osteogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL significant correlation between the osteoblastic marker bap , tgf-beta1 , and 
17 the osteoblastic marker bap , tgf-beta1 , and bfgf suggests activated osteoblastic cells as a major source of systemically increased bone 
0 tgf-beta1 , and bfgf suggests strain-activated osteoblastic cells as a major source of systemically increased bone growth factors during callus distraction 
0 suggests strain-activated osteoblastic cells as a major source of systemically increased bone growth factors during callus distraction . NULL NULL NULL 
0 osteoblastic cells as a major source of systemically increased bone growth factors during callus distraction . NULL NULL NULL NULL NULL 
0 major source of systemically increased bone growth factors during callus distraction . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL the systemic increase in bfgf and mmp-1 might reflect an increased local stimulation 
0 NULL NULL the systemic increase in bfgf and mmp-1 might reflect an increased local stimulation of angiogenesis during distraction osteogenesis . 
17 the systemic increase in bfgf and mmp-1 might reflect an increased local stimulation of angiogenesis during distraction osteogenesis . NULL NULL 
17 increase in bfgf and mmp-1 might reflect an increased local stimulation of angiogenesis during distraction osteogenesis . NULL NULL NULL NULL 
3 bfgf and mmp-1 might reflect an increased local stimulation of angiogenesis during distraction osteogenesis . NULL NULL NULL NULL NULL NULL 
0 mmp-1 might reflect an increased local stimulation of angiogenesis during distraction osteogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
0 might reflect an increased local stimulation of angiogenesis during distraction osteogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenic and antitumor effects of a protein kinase cbeta inhibitor in 
18 NULL NULL NULL NULL NULL NULL NULL antiangiogenic and antitumor effects of a protein kinase cbeta inhibitor in human breast cancer 
0 NULL NULL NULL NULL antiangiogenic and antitumor effects of a protein kinase cbeta inhibitor in human breast cancer and ovarian cancer 
0 NULL antiangiogenic and antitumor effects of a protein kinase cbeta inhibitor in human breast cancer and ovarian cancer xenografts . NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL in cell culture , the compound 317615 2hcl , a potent inhibitor of 
18 cell culture , the compound 317615 2hcl , a potent inhibitor of vegf-stimulated huvec proliferation , was not very effective against 
17 , the compound 317615 2hcl , a potent inhibitor of stimulated huvec proliferation , was not very effective against mx-1 breast 
1 compound 317615 2hcl , a potent inhibitor of vegf-stimulated huvec proliferation , was not very effective against mx-1 breast cancer cells 
18 potent inhibitor of vegf-stimulated huvec proliferation , was not very effective against mx-1 breast cancer cells ( ic50= 8.1 microm ) 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL exposure to combinations of paclitaxel or carboplatin and 317615 x 2hcl 
0 or carboplatin and 317615 x 2hcl with mx-1 cells in culture resulted in cell survival that reflected primarily additivity of the 
17 carboplatin and 317615 x 2hcl with mx-1 cells in culture resulted in cell survival that reflected primarily additivity of the two 
5 x 2hcl with mx-1 cells in culture resulted in cell survival that reflected primarily additivity of the two agents . NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL exposure of skov-3 cells to paclitaxel or carboplatin along with 317615 
17 skov-3 cells to paclitaxel or carboplatin along with 317615 2hcl resulted in cell survivals that reflected additivity of 317615 x 2hcl 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL administration of 317615 x 2hci orally twice daily to nude mice 
17 to nude mice bearing subcutaneous mx-1 tumors or skov-3 tumors resulted in a decreased number of intratumoral vessels as determined by 
18 bearing subcutaneous mx-1 tumors or skov-3 tumors resulted in a decreased number of intratumoral vessels as determined by cd31 and cd105 
0 number of intratumoral vessels as determined by cd31 and cd105 staining with decreases of 35 % and 43 % in mx-1 
0 intratumoral vessels as determined by cd31 and cd105 staining with decreases of 35 % and 43 % in mx-1 tumors and 
0 NULL NULL NULL NULL NULL 317615 x 2hcl was an active antitumor agent against the mx-1 xenograft and increased the tumor 
17 was an active antitumor agent against the mx-1 xenograft and increased the tumor growth delay produced by paclitaxel by 1.7-fold and 
0 active antitumor agent against the mx-1 xenograft and increased the tumor growth delay produced by paclitaxel by 1.7-fold and the tumor 
4 antitumor agent against the mx-1 xenograft and increased the tumor growth delay produced by paclitaxel by 1.7-fold and the tumor growth 
18 agent against the mx-1 xenograft and increased the tumor growth delay produced by paclitaxel by 1.7-fold and the tumor growth delay 
0 against the mx-1 xenograft and increased the tumor growth delay produced by paclitaxel by 1.7-fold and the tumor growth delay produced 
0 tumor growth delay produced by paclitaxel by 1.7-fold and the tumor growth delay produced by carboplatin by 3.8-fold . NULL NULL 
4 growth delay produced by paclitaxel by 1.7-fold and the tumor growth delay produced by carboplatin by 3.8-fold . NULL NULL NULL 
18 delay produced by paclitaxel by 1.7-fold and the tumor growth delay produced by carboplatin by 3.8-fold . NULL NULL NULL NULL 
0 produced by paclitaxel by 1.7-fold and the tumor growth delay produced by carboplatin by 3.8-fold . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL administration of 317615 x 2hcl also increased the tumor growth delay 
17 NULL NULL NULL NULL administration of 317615 x 2hcl also increased the tumor growth delay produced by fractionated radiation therapy in 
0 NULL NULL administration of 317615 x 2hcl also increased the tumor growth delay produced by fractionated radiation therapy in the mx-1 
4 NULL administration of 317615 x 2hcl also increased the tumor growth delay produced by fractionated radiation therapy in the mx-1 tumor 
18 administration of 317615 x 2hcl also increased the tumor growth delay produced by fractionated radiation therapy in the mx-1 tumor . 
0 of 317615 x 2hcl also increased the tumor growth delay produced by fractionated radiation therapy in the mx-1 tumor . NULL 
0 2hcl also increased the tumor growth delay produced by fractionated radiation therapy in the mx-1 tumor . NULL NULL NULL NULL 
0 also increased the tumor growth delay produced by fractionated radiation therapy in the mx-1 tumor . NULL NULL NULL NULL NULL 
0 growth delay produced by fractionated radiation therapy in the mx-1 tumor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment with 317615 x 2hcl alone increased the lifespan of animals 
0 NULL NULL NULL NULL treatment with 317615 x 2hcl alone increased the lifespan of animals bearing intraperitoneal skov-3 xenografts by 1.9 
0 animals bearing intraperitoneal skov-3 xenografts by 1.9 fold compared with untreated control animals . NULL NULL NULL NULL NULL NULL NULL 
0 bearing intraperitoneal skov-3 xenografts by 1.9 fold compared with untreated control animals . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL the combination of paclitaxel and 317615 x 2hcl resulted in 100 % 120-day survival of skov-3 bearing animals . 
0 paclitaxel and 317615 x 2hcl resulted in 100 % 120-day survival of skov-3 bearing animals . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL administration of 317615 x 2hcl along with carboplatin to animals bearing 
0 x 2hcl along with carboplatin to animals bearing the skov-3 tumor produced a 1.8-fold increase in lifespan compared with carboplatin alone 
0 2hcl along with carboplatin to animals bearing the skov-3 tumor produced a 1.8-fold increase in lifespan compared with carboplatin alone . 
0 carboplatin to animals bearing the skov-3 tumor produced a 1.8-fold increase in lifespan compared with carboplatin alone . NULL NULL NULL 
3 NULL NULL NULL 317615 x 2hcl is a promising new angiogenic agent that is in early phase clinical testing . NULL 
0 a promising new antiangiogenic agent that is in early phase clinical testing . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL fibroblast growth factor 2 promotes microvessel formation from mouse embryonic aorta . 
17 NULL NULL NULL NULL NULL NULL fibroblast growth factor 2 promotes microvessel formation from mouse embryonic aorta . NULL NULL NULL 
2 NULL NULL NULL NULL fibroblast growth factor 2 promotes microvessel formation from mouse embryonic aorta . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL to delineate the roles that oxygen and fibroblast growth factors ( fgfs ) play 
0 NULL NULL to delineate the roles that oxygen and fibroblast growth factors ( fgfs ) play in the process of angiogenesis 
16 roles that oxygen and fibroblast growth factors ( fgfs ) play in the process of angiogenesis from the embryonic aorta , 
3 growth factors ( fgfs ) play in the process of angiogenesis from the embryonic aorta , we cultured mouse embryonic aorta 
19 the process of angiogenesis from the embryonic aorta , we cultured mouse embryonic aorta explants ( thoracic level to lateral vessels 
0 and metanephros ) in a three-dimensional type i collagen gel matrix . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL during 8 days of culture under 5 % o ( 2 ) , but not 
19 ( 2 ) , but not room air , the addition of fgf2 to explants stimulated the formation of gs-ib ( 
17 not room air , the addition of fgf2 to explants stimulated the formation of gs-ib ( 4- ) positive , cd31-positive 
2 air , the addition of fgf2 to explants stimulated the formation of gs-ib ( 4- ) positive , cd31-positive , and 
0 to explants stimulated the formation of gs-ib ( 4- ) positive , cd31-positive , and flk-1-positive microvessels in a concentration-dependent manner 
0 stimulated the formation of gs-ib ( 4- ) positive , positive , and flk-1-positive microvessels in a concentration-dependent manner . NULL 
0 of gs-ib ( 4- ) positive , cd31-positive , and positive microvessels in a concentration-dependent manner . NULL NULL NULL NULL 
0 ) positive , cd31-positive , and flk-1-positive microvessels in a dependent manner . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL stimulated microvessel formation was inhibited by sequestration of fgf2 via addition 
2 NULL NULL NULL NULL NULL NULL NULL NULL fgf2-stimulated microvessel formation was inhibited by sequestration of fgf2 via addition of soluble 
18 NULL NULL NULL NULL NULL NULL fgf2-stimulated microvessel formation was inhibited by sequestration of fgf2 via addition of soluble fgf receptor 
19 fgf2-stimulated microvessel formation was inhibited by sequestration of fgf2 via addition of soluble fgf receptor ( fgfr ) chimera protein or 
0 via addition of soluble fgf receptor ( fgfr ) chimera protein or anti-fgf2 antibodies . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL fgfr1 and fgfr2 were present on explants . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL levels of fgfr1 , but not fgfr2 , were increased in 
17 NULL levels of fgfr1 , but not fgfr2 , were increased in embryonic aorta cultured under 5 % o ( 2 
19 , but not fgfr2 , were increased in embryonic aorta cultured under 5 % o ( 2 ) relative to room 
9 NULL NULL our data suggest that low oxygen upregulates fgfr1 expression in embryonic aorta in vitro and renders it more responsive 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL insulin-like growth factor-i receptor-mediated vasculogenesis/angiogenesis in human lung development . NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL insulin-like growth factor-i mediated vasculogenesis/angiogenesis in human lung development . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL insulin-like growth factor-i receptor-mediated vasculogenesis in human lung development . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL insulin-like growth factor-i receptor-mediated angiogenesis in human lung development . NULL NULL NULL NULL NULL 
2 NULL NULL insulin-like growth factor-i receptor-mediated vasculogenesis/angiogenesis in human lung development . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the structural and functional development of the pulmonary system is dependent upon 
2 NULL NULL NULL NULL NULL NULL the structural and functional development of the pulmonary system is dependent upon appropriate early vascularization 
17 the structural and functional development of the pulmonary system is dependent upon appropriate early vascularization of the embryonic lung . NULL 
3 development of the pulmonary system is dependent upon appropriate early vascularization of the embryonic lung . NULL NULL NULL NULL NULL 
0 in vitro studies in a rat model indicated that insulin-like growth factor-i ( igf-i ) is a potent angiogenic agent for 
3 that insulin-like growth factor-i ( igf-i ) is a potent angiogenic agent for fetal lung endothelial cells . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL to assess its role on human vascular lung development , we first examined the 
2 NULL NULL to assess its role on human vascular lung development , we first examined the expression of igf-i/ii and igf 
9 on human vascular lung development , we first examined the expression of igf-i/ii and igf receptor type i ( igf-ir ) 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL immunohistochemical and in situ hybridization studies revealed the presence of igf-i/ii-igf-ir 
9 NULL NULL immunohistochemical and in situ hybridization studies revealed the presence of igf-i/ii-igf-ir ligands and mrna transcripts in embryonic lungs as 
10 NULL NULL immunohistochemical and in situ hybridization studies revealed the presence of igf-i/ii-igf-ir ligands and mrna transcripts in embryonic lungs as 
0 situ hybridization studies revealed the presence of igf-i/ii-igf-ir ligands and mrna transcripts in embryonic lungs as early as 4 wk gestation 
0 anti-igf-ir neutralizing antibody on human fetal lung explants demonstrated a significant blockade of igf-ir signaling . NULL NULL NULL NULL NULL 
18 neutralizing antibody on human fetal lung explants demonstrated a significant blockade of igf-ir signaling . NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inactivation of igf-ir resulted in a loss of endothelial cells , 
17 NULL NULL NULL NULL NULL NULL NULL inactivation of igf-ir resulted in a loss of endothelial cells , accompanied by dramatic 
18 NULL NULL NULL NULL inactivation of igf-ir resulted in a loss of endothelial cells , accompanied by dramatic changes in fetal 
16 in a loss of endothelial cells , accompanied by dramatic changes in fetal lung explant morphology . NULL NULL NULL NULL 
19 NULL terminal transferase dutp end-labeling assay and tem studies of treated lungs demonstrated numerous apoptotic mesenchymal cells . NULL NULL NULL 
2 validated the importance of the igf-igf-ir system for lung vascular development . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL these data provide the first demonstration of igf-i/ii expression in the human lung in early gestation and indicate that 
0 in early gestation and indicate that the igf family of growth factors , acting through the igf-ir , is required as 
17 of growth factors , acting through the igf-ir , is required as a survival factor during normal human lung vascularization . 
0 , acting through the igf-ir , is required as a survival factor during normal human lung vascularization . NULL NULL NULL 
3 is required as a survival factor during normal human lung vascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL enhanced expression of vascular endothelial growth factor by periodontal pathogens in 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL enhanced expression of vascular endothelial growth factor by periodontal pathogens in gingival 
0 NULL NULL NULL NULL NULL enhanced expression of vascular endothelial growth factor by periodontal pathogens in gingival fibroblasts . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) has recently attracted attention as a 
3 attracted attention as a potent inducer of vascular permeability and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL aberrant angiogenesis is often associated with lesion formation in chronic periodontitis 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL aberrant angiogenesis is often associated with lesion formation in chronic periodontitis . 
16 NULL NULL NULL NULL NULL NULL aberrant angiogenesis is often associated with lesion formation in chronic periodontitis . NULL NULL NULL 
2 NULL NULL NULL aberrant angiogenesis is often associated with lesion formation in chronic periodontitis . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the aim of the present study was to investigate the properties of vegf expression in 
0 the aim of the present study was to investigate the properties of vegf expression in human gingival fibroblasts ( hgf ) 
9 the present study was to investigate the properties of vegf expression in human gingival fibroblasts ( hgf ) culture . NULL 
0 of vegf expression in human gingival fibroblasts ( hgf ) culture . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL hgf were stimulated with lipopolysaccharide ( lps ) , vesicle ( ve ) 
0 lps ) , vesicle ( ve ) and outer membrane protein ( omp ) from actinobacillus actinomycetemcomitans and porphyromonas gingivalis . 
9 NULL NULL NULL NULL NULL NULL NULL NULL hgf constitutively produced vegf and levels were significantly enhanced ( p less than 
0 NULL NULL NULL NULL NULL hgf constitutively produced vegf and levels were significantly enhanced ( p less than 0.01 ) by 
17 NULL NULL hgf constitutively produced vegf and levels were significantly enhanced ( p less than 0.01 ) by stimulation with ve 
17 were significantly enhanced ( p less than 0.01 ) by stimulation with ve and omp from a. actinomycetemcomitans and p. gingivalis 
0 NULL NULL NULL NULL on the other hand , vegf levels were not increased by lps stimulation . NULL NULL NULL 
17 NULL on the other hand , vegf levels were not increased by lps stimulation . NULL NULL NULL NULL NULL NULL 
0 other hand , vegf levels were not increased by lps stimulation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL vegf mrna expression was also observed in ve- and omp-stimulated hgf . 
10 NULL NULL NULL NULL NULL NULL NULL NULL vegf mrna expression was also observed in ve- and omp-stimulated hgf . NULL 
0 NULL NULL NULL NULL NULL vegf mrna expression was also observed in ve- and omp-stimulated hgf . NULL NULL NULL NULL 
17 NULL vegf mrna expression was also observed in ve- and stimulated hgf . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL a vascular permeability enhancement ( vpe ) assay was performed using guinea pigs to 
17 pigs to ascertain whether supernatant from cultures of ve- and stimulated hgf enhance vascular permeability in vivo . NULL NULL NULL 
17 ascertain whether supernatant from cultures of ve- and omp-stimulated hgf enhance vascular permeability in vivo . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL supernatant from cultures of ve- and stimulated hgf strongly induced vpe . NULL NULL NULL NULL NULL 
0 NULL supernatant from cultures of ve- and omp-stimulated hgf strongly induced vpe . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL this was markedly suppressed upon simultaneous injection of anti-vegf polyclonal antibodies with the supernatant 
19 NULL NULL NULL NULL this was markedly suppressed upon simultaneous injection of anti-vegf polyclonal antibodies with the supernatant . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL heating and protease treatment of the stimulants reduced the vegf enhancing levels in ve 
18 NULL NULL NULL heating and protease treatment of the stimulants reduced the vegf enhancing levels in ve and omp in vitro 
17 heating and protease treatment of the stimulants reduced the vegf enhancing levels in ve and omp in vitro . NULL NULL 
0 and protease treatment of the stimulants reduced the vegf enhancing levels in ve and omp in vitro . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results suggest that ve and omp may be crucial heat-labile and 
0 NULL these results suggest that ve and omp may be crucial heat-labile and protease-sensitive components of periodontal pathogens that enhance vegf 
0 suggest that ve and omp may be crucial heat-labile and sensitive components of periodontal pathogens that enhance vegf expression . NULL 
17 be crucial heat-labile and protease-sensitive components of periodontal pathogens that enhance vegf expression . NULL NULL NULL NULL NULL NULL NULL 
9 heat-labile and protease-sensitive components of periodontal pathogens that enhance vegf expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , vegf might be associated with the etiology of periodontitis 
0 NULL NULL NULL NULL in addition , vegf might be associated with the etiology of periodontitis in its early stages according 
3 the etiology of periodontitis in its early stages according to neovascularization stimulated by periodontal pathogens causing swelling and edema . NULL 
17 etiology of periodontitis in its early stages according to neovascularization stimulated by periodontal pathogens causing swelling and edema . NULL NULL 
19 NULL NULL NULL NULL NULL combined topical fluconazole and corticosteroid treatment for experimental candida albicans keratomycosis . NULL NULL NULL NULL 
19 point and concentration of topical corticosteroids in candida albicans keratitis treated with fluconazole . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL methods : corneas of 105 rabbits were infected with viable yeast cells of c. albicans ( 2.5 x 
19 a 48-hour incubation period , seven groups of animals were treated for 21 days with fluconazole , with group i acting 
0 days with fluconazole , with group i acting as a control , and groups ii to vii receiving adjunct therapy with 
0 acting as a control , and groups ii to vii receiving adjunct therapy with the corticosteroid prednisolone ( 5 or 10 
19 a control , and groups ii to vii receiving adjunct therapy with the corticosteroid prednisolone ( 5 or 10 times daily 
0 daily ; 3 , 9 , or 15 days after infection ) . NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL the degree of corneal infiltration , ulceration , corneal clouding , hypopyon , conjunctivitis , 
3 , ulceration , corneal clouding , hypopyon , conjunctivitis , neovascularization , and corneal perforation was monitored over a 24-day period 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : the control group showed the highest level of corneal 
0 NULL NULL NULL NULL NULL NULL NULL results : the control group showed the highest level of corneal clouding and neovascularization 
0 NULL NULL NULL NULL NULL results : the control group showed the highest level of corneal clouding and neovascularization . NULL 
3 control group showed the highest level of corneal clouding and neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 , by day 24 , the majority of groups also treated with prednisolone displayed significantly less corneal clouding and neovascularization . 
3 also treated with prednisolone displayed significantly less corneal clouding and neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL an immediate decrease in corneal clouding was observed in groups treated with additional 
0 NULL NULL NULL an immediate decrease in corneal clouding was observed in groups treated with additional low- or high-dose prednisolone from 
19 an immediate decrease in corneal clouding was observed in groups treated with additional low- or high-dose prednisolone from day 9 after 
0 with additional low- or high-dose prednisolone from day 9 after inoculation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL after additional prednisolone treatment from day 9 or 15 after inoculation , no significant 
0 after additional prednisolone treatment from day 9 or 15 after inoculation , no significant difference was detected in the recultivation rate 
0 treatment from day 9 or 15 after inoculation , no significant difference was detected in the recultivation rate of c. albicans 
0 9 or 15 after inoculation , no significant difference was detected in the recultivation rate of c. albicans compared with the 
0 in the recultivation rate of c. albicans compared with the control . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL early administration of prednisolone ( day 3 , low and high dose 
0 prednisolone ( day 3 , low and high dose ) resulted in the recultivation of significantly more c. albicans . NULL 
19 NULL NULL NULL conclusions : fluconazole plus adjunct high-dose prednisolone treatment was most effective when administered 9 days after infection . 
0 conclusions : fluconazole plus adjunct high-dose prednisolone treatment was most effective when administered 9 days after infection . NULL NULL NULL 
0 fluconazole plus adjunct high-dose prednisolone treatment was most effective when administered 9 days after infection . NULL NULL NULL NULL NULL 
0 prednisolone treatment was most effective when administered 9 days after infection . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the delayed application of corticosteroids after treatment with antimycotic drugs in cases 
19 NULL NULL NULL NULL NULL NULL NULL NULL the delayed application of corticosteroids after treatment with antimycotic drugs in cases of 
19 NULL NULL NULL NULL the delayed application of corticosteroids after treatment with antimycotic drugs in cases of fungal keratitis is therefore 
0 of fungal keratitis is therefore not contraindicated and may be beneficial in patients . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL solid tumor therapy : manipulation of the vasculature with tnf . NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL solid tumor therapy : manipulation of the vasculature with tnf . NULL NULL 
16 NULL NULL NULL NULL NULL NULL solid tumor therapy : manipulation of the vasculature with tnf . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL drug delivery to solid tumors is one of the most challenging aspects 
0 tumors is one of the most challenging aspects in cancer therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL whereas agents seem promising in the test tube , clinical trials often fail due to unfavorable pharmacokinetics , poor delivery 
0 whereas agents seem promising in the test tube , clinical trials often fail due to unfavorable pharmacokinetics , poor delivery , 
0 clinical trials often fail due to unfavorable pharmacokinetics , poor delivery , low local concentrations , and limited accumulation in the 
0 pharmacokinetics , poor delivery , low local concentrations , and limited accumulation in the target cell . NULL NULL NULL NULL 
0 , poor delivery , low local concentrations , and limited accumulation in the target cell . NULL NULL NULL NULL NULL 
0 , low local concentrations , and limited accumulation in the target cell . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL a major step forwards in the treatment of solid tumors is the 
19 NULL NULL NULL NULL a major step forwards in the treatment of solid tumors is the recognition of the tumor-associated vasculature 
0 the treatment of solid tumors is the recognition of the associated vasculature as an important target for therapy . NULL NULL 
0 tumors is the recognition of the tumor-associated vasculature as an important target for therapy . NULL NULL NULL NULL NULL NULL 
0 is the recognition of the tumor-associated vasculature as an important target for therapy . NULL NULL NULL NULL NULL NULL NULL 
0 recognition of the tumor-associated vasculature as an important target for therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of tumor vascular development has a direct effect on the 
0 NULL NULL NULL NULL NULL NULL NULL NULL inhibition of tumor vascular development has a direct effect on the growth and 
2 NULL NULL NULL NULL NULL NULL inhibition of tumor vascular development has a direct effect on the growth and progression of 
0 NULL NULL NULL inhibition of tumor vascular development has a direct effect on the growth and progression of the tumor . 
16 NULL NULL inhibition of tumor vascular development has a direct effect on the growth and progression of the tumor . NULL 
4 of tumor vascular development has a direct effect on the growth and progression of the tumor . NULL NULL NULL NULL 
2 vascular development has a direct effect on the growth and progression of the tumor . NULL NULL NULL NULL NULL NULL 
0 a direct effect on the growth and progression of the tumor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
6 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL destruction of an existing vasculature also directly inflicts serious damage to 
6 NULL destruction of an existing vasculature also directly inflicts serious damage to the tumor cell . NULL NULL NULL NULL NULL 
0 an existing vasculature also directly inflicts serious damage to the tumor cell . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL moreover , the tumor vascular bed can be manipulated facilitating enhanced permissiveness of the 
0 moreover , the tumor vascular bed can be manipulated facilitating enhanced permissiveness of the tumor for administered chemotherapeutics . NULL NULL 
0 vascular bed can be manipulated facilitating enhanced permissiveness of the tumor for administered chemotherapeutics . NULL NULL NULL NULL NULL NULL 
19 can be manipulated facilitating enhanced permissiveness of the tumor for administered chemotherapeutics . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL in this review , we focus on the use of tumor necrosis factor alpha ( tnf ) in local 
0 in this review , we focus on the use of tumor necrosis factor alpha ( tnf ) in local and systemic 
0 this review , we focus on the use of tumor necrosis factor alpha ( tnf ) in local and systemic therapy 
19 necrosis factor alpha ( tnf ) in local and systemic therapy in conjunction with chemotherapy . NULL NULL NULL NULL NULL 
0 tnf ) in local and systemic therapy in conjunction with chemotherapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL in these settings tnf demonstrates potent and selective activity on the tumor vascular bed , which strongly improves tumor 
0 these settings tnf demonstrates potent and selective activity on the tumor vascular bed , which strongly improves tumor response . NULL 
17 selective activity on the tumor vascular bed , which strongly improves tumor response . NULL NULL NULL NULL NULL NULL NULL 
0 activity on the tumor vascular bed , which strongly improves tumor response . NULL NULL NULL NULL NULL NULL NULL NULL 
0 on the tumor vascular bed , which strongly improves tumor response . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL tissue integration and implant characteristics of various biomaterials commonly used for inguinal hernia repair have not been studied extensively . 
0 implant characteristics of various biomaterials commonly used for inguinal hernia repair have not been studied extensively . NULL NULL NULL NULL 
0 aim of this study is to compare behavior and tissue response between two new polyester prostheses and a commonly used polypropylene 
0 tissue response between two new polyester prostheses and a commonly used polypropylene ( pp ) mesh . NULL NULL NULL NULL 
0 meshes were fixed in the preperitoneal space with a centrally placed single suture . NULL NULL NULL NULL NULL NULL NULL 
3 and fat encapsulation , connective tissue , foreign-body reaction , neovascularization , hemorrhage , necrosis , and exudate . NULL NULL 
5 connective tissue , foreign-body reaction , neovascularization , hemorrhage , necrosis , and exudate . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL pp mesh resulted in more fibrous encapsulation and stiffness than pf and ps 
17 NULL NULL NULL NULL NULL NULL NULL NULL pp also resulted in less connective tissue formation and foreign-body reaction than pf 
2 NULL NULL NULL pp also resulted in less connective tissue formation and foreign-body reaction than pf and ps prostheses . NULL 
5 NULL NULL there was no difference in fat encapsulation , necrosis , hemorrhage , or exudate between prostheses . NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL therapeutic targeting of the survivin pathway in cancer : initiation of mitochondrial 
0 NULL therapeutic targeting of the survivin pathway in cancer : initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis . NULL 
0 of the survivin pathway in cancer : initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis . NULL NULL NULL NULL 
18 survivin pathway in cancer : initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis . NULL NULL NULL NULL NULL NULL 
0 in cancer : initiation of mitochondrial apoptosis and suppression of associated angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 cancer : initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL purpose : molecular antagonists of the inhibitor of apoptosis protein survivin have shown promise as novel anticancer 
0 NULL NULL purpose : molecular antagonists of the inhibitor of apoptosis protein survivin have shown promise as novel anticancer strategies for 
0 NULL purpose : molecular antagonists of the inhibitor of apoptosis protein survivin have shown promise as novel anticancer strategies for triggering 
0 survivin have shown promise as novel anticancer strategies for triggering tumor cell apoptosis , dysregulating mitotic progression , and inhibiting tumor 
5 shown promise as novel anticancer strategies for triggering tumor cell apoptosis , dysregulating mitotic progression , and inhibiting tumor growth in 
0 anticancer strategies for triggering tumor cell apoptosis , dysregulating mitotic progression , and inhibiting tumor growth in preclinical models . NULL 
18 triggering tumor cell apoptosis , dysregulating mitotic progression , and inhibiting tumor growth in preclinical models . NULL NULL NULL NULL 
0 tumor cell apoptosis , dysregulating mitotic progression , and inhibiting tumor growth in preclinical models . NULL NULL NULL NULL NULL 
4 cell apoptosis , dysregulating mitotic progression , and inhibiting tumor growth in preclinical models . NULL NULL NULL NULL NULL NULL 
5 NULL NULL however , how survivin couples to the cell death machinery has remained elusive , and the relevant cellular targets 
0 death machinery has remained elusive , and the relevant cellular targets of survivin antagonists have not been completely elucidated . NULL 
19 : human umbilical vein and dermal microvascular endothelial cells were infected with replication-deficient adenoviruses encoding survivin ( pad-survivin ) , green 
0 umbilical vein and dermal microvascular endothelial cells were infected with deficient adenoviruses encoding survivin ( pad-survivin ) , green fluorescent protein 
0 replication-deficient adenoviruses encoding survivin ( pad-survivin ) , green fluorescent protein ( pad-gfp ) , or a phosphorylation-defective survivin thr ( 
0 , green fluorescent protein ( pad-gfp ) , or a phosphorylation survivin thr ( 34 ) -- > ala ( pad-t34a 
0 , green fluorescent protein ( pad-gfp ) , or a defective survivin thr ( 34 ) -- > ala ( pad-t34a 
0 ( 34 ) -- > ala ( pad-t34a ) dominant negative mutant . NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL the effect of wild-type or mutant survivin was investigated on capillary network 
17 capillary network stability , endothelial cell viability , and caspase activation in vitro and on kinetics of tumor growth and development 
0 , and caspase activation in vitro and on kinetics of tumor growth and development of angiogenesis in a breast cancer xenograft 
4 and caspase activation in vitro and on kinetics of tumor growth and development of angiogenesis in a breast cancer xenograft model 
0 activation in vitro and on kinetics of tumor growth and development of angiogenesis in a breast cancer xenograft model in vivo 
3 vitro and on kinetics of tumor growth and development of angiogenesis in a breast cancer xenograft model in vivo . NULL 
5 NULL NULL NULL NULL NULL NULL NULL NULL the cell death pathway initiated by survivin targeting was mapped with respect to 
17 NULL NULL NULL NULL NULL NULL the cell death pathway initiated by survivin targeting was mapped with respect to cytochrome c 
19 NULL NULL NULL the cell death pathway initiated by survivin targeting was mapped with respect to cytochrome c release , changes 
14 by survivin targeting was mapped with respect to cytochrome c release , changes in mitochondrial transmembrane potential , and apoptosome requirements 
0 targeting was mapped with respect to cytochrome c release , changes in mitochondrial transmembrane potential , and apoptosome requirements using mouse 
0 respect to cytochrome c release , changes in mitochondrial transmembrane potential , and apoptosome requirements using mouse embryonic fibroblasts deficient in 
9 transmembrane potential , and apoptosome requirements using mouse embryonic fibroblasts deficient in apaf-1 or caspase-9 . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : adenoviral transduction of endothelial cells with pad-survivin inhibited growth 
0 NULL results : adenoviral transduction of endothelial cells with pad-survivin inhibited growth factor deprivation- or ceramide-induced apoptosis , reduced caspase-3 and 
0 results : adenoviral transduction of endothelial cells with pad-survivin inhibited growth factor deprivation- or ceramide-induced apoptosis , reduced caspase-3 and -7 
0 of endothelial cells with pad-survivin inhibited growth factor deprivation- or induced apoptosis , reduced caspase-3 and -7 generation , and stabilized 
0 endothelial cells with pad-survivin inhibited growth factor deprivation- or ceramide-induced apoptosis , reduced caspase-3 and -7 generation , and stabilized three-dimensional 
18 with pad-survivin inhibited growth factor deprivation- or ceramide-induced apoptosis , reduced caspase-3 and -7 generation , and stabilized three-dimensional capillary networks 
9 factor deprivation- or ceramide-induced apoptosis , reduced caspase-3 and -7 generation , and stabilized three-dimensional capillary networks in vitro . NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL conversely , expression of pad-t34a caused apoptosis in umbilical vein and dermal microvascular 
17 NULL NULL NULL NULL NULL conversely , expression of pad-t34a caused apoptosis in umbilical vein and dermal microvascular endothelial cells and 
5 NULL NULL NULL NULL conversely , expression of pad-t34a caused apoptosis in umbilical vein and dermal microvascular endothelial cells and resulted 
17 apoptosis in umbilical vein and dermal microvascular endothelial cells and resulted in caspase-3 activity . NULL NULL NULL NULL NULL NULL 
0 vein and dermal microvascular endothelial cells and resulted in caspase-3 activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
5 NULL NULL NULL NULL NULL NULL NULL NULL NULL cell death induced by survivin targeting exhibited the hallmarks of mitochondrial-dependent apoptosis 
17 NULL NULL NULL NULL NULL NULL NULL NULL cell death induced by survivin targeting exhibited the hallmarks of mitochondrial-dependent apoptosis with 
19 NULL NULL NULL NULL NULL cell death induced by survivin targeting exhibited the hallmarks of mitochondrial-dependent apoptosis with release of cytochrome 
0 NULL NULL NULL NULL cell death induced by survivin targeting exhibited the hallmarks of mitochondrial-dependent apoptosis with release of cytochrome c 
0 cell death induced by survivin targeting exhibited the hallmarks of dependent apoptosis with release of cytochrome c and loss of mitochondrial 
0 death induced by survivin targeting exhibited the hallmarks of mitochondrial-dependent apoptosis with release of cytochrome c and loss of mitochondrial transmembrane 
14 by survivin targeting exhibited the hallmarks of mitochondrial-dependent apoptosis with release of cytochrome c and loss of mitochondrial transmembrane potential and 
0 hallmarks of mitochondrial-dependent apoptosis with release of cytochrome c and loss of mitochondrial transmembrane potential and was suppressed in apaf-1 or 
0 with release of cytochrome c and loss of mitochondrial transmembrane potential and was suppressed in apaf-1 or caspase-9 knockout mouse embryonic 
0 cytochrome c and loss of mitochondrial transmembrane potential and was suppressed in apaf-1 or caspase-9 knockout mouse embryonic fibroblasts . NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL when injected in human breast cancer xenografts , pad-t34a inhibited growth of 
18 NULL when injected in human breast cancer xenografts , pad-t34a inhibited growth of established tumors and triggered tumor cell apoptosis in 
4 when injected in human breast cancer xenografts , pad-t34a inhibited growth of established tumors and triggered tumor cell apoptosis in vivo 
0 in human breast cancer xenografts , pad-t34a inhibited growth of established tumors and triggered tumor cell apoptosis in vivo . NULL 
17 cancer xenografts , pad-t34a inhibited growth of established tumors and triggered tumor cell apoptosis in vivo . NULL NULL NULL NULL 
0 xenografts , pad-t34a inhibited growth of established tumors and triggered tumor cell apoptosis in vivo . NULL NULL NULL NULL NULL 
5 pad-t34a inhibited growth of established tumors and triggered tumor cell apoptosis in vivo . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL this was associated with a approximately 60 % reduction in tumor-derived blood vessels 
18 NULL NULL this was associated with a approximately 60 % reduction in tumor-derived blood vessels by quantitative morphometry of cd31-stained tumor 
0 this was associated with a approximately 60 % reduction in derived blood vessels by quantitative morphometry of cd31-stained tumor areas , 
0 reduction in tumor-derived blood vessels by quantitative morphometry of cd31-stained tumor areas , and appearance of endothelial cell apoptosis by internucleosomal 
0 vessels by quantitative morphometry of cd31-stained tumor areas , and appearance of endothelial cell apoptosis by internucleosomal dna fragmentation in vivo 
5 of cd31-stained tumor areas , and appearance of endothelial cell apoptosis by internucleosomal dna fragmentation in vivo . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL conclusions : survivin functions as a novel upstream regulator of mitochondrial-dependent apoptosis , and 
0 NULL NULL conclusions : survivin functions as a novel upstream regulator of mitochondrial-dependent apoptosis , and molecular targeting of this pathway 
0 conclusions : survivin functions as a novel upstream regulator of dependent apoptosis , and molecular targeting of this pathway results in 
0 : survivin functions as a novel upstream regulator of mitochondrial-dependent apoptosis , and molecular targeting of this pathway results in anticancer 
0 a novel upstream regulator of mitochondrial-dependent apoptosis , and molecular targeting of this pathway results in anticancer activity via a dual 
0 of mitochondrial-dependent apoptosis , and molecular targeting of this pathway results in anticancer activity via a dual mechanism of induction of 
0 , and molecular targeting of this pathway results in anticancer activity via a dual mechanism of induction of tumor cell apoptosis 
0 of this pathway results in anticancer activity via a dual mechanism of induction of tumor cell apoptosis and suppression of angiogenesis 
17 pathway results in anticancer activity via a dual mechanism of induction of tumor cell apoptosis and suppression of angiogenesis . NULL 
0 in anticancer activity via a dual mechanism of induction of tumor cell apoptosis and suppression of angiogenesis . NULL NULL NULL 
5 activity via a dual mechanism of induction of tumor cell apoptosis and suppression of angiogenesis . NULL NULL NULL NULL NULL 
18 a dual mechanism of induction of tumor cell apoptosis and suppression of angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 mechanism of induction of tumor cell apoptosis and suppression of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL ccl16 activates an angiogenic program in vascular endothelial cells . NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL ccl16 activates an angiogenic program in vascular endothelial cells . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL ccl16 activates an angiogenic program in vascular endothelial cells . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL besides regulating leukocyte trafficking in normal and injured tissues , several chemokines 
14 NULL NULL NULL NULL NULL NULL NULL besides regulating leukocyte trafficking in normal and injured tissues , several chemokines may positively 
18 normal and injured tissues , several chemokines may positively or negatively regulate angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
18 and injured tissues , several chemokines may positively or negatively regulate angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 injured tissues , several chemokines may positively or negatively regulate angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL here we report that ccl16 activates an angiogenic program in vascular endothelial cells by activating ccr1 
3 NULL NULL NULL here we report that ccl16 activates an angiogenic program in vascular endothelial cells by activating ccr1 . NULL 
0 NULL NULL here we report that ccl16 activates an angiogenic program in vascular endothelial cells by activating ccr1 . NULL NULL 
17 ccl16 activates an angiogenic program in vascular endothelial cells by activating ccr1 . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL ccl16 induces dose-dependent random and directional migration of endothelial cells isolated from 
0 NULL NULL NULL NULL NULL NULL NULL NULL ccl16 induces dependent random and directional migration of endothelial cells isolated from large 
14 NULL NULL NULL NULL ccl16 induces dose-dependent random and directional migration of endothelial cells isolated from large vessels and liver capillaries 
0 ccl16 induces dose-dependent random and directional migration of endothelial cells isolated from large vessels and liver capillaries without inducing their proliferation 
1 isolated from large vessels and liver capillaries without inducing their proliferation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL it also promotes endothelial differentiation into capillary-like structures in an in vitro assay 
2 NULL NULL NULL NULL NULL NULL it also promotes endothelial differentiation into capillary-like structures in an in vitro assay and is 
3 into capillary-like structures in an in vitro assay and is angiogenic in the chick chorionallantoic membrane . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL these angiogenic activities are neutralized by a specific antibody against ccl16 . 
0 NULL NULL NULL NULL NULL NULL NULL NULL these angiogenic activities are neutralized by a specific antibody against ccl16 . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the direct angiogenic activity of ccl16 is further amplified by its ability 
3 NULL NULL NULL NULL NULL NULL NULL NULL the direct angiogenic activity of ccl16 is further amplified by its ability to 
0 NULL NULL NULL NULL NULL NULL NULL the direct angiogenic activity of ccl16 is further amplified by its ability to prime 
0 NULL NULL the direct angiogenic activity of ccl16 is further amplified by its ability to prime endothelium to a mitogen signal 
0 direct angiogenic activity of ccl16 is further amplified by its ability to prime endothelium to a mitogen signal induced by vascular 
0 by its ability to prime endothelium to a mitogen signal induced by vascular endothelial growth factor a and to raise their 
0 prime endothelium to a mitogen signal induced by vascular endothelial growth factor a and to raise their basal production of cxcl8 
9 vascular endothelial growth factor a and to raise their basal production of cxcl8 and ccl2 , 2 other angiogenic chemokines . 
3 their basal production of cxcl8 and ccl2 , 2 other angiogenic chemokines . NULL NULL NULL NULL NULL NULL NULL NULL 
18 urea hydrochloric acid salt ) , a ccr1 antagonist , inhibits angiogenic properties of ccl16 , whereas blocking of ccr8 or 
3 hydrochloric acid salt ) , a ccr1 antagonist , inhibits angiogenic properties of ccl16 , whereas blocking of ccr8 or desensitizing 
0 acid salt ) , a ccr1 antagonist , inhibits angiogenic properties of ccl16 , whereas blocking of ccr8 or desensitizing ccr2 
18 ccr1 antagonist , inhibits angiogenic properties of ccl16 , whereas blocking of ccr8 or desensitizing ccr2 , which are both well 
17 well known receptors for ccl16 , did not abolish endothelial activation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL ccl16 may be specifically linked to ccr1 expressed on endothelial cells . NULL NULL NULL 
9 NULL NULL NULL ccl16 may be specifically cross-linked to ccr1 expressed on endothelial cells . NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL the largely restricted ccl16 expression in the liver suggests that this chemokine may 
9 NULL NULL NULL NULL NULL NULL the largely restricted ccl16 expression in the liver suggests that this chemokine may play a 
16 ccl16 expression in the liver suggests that this chemokine may play a role in hepatic vascular formation during development and in 
16 in the liver suggests that this chemokine may play a role in hepatic vascular formation during development and in angiogenesis associated 
2 that this chemokine may play a role in hepatic vascular formation during development and in angiogenesis associated to hepatic diseases . 
0 chemokine may play a role in hepatic vascular formation during development and in angiogenesis associated to hepatic diseases . NULL NULL 
3 a role in hepatic vascular formation during development and in angiogenesis associated to hepatic diseases . NULL NULL NULL NULL NULL 
0 role in hepatic vascular formation during development and in angiogenesis associated to hepatic diseases . NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL autocrine angiotensin system regulation of bovine aortic endothelial cell migration and plasminogen activator involves 
14 NULL autocrine angiotensin system regulation of bovine aortic endothelial cell migration and plasminogen activator involves modulation of proto-oncogene pp60c-src expression . 
0 system regulation of bovine aortic endothelial cell migration and plasminogen activator involves modulation of proto-oncogene pp60c-src expression . NULL NULL NULL 
0 regulation of bovine aortic endothelial cell migration and plasminogen activator involves modulation of proto-oncogene pp60c-src expression . NULL NULL NULL NULL 
16 of bovine aortic endothelial cell migration and plasminogen activator involves modulation of proto-oncogene pp60c-src expression . NULL NULL NULL NULL NULL 
9 cell migration and plasminogen activator involves modulation of proto-oncogene pp60c-src expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL rapid endothelial cell migration and inhibition of thrombosis are critical for the resolution of 
0 NULL NULL NULL NULL NULL rapid endothelial cell migration and inhibition of thrombosis are critical for the resolution of denudation injuries 
0 NULL rapid endothelial cell migration and inhibition of thrombosis are critical for the resolution of denudation injuries to the vessel wall 
0 and inhibition of thrombosis are critical for the resolution of denudation injuries to the vessel wall . NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of the endothelial cell autocrine angiotensin system , with either 
0 cell autocrine angiotensin system , with either the angiotensin-converting enzyme inhibitor lisinopril or the angiotensin ii receptor antagonist sar1 , ile8-angiotensin 
0 the angiotensin ii receptor antagonist sar1 , ile8-angiotensin ii , leads to increased endothelial cell migration and urokinase-like plasminogen activator ( 
17 ii receptor antagonist sar1 , ile8-angiotensin ii , leads to increased endothelial cell migration and urokinase-like plasminogen activator ( u-pa ) 
14 sar1 , ile8-angiotensin ii , leads to increased endothelial cell migration and urokinase-like plasminogen activator ( u-pa ) activity ( bell 
0 , leads to increased endothelial cell migration and urokinase-like plasminogen activator ( u-pa ) activity ( bell , l. , and 
0 endothelial cell migration and urokinase-like plasminogen activator ( u-pa ) activity ( bell , l. , and j. a . NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of the autocrine angiotensin system with the converting-enzyme inhibitor or 
0 NULL inhibition of the autocrine angiotensin system with the converting-enzyme inhibitor or the receptor antagonist also leads to increased expression of 
0 system with the converting-enzyme inhibitor or the receptor antagonist also leads to increased expression of the proto-oncogene c-src : pp60c-src mrna 
17 the converting-enzyme inhibitor or the receptor antagonist also leads to increased expression of the proto-oncogene c-src : pp60c-src mrna increased 7-11-fold 
9 converting-enzyme inhibitor or the receptor antagonist also leads to increased expression of the proto-oncogene c-src : pp60c-src mrna increased 7-11-fold , 
0 leads to increased expression of the proto-oncogene c-src : pp60c-src mrna increased 7-11-fold , c-src protein 3-fold , and c-src kinase 
17 to increased expression of the proto-oncogene c-src : pp60c-src mrna increased 7-11-fold , c-src protein 3-fold , and c-src kinase activity 
0 the proto-oncogene c-src : pp60c-src mrna increased 7-11-fold , c-src protein 3-fold , and c-src kinase activity 2-3-fold . NULL NULL 
0 increased 7-11-fold , c-src protein 3-fold , and c-src kinase activity 2-3-fold . NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL endothelial cell expression of c-src was constitutively elevated after stable infection with a 
17 NULL NULL NULL endothelial cell expression of c-src was constitutively elevated after stable infection with a retroviral vector containing the c-src 
0 endothelial cell expression of c-src was constitutively elevated after stable infection with a retroviral vector containing the c-src coding sequence . 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL constitutively increased c-src kinase activity reconstituted the increases in migration and u-pa 
0 NULL NULL NULL NULL NULL NULL constitutively increased c-src kinase activity reconstituted the increases in migration and u-pa observed with angiotensin 
0 NULL NULL NULL NULL NULL constitutively increased c-src kinase activity reconstituted the increases in migration and u-pa observed with angiotensin system 
17 NULL NULL NULL constitutively increased c-src kinase activity reconstituted the increases in migration and u-pa observed with angiotensin system interruption . 
0 NULL constitutively increased c-src kinase activity reconstituted the increases in migration and u-pa observed with angiotensin system interruption . NULL NULL 
0 c-src kinase activity reconstituted the increases in migration and u-pa observed with angiotensin system interruption . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL antisera to bovine u-pa blocked the increase in migration associated with increased c-src expression . 
0 NULL NULL NULL NULL antisera to bovine u-pa blocked the increase in migration associated with increased c-src expression . NULL NULL 
0 NULL NULL antisera to bovine u-pa blocked the increase in migration associated with increased c-src expression . NULL NULL NULL NULL 
0 NULL antisera to bovine u-pa blocked the increase in migration associated with increased c-src expression . NULL NULL NULL NULL NULL 
17 to bovine u-pa blocked the increase in migration associated with increased c-src expression . NULL NULL NULL NULL NULL NULL NULL 
9 u-pa blocked the increase in migration associated with increased c-src expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL these data suggest that increases in endothelial cell migration and plasminogen activator after angiotensin system 
14 NULL NULL these data suggest that increases in endothelial cell migration and plasminogen activator after angiotensin system inhibition are at least 
0 data suggest that increases in endothelial cell migration and plasminogen activator after angiotensin system inhibition are at least partially pp60c-src mediated 
18 in endothelial cell migration and plasminogen activator after angiotensin system inhibition are at least partially pp60c-src mediated . NULL NULL NULL 
16 activator after angiotensin system inhibition are at least partially pp60c-src mediated . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL elevated c-src expression with angiotensin system inhibition may act to enhance 
9 NULL NULL NULL NULL NULL NULL NULL NULL elevated c-src expression with angiotensin system inhibition may act to enhance intimal wound 
18 NULL NULL NULL NULL elevated c-src expression with angiotensin system inhibition may act to enhance intimal wound closure and to reduce 
0 NULL NULL elevated c-src expression with angiotensin system inhibition may act to enhance intimal wound closure and to reduce luminal thrombogenicity 
0 elevated c-src expression with angiotensin system inhibition may act to enhance intimal wound closure and to reduce luminal thrombogenicity in vivo 
0 with angiotensin system inhibition may act to enhance intimal wound closure and to reduce luminal thrombogenicity in vivo . NULL NULL 
0 inhibition may act to enhance intimal wound closure and to reduce luminal thrombogenicity in vivo . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis 
3 NULL NULL NULL NULL NULL NULL cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic 
0 NULL NULL NULL NULL NULL cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue 
0 NULL NULL cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively 
17 cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form 
3 regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible 
0 and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1 . NULL NULL NULL NULL 
0 induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1 . NULL NULL NULL NULL NULL 
0 angiogenesis in nonischemic tissue by a constitutively active form of inducible factor 1 . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL understanding molecular mechanisms regulating angiogenesis may lead to novel therapies for ischemic disorders . 
3 NULL NULL NULL NULL NULL NULL understanding molecular mechanisms regulating angiogenesis may lead to novel therapies for ischemic disorders . NULL 
0 NULL NULL NULL NULL understanding molecular mechanisms regulating angiogenesis may lead to novel therapies for ischemic disorders . NULL NULL NULL 
0 NULL understanding molecular mechanisms regulating angiogenesis may lead to novel therapies for ischemic disorders . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inducible factor 1 ( hif-1 ) activates vascular endothelial growth factor 
17 NULL NULL NULL NULL hypoxia-inducible factor 1 ( hif-1 ) activates vascular endothelial growth factor ( vegf ) gene expression in 
0 NULL hypoxia-inducible factor 1 ( hif-1 ) activates vascular endothelial growth factor ( vegf ) gene expression in hypoxic/ischemic tissue . 
9 ) activates vascular endothelial growth factor ( vegf ) gene expression in hypoxic/ischemic tissue . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL in this study we demonstrate that exposure of primary cultures of cardiac and vascular cells to hypoxia 
0 to hypoxia or adca5 , an adenovirus encoding a constitutively active form of hif-1alpha , modulates the expression of genes encoding 
0 hypoxia or adca5 , an adenovirus encoding a constitutively active form of hif-1alpha , modulates the expression of genes encoding the 
16 an adenovirus encoding a constitutively active form of hif-1alpha , modulates the expression of genes encoding the angiogenic factors angiopoietin-1 ( 
9 encoding a constitutively active form of hif-1alpha , modulates the expression of genes encoding the angiogenic factors angiopoietin-1 ( angpt1 ) 
3 of hif-1alpha , modulates the expression of genes encoding the angiogenic factors angiopoietin-1 ( angpt1 ) , angpt2 , placental growth 
0 angiogenic factors angiopoietin-1 ( angpt1 ) , angpt2 , placental growth factor , and platelet-derived growth factor-b . NULL NULL NULL 
0 angpt1 ) , angpt2 , placental growth factor , and derived growth factor-b . NULL NULL NULL NULL NULL NULL NULL 
0 ) , angpt2 , placental growth factor , and platelet-derived growth factor-b . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL loss effects were also observed in hif-1alpha-null embryonic stem cells . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL function effects were also observed in hif-1alpha-null embryonic stem cells . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL loss-of-function effects were also observed in hif-1alpha-null embryonic stem cells . NULL 
0 NULL NULL NULL NULL NULL NULL loss-of-function effects were also observed in hif-1alpha-null embryonic stem cells . NULL NULL NULL NULL 
0 NULL NULL NULL NULL loss-of-function effects were also observed in null embryonic stem cells . NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL depending on the cell type , expression of angpt1 and angpt2 was either activated or repressed in 
17 cell type , expression of angpt1 and angpt2 was either activated or repressed in response to hypoxia or adca5 . NULL 
0 of angpt1 and angpt2 was either activated or repressed in response to hypoxia or adca5 . NULL NULL NULL NULL NULL 
0 in all cases , there was complete concordance between the effects of hypoxia and adca5 . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL injection of adca5 into mouse eyes induced neovascularization in multiple capillary 
17 NULL NULL NULL NULL injection of adca5 into mouse eyes induced neovascularization in multiple capillary beds , including those not responsive 
3 NULL NULL NULL injection of adca5 into mouse eyes induced neovascularization in multiple capillary beds , including those not responsive to 
0 NULL NULL NULL NULL NULL NULL NULL analysis of gene expression revealed increased expression of angpt1 , angpt2 , platelet-derived growth 
17 NULL NULL NULL NULL NULL analysis of gene expression revealed increased expression of angpt1 , angpt2 , platelet-derived growth factor-b , 
10 NULL NULL NULL NULL analysis of gene expression revealed increased expression of angpt1 , angpt2 , platelet-derived growth factor-b , placental 
0 gene expression revealed increased expression of angpt1 , angpt2 , derived growth factor-b , placental growth factor , and vegf mrna 
0 expression revealed increased expression of angpt1 , angpt2 , platelet-derived growth factor-b , placental growth factor , and vegf mrna in 
0 of angpt1 , angpt2 , platelet-derived growth factor-b , placental growth factor , and vegf mrna in adca5-injected eyes . NULL 
0 platelet-derived growth factor-b , placental growth factor , and vegf mrna in adca5-injected eyes . NULL NULL NULL NULL NULL NULL 
19 factor-b , placental growth factor , and vegf mrna in injected eyes . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results indicate that hif-1 functions as a master regulator of angiogenesis 
0 NULL NULL NULL NULL NULL these results indicate that hif-1 functions as a master regulator of angiogenesis by controlling the expression 
16 NULL these results indicate that hif-1 functions as a master regulator of angiogenesis by controlling the expression of multiple angiogenic growth 
3 results indicate that hif-1 functions as a master regulator of angiogenesis by controlling the expression of multiple angiogenic growth factors and 
16 that hif-1 functions as a master regulator of angiogenesis by controlling the expression of multiple angiogenic growth factors and that adenovirus-mediated 
0 functions as a master regulator of angiogenesis by controlling the expression of multiple angiogenic growth factors and that adenovirus-mediated expression of 
3 master regulator of angiogenesis by controlling the expression of multiple angiogenic growth factors and that adenovirus-mediated expression of a constitutively active 
0 regulator of angiogenesis by controlling the expression of multiple angiogenic growth factors and that adenovirus-mediated expression of a constitutively active form 
0 controlling the expression of multiple angiogenic growth factors and that mediated expression of a constitutively active form of hif-1alpha is sufficient 
9 the expression of multiple angiogenic growth factors and that adenovirus-mediated expression of a constitutively active form of hif-1alpha is sufficient to 
0 angiogenic growth factors and that adenovirus-mediated expression of a constitutively active form of hif-1alpha is sufficient to induce angiogenesis in nonischemic 
0 growth factors and that adenovirus-mediated expression of a constitutively active form of hif-1alpha is sufficient to induce angiogenesis in nonischemic tissue 
0 adenovirus-mediated expression of a constitutively active form of hif-1alpha is sufficient to induce angiogenesis in nonischemic tissue of an adult animal 
17 of a constitutively active form of hif-1alpha is sufficient to induce angiogenesis in nonischemic tissue of an adult animal . NULL 
3 a constitutively active form of hif-1alpha is sufficient to induce angiogenesis in nonischemic tissue of an adult animal . NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL differential regulation of in vivo angiogenesis by angiotensin ii receptors . NULL 
3 NULL NULL NULL NULL NULL differential regulation of in vivo angiogenesis by angiotensin ii receptors . NULL NULL NULL NULL NULL 
0 NULL NULL angiotensin ii ( ang ii ) , a key regulator of blood pressure and body fluid homeostasis , exerts 
0 NULL angiotensin ii ( ang ii ) , a key regulator of blood pressure and body fluid homeostasis , exerts mitogenic 
16 of blood pressure and body fluid homeostasis , exerts mitogenic effects on endothelial cells . NULL NULL NULL NULL NULL NULL 
16 NULL we therefore hypothesized that ang ii could be a mediator between homeostatic changes within the vascular perfusion bed and growth 
16 hypothesized that ang ii could be a mediator between homeostatic changes within the vascular perfusion bed and growth factor-driven angiogenesis . 
0 could be a mediator between homeostatic changes within the vascular perfusion bed and growth factor-driven angiogenesis . NULL NULL NULL NULL 
0 mediator between homeostatic changes within the vascular perfusion bed and growth factor-driven angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 homeostatic changes within the vascular perfusion bed and growth factor-driven angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL in the present study , we applied the alginate implant angiogenesis model in 
3 in the present study , we applied the alginate implant angiogenesis model in mice with normal ang ii levels , elevated 
0 alginate implant angiogenesis model in mice with normal ang ii levels , elevated ang ii levels by transgenic overexpression of angiotensinogen 
17 angiogenesis model in mice with normal ang ii levels , elevated ang ii levels by transgenic overexpression of angiotensinogen ( aogen 
0 mice with normal ang ii levels , elevated ang ii levels by transgenic overexpression of angiotensinogen ( aogen ) , or 
0 normal ang ii levels , elevated ang ii levels by transgenic overexpression of angiotensinogen ( aogen ) , or in at2 
9 ang ii levels , elevated ang ii levels by transgenic overexpression of angiotensinogen ( aogen ) , or in at2 receptor-deficient 
9 overexpression of angiotensinogen ( aogen ) , or in at2 deficient mice . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL we demonstrate that a decrease in the amount of circulating ang ii by the angiotensin-converting 
0 NULL we demonstrate that a decrease in the amount of circulating ang ii by the angiotensin-converting enzyme ( ace ) inhibitor 
0 circulating ang ii by the angiotensin-converting enzyme ( ace ) inhibitor enalapril or the at1 receptor antagonist losartan induced a stimulation 
17 ace ) inhibitor enalapril or the at1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function 
17 inhibitor enalapril or the at1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ang 
3 at1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ang ii through the at1 
0 losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ang ii through the at1 receptor . NULL 
0 induced a stimulation of in vivo angiogenesis implying an inhibitory function of ang ii through the at1 receptor . NULL NULL 
17 NULL NULL NULL NULL NULL NULL however , the strong increase of angiogenesis in aogen-transgenic mice compared with mice with normal 
3 NULL NULL NULL NULL however , the strong increase of angiogenesis in aogen-transgenic mice compared with mice with normal ang ii 
0 NULL NULL however , the strong increase of angiogenesis in transgenic mice compared with mice with normal ang ii levels suggests 
0 in aogen-transgenic mice compared with mice with normal ang ii levels suggests additional stimulatory activity . NULL NULL NULL NULL NULL 
0 compared with mice with normal ang ii levels suggests additional stimulatory activity . NULL NULL NULL NULL NULL NULL NULL NULL 
0 with mice with normal ang ii levels suggests additional stimulatory activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL we showed that the ang ii-induced stimulation of angiogenesis is linked to 
17 NULL NULL NULL NULL NULL we showed that the ang induced stimulation of angiogenesis is linked to the at2 receptor as 
17 NULL NULL NULL NULL we showed that the ang ii-induced stimulation of angiogenesis is linked to the at2 receptor as an 
3 NULL NULL we showed that the ang ii-induced stimulation of angiogenesis is linked to the at2 receptor as an impaired induction 
0 we showed that the ang ii-induced stimulation of angiogenesis is linked to the at2 receptor as an impaired induction of angiogenesis 
18 of angiogenesis is linked to the at2 receptor as an impaired induction of angiogenesis was obtained in at2 receptor knockout mice 
17 angiogenesis is linked to the at2 receptor as an impaired induction of angiogenesis was obtained in at2 receptor knockout mice . 
3 linked to the at2 receptor as an impaired induction of angiogenesis was obtained in at2 receptor knockout mice . NULL NULL 
0 the at2 receptor as an impaired induction of angiogenesis was obtained in at2 receptor knockout mice . NULL NULL NULL NULL 
16 these findings provide the first evidence that the at2 receptor mediates a stimulation of in vivo angiogenesis and indicate that ang 
17 provide the first evidence that the at2 receptor mediates a stimulation of in vivo angiogenesis and indicate that ang ii is 
3 that the at2 receptor mediates a stimulation of in vivo angiogenesis and indicate that ang ii is a humoral regulator of 
0 vivo angiogenesis and indicate that ang ii is a humoral regulator of peripheral angiogenesis involving two receptor subtypes with opposing actions 
3 indicate that ang ii is a humoral regulator of peripheral angiogenesis involving two receptor subtypes with opposing actions . NULL NULL 
0 that ang ii is a humoral regulator of peripheral angiogenesis involving two receptor subtypes with opposing actions . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL levels of expression of cyr61 and ctgf are prognostic for tumor 
9 NULL NULL NULL NULL NULL NULL NULL NULL levels of expression of cyr61 and ctgf are prognostic for tumor progression and 
0 levels of expression of cyr61 and ctgf are prognostic for tumor progression and survival of individuals with gliomas . NULL NULL 
2 of expression of cyr61 and ctgf are prognostic for tumor progression and survival of individuals with gliomas . NULL NULL NULL 
5 of cyr61 and ctgf are prognostic for tumor progression and survival of individuals with gliomas . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the biological properties of ccn proteins include stimulation of cell proliferation , migration 
17 NULL NULL NULL the biological properties of ccn proteins include stimulation of cell proliferation , migration , and adhesion , as 
1 the biological properties of ccn proteins include stimulation of cell proliferation , migration , and adhesion , as well as angiogenesis 
14 properties of ccn proteins include stimulation of cell proliferation , migration , and adhesion , as well as angiogenesis and tumorigenesis 
15 proteins include stimulation of cell proliferation , migration , and adhesion , as well as angiogenesis and tumorigenesis . NULL NULL 
3 proliferation , migration , and adhesion , as well as angiogenesis and tumorigenesis . NULL NULL NULL NULL NULL NULL NULL 
0 we quantified cyr61 , ctgf , wisp-1 , and nov mrna expression levels in samples from sixty-six primary gliomas and five 
10 quantified cyr61 , ctgf , wisp-1 , and nov mrna expression levels in samples from sixty-six primary gliomas and five normal 
0 cyr61 , ctgf , wisp-1 , and nov mrna expression levels in samples from sixty-six primary gliomas and five normal brain 
9 NULL statistical analysis was performed to explore the links between expression of the ccn genes and clinical and pathological parameters . 
0 explore the links between expression of the ccn genes and clinical and pathological parameters . NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL overexpression of cyr61 , ctgf , wisp-1 , and nov occurred 
0 NULL NULL NULL NULL NULL NULL NULL NULL interestingly , significant associations were found between cyr61 expression versus tumor grade , 
9 NULL NULL interestingly , significant associations were found between cyr61 expression versus tumor grade , pathology , gender , and age 
0 interestingly , significant associations were found between cyr61 expression versus tumor grade , pathology , gender , and age at diagnosis 
0 NULL NULL NULL NULL NULL NULL NULL also , a significant correlation existed between ctgf mrna levels versus tumor grade , 
0 NULL NULL also , a significant correlation existed between ctgf mrna levels versus tumor grade , gender , and pathology . 
0 NULL also , a significant correlation existed between ctgf mrna levels versus tumor grade , gender , and pathology . NULL 
0 , a significant correlation existed between ctgf mrna levels versus tumor grade , gender , and pathology . NULL NULL NULL 
0 NULL NULL in contrast to cyr61 and ctgf , no significant association was found between expression of either wisp-1 or nov 
0 NULL in contrast to cyr61 and ctgf , no significant association was found between expression of either wisp-1 or nov versus 
9 cyr61 and ctgf , no significant association was found between expression of either wisp-1 or nov versus any of the pathological 
0 NULL NULL NULL NULL NULL NULL NULL furthermore , cox regression analysis showed that cyr61 and ctgf expression had a significant 
0 NULL NULL NULL NULL NULL furthermore , cox regression analysis showed that cyr61 and ctgf expression had a significant correlation with 
9 furthermore , cox regression analysis showed that cyr61 and ctgf expression had a significant correlation with patient survival . NULL NULL 
0 regression analysis showed that cyr61 and ctgf expression had a significant correlation with patient survival . NULL NULL NULL NULL NULL 
5 cyr61 and ctgf expression had a significant correlation with patient survival . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results suggest that cyr61 and ctgf may play a role in 
16 NULL NULL these results suggest that cyr61 and ctgf may play a role in the progression of gliomas ; their levels 
16 these results suggest that cyr61 and ctgf may play a role in the progression of gliomas ; their levels at diagnosis 
2 that cyr61 and ctgf may play a role in the progression of gliomas ; their levels at diagnosis may have prognostic 
0 play a role in the progression of gliomas ; their levels at diagnosis may have prognostic significance ; and these proteins 
0 prognostic significance ; and these proteins might serve as valuable targets for therapeutic intervention . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL oxygen metabolism has an important role in the pathogenesis of rheumatoid arthritis . NULL NULL 
0 NULL NULL NULL NULL NULL oxygen metabolism has an important role in the pathogenesis of rheumatoid arthritis . NULL NULL NULL 
0 NULL NULL oxygen metabolism has an important role in the pathogenesis of rheumatoid arthritis . NULL NULL NULL NULL NULL NULL 
8 NULL NULL NULL NULL reactive oxygen species ( ros ) produced in the course of cellular oxidative phosphorylation , and by 
0 ( ros ) produced in the course of cellular oxidative phosphorylation , and by activated phagocytic cells during oxidative bursts , 
17 in the course of cellular oxidative phosphorylation , and by activated phagocytic cells during oxidative bursts , exceed the physiological buffering 
8 NULL NULL NULL NULL NULL NULL NULL NULL the excessive production of ros can damage protein , lipids , nucleic acids 
11 NULL NULL NULL NULL the excessive production of ros can damage protein , lipids , nucleic acids , and matrix components 
6 NULL NULL NULL NULL the excessive production of ros can damage protein , lipids , nucleic acids , and matrix components 
0 NULL NULL NULL the excessive production of ros can damage protein , lipids , nucleic acids , and matrix components . 
0 can damage protein , lipids , nucleic acids , and matrix components . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL they also serve as important intracellular signaling molecules that amplify the synovial inflammatory-proliferative response . 
0 serve as important intracellular signaling molecules that amplify the synovial proliferative response . NULL NULL NULL NULL NULL NULL NULL NULL 
0 as important intracellular signaling molecules that amplify the synovial inflammatory-proliferative response . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL repetitive cycles of hypoxia and reoxygenation associated with changes in synovial perfusion are postulated to activate hypoxia-inducible 
0 NULL NULL repetitive cycles of hypoxia and reoxygenation associated with changes in synovial perfusion are postulated to activate hypoxia-inducible factor-1alpha and 
19 cycles of hypoxia and reoxygenation associated with changes in synovial perfusion are postulated to activate hypoxia-inducible factor-1alpha and nuclear factor-kappab , 
17 reoxygenation associated with changes in synovial perfusion are postulated to activate hypoxia-inducible factor-1alpha and nuclear factor-kappab , two key transcription factors 
0 associated with changes in synovial perfusion are postulated to activate inducible factor-1alpha and nuclear factor-kappab , two key transcription factors that 
0 postulated to activate hypoxia-inducible factor-1alpha and nuclear factor-kappab , two key transcription factors that are regulated by changes in cellular oxygenation 
0 to activate hypoxia-inducible factor-1alpha and nuclear factor-kappab , two key transcription factors that are regulated by changes in cellular oxygenation and 
16 and nuclear factor-kappab , two key transcription factors that are regulated by changes in cellular oxygenation and cytokine stimulation , and 
0 factor-kappab , two key transcription factors that are regulated by changes in cellular oxygenation and cytokine stimulation , and that in 
0 that are regulated by changes in cellular oxygenation and cytokine stimulation , and that in turn orchestrate the expression of a 
0 and cytokine stimulation , and that in turn orchestrate the expression of a spectrum of genes critical to the persistence of 
0 in turn orchestrate the expression of a spectrum of genes critical to the persistence of synovitis . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL an understanding of the complex interactions involved in these pathways might allow the development of novel 
0 NULL NULL NULL NULL an understanding of the complex interactions involved in these pathways might allow the development of novel therapeutic 
0 NULL an understanding of the complex interactions involved in these pathways might allow the development of novel therapeutic strategies for rheumatoid 
0 the complex interactions involved in these pathways might allow the development of novel therapeutic strategies for rheumatoid arthritis . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL intrauterine growth restriction ( iugr ) still accounts for a large incidence 
0 NULL NULL NULL NULL many of the circulatory and transport properties of the sheep placenta are similar to those of the 
0 sheep offers an excellent model in which to study the development of iugr . NULL NULL NULL NULL NULL NULL NULL 
0 two natural models of ovine iugr are those of hyperthermic exposure during pregnancy , and adolescent overfeeding , also during pregnancy 
18 NULL NULL NULL NULL NULL NULL both models yield significantly reduced placental weights and an asymmetrically growth-restricted fetus , and display 
4 both models yield significantly reduced placental weights and an asymmetrically growth fetus , and display altered maternal hormone concentrations , indicative 
18 both models yield significantly reduced placental weights and an asymmetrically restricted fetus , and display altered maternal hormone concentrations , indicative 
0 placental weights and an asymmetrically growth-restricted fetus , and display altered maternal hormone concentrations , indicative of an impaired trophoblast capacity 
18 and display altered maternal hormone concentrations , indicative of an impaired trophoblast capacity . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL additionally , impaired placental angiogenesis and uteroplacental blood flow appears to be an 
3 NULL NULL NULL NULL NULL NULL additionally , impaired placental angiogenesis and uteroplacental blood flow appears to be an early defect 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL the effects of these alterations in placental functional development appear to be 
16 NULL NULL NULL NULL NULL NULL the effects of these alterations in placental functional development appear to be irreversible . NULL 
2 NULL NULL the effects of these alterations in placental functional development appear to be irreversible . NULL NULL NULL NULL NULL 
18 iugr fetuses are both hypoxic and hypoglycaemic , and have reduced insulin and insulin-like growth factor-1 ( igf-1 ) , and 
0 hypoxic and hypoglycaemic , and have reduced insulin and insulin-like growth factor-1 ( igf-1 ) , and elevated concentrations of lactate 
17 insulin and insulin-like growth factor-1 ( igf-1 ) , and elevated concentrations of lactate . NULL NULL NULL NULL NULL NULL 
0 , on a weight basis , remain constant compared with control pregnancies . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL maintained utilization of these substrates , in a substrate-deficient environment , 
0 NULL NULL maintained utilization of these substrates , in a deficient environment , suggests increased sensitivities to metabolic signals , which 
0 of these substrates , in a substrate-deficient environment , suggests increased sensitivities to metabolic signals , which may play a role 
0 in a substrate-deficient environment , suggests increased sensitivities to metabolic signals , which may play a role in the development of 
0 , suggests increased sensitivities to metabolic signals , which may play a role in the development of metabolic diseases in later 
0 increased sensitivities to metabolic signals , which may play a role in the development of metabolic diseases in later adult life 
0 metabolic signals , which may play a role in the development of metabolic diseases in later adult life . NULL NULL 
16 NULL randomized , open label , prospective study on the effect of zoledronic acid on the prevention of bone metastases in 
18 prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that 
0 the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present 
0 metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline . NULL NULL NULL NULL 
0 with recurrent solid tumors that did not present with bone metastases at baseline . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL objectives : bisphosphonates have been used successfully in the treatment of hypercalcemia and to reduce skeletal-related 
19 NULL objectives : bisphosphonates have been used successfully in the treatment of hypercalcemia and to reduce skeletal-related complications of bone metastases 
0 been used successfully in the treatment of hypercalcemia and to reduce skeletal-related complications of bone metastases . NULL NULL NULL NULL 
0 treatment of hypercalcemia and to reduce skeletal-related complications of bone metastases . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 and in vivo evidence suggest that they may also have direct antitumor effects via induction of apoptosis , inhibition of the 
0 vivo evidence suggest that they may also have direct antitumor effects via induction of apoptosis , inhibition of the invasive potential 
0 suggest that they may also have direct antitumor effects via induction of apoptosis , inhibition of the invasive potential of tumor 
0 they may also have direct antitumor effects via induction of apoptosis , inhibition of the invasive potential of tumor cell lines 
18 also have direct antitumor effects via induction of apoptosis , inhibition of the invasive potential of tumor cell lines in vitro 
0 effects via induction of apoptosis , inhibition of the invasive potential of tumor cell lines in vitro , inhibition of angiogenesis 
0 induction of apoptosis , inhibition of the invasive potential of tumor cell lines in vitro , inhibition of angiogenesis , and 
18 the invasive potential of tumor cell lines in vitro , inhibition of angiogenesis , and reduction in tumor growth indirectly via 
3 potential of tumor cell lines in vitro , inhibition of angiogenesis , and reduction in tumor growth indirectly via effects on 
18 cell lines in vitro , inhibition of angiogenesis , and reduction in tumor growth indirectly via effects on accessory cells . 
0 in vitro , inhibition of angiogenesis , and reduction in tumor growth indirectly via effects on accessory cells . NULL NULL 
4 vitro , inhibition of angiogenesis , and reduction in tumor growth indirectly via effects on accessory cells . NULL NULL NULL 
0 of angiogenesis , and reduction in tumor growth indirectly via effects on accessory cells . NULL NULL NULL NULL NULL NULL 
16 randomized , open label , prospective study that examined the effect of preventive zoledronic acid treatment on the development of bone 
19 prospective study that examined the effect of preventive zoledronic acid treatment on the development of bone metastases in patients with recurrent 
2 examined the effect of preventive zoledronic acid treatment on the development of bone metastases in patients with recurrent solid tumors , 
0 of preventive zoledronic acid treatment on the development of bone metastases in patients with recurrent solid tumors , without bone metastases 
0 metastases in patients with recurrent solid tumors , without bone metastases at the time of randomization . NULL NULL NULL NULL 
0 NULL NULL NULL methods : forty patients with recurrent or metastatic advanced cancer , without bone metastases , were randomized into 
0 patients with recurrent or metastatic advanced cancer , without bone metastases , were randomized into the trial to either receive zoledronic 
19 into the trial to either receive zoledronic acid or no treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL patients were followed up until bone metastases were established . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL patients were followed up until bone metastases were established . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : the percentage of patients being bone metastases free at 
0 NULL NULL results : the percentage of patients being bone metastases free at 12 mo was 60 % in the zoledronic 
0 NULL results : the percentage of patients being bone metastases free at 12 mo was 60 % in the zoledronic acid 
0 % in the zoledronic acid and 10 % in the control group ( p less than 0.0005 ) , while the 
0 NULL NULL NULL NULL NULL NULL NULL conclusions : the results have shown that bisphosphonates as adjuvant treatment might be useful 
19 conclusions : the results have shown that bisphosphonates as adjuvant treatment might be useful for the prevention of bone metastases ; 
18 that bisphosphonates as adjuvant treatment might be useful for the prevention of bone metastases ; however , there is need for 
0 adjuvant treatment might be useful for the prevention of bone metastases ; however , there is need for blinded randomized data 
19 NULL NULL NULL NULL NULL NULL in the meantime preventive use of bisphosphonates in patients without any bone metastases should not 
0 meantime preventive use of bisphosphonates in patients without any bone metastases should not be used outside the scope of a clinical 
0 bisphosphonates in patients without any bone metastases should not be used outside the scope of a clinical trial . NULL NULL 
0 metastases should not be used outside the scope of a clinical trial . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL impaired coronary collateral vessel development in patients with proliferative diabetic retinopathy 
2 NULL NULL NULL NULL NULL NULL impaired coronary collateral vessel development in patients with proliferative diabetic retinopathy . NULL NULL NULL 
0 NULL NULL impaired coronary collateral vessel development in patients with proliferative diabetic retinopathy . NULL NULL NULL NULL NULL NULL NULL 
0 NULL background : diabetic patients have been reported to have impaired coronary collateral vessel growth , although they have excessive neovascularization 
4 patients have been reported to have impaired coronary collateral vessel growth , although they have excessive neovascularization in the retina . 
3 impaired coronary collateral vessel growth , although they have excessive neovascularization in the retina . NULL NULL NULL NULL NULL NULL 
0 compare coronary collateral circulation ( ccc ) in patients with proliferative diabetic retinopathy ( pdr ) with that in patients without 
0 diabetic patients with chronic total occlusion in at least one major epicardial coronary artery were enrolled in the study . NULL 
0 NULL NULL NULL NULL NULL NULL NULL serum vascular endothelial growth factor ( vegf ) levels were measured using the enzyme-linked 
0 NULL NULL serum vascular endothelial growth factor ( vegf ) levels were measured using the enzyme-linked immunosorbent assay ( elisa ) 
0 growth factor ( vegf ) levels were measured using the linked immunosorbent assay ( elisa ) kit . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : the mean rentrop collateral score was higher in group 
0 NULL NULL NULL NULL NULL NULL NULL NULL serum vegf levels were higher in patients with pdr than in those without 
0 , patients with poor and good ccc had similar vegf levels . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 findings have suggested that diabetes mellitus may have a different action on retinal and coronary circulation . NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL mechanisms of pericyte recruitment in tumour angiogenesis : a new role for metalloproteinases . 
3 NULL NULL NULL NULL mechanisms of pericyte recruitment in tumour angiogenesis : a new role for metalloproteinases . NULL NULL NULL 
0 mechanisms of pericyte recruitment in tumour angiogenesis : a new role for metalloproteinases . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL pericytes occur in tumour blood vessels and are critical for the development of a functional vascular network . NULL 
2 occur in tumour blood vessels and are critical for the development of a functional vascular network . NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL targeting tumour pericytes is a promising anti-angiogenic therapy but requires identifying 
3 NULL NULL NULL NULL targeting tumour pericytes is a promising angiogenic therapy but requires identifying the mechanisms of their recruitment in 
18 NULL NULL NULL targeting tumour pericytes is a promising anti-angiogenic therapy but requires identifying the mechanisms of their recruitment in tumour 
0 NULL targeting tumour pericytes is a promising anti-angiogenic therapy but requires identifying the mechanisms of their recruitment in tumour and addressing 
14 promising anti-angiogenic therapy but requires identifying the mechanisms of their recruitment in tumour and addressing whether these mechanisms can be selectively 
0 NULL NULL NULL NULL NULL NULL NULL NULL among the pathways involved in pericyte recruitment during embryonic development , the contribution 
0 NULL NULL NULL NULL NULL NULL NULL among the pathways involved in pericyte recruitment during embryonic development , the contribution of 
14 NULL NULL NULL NULL among the pathways involved in pericyte recruitment during embryonic development , the contribution of platelet-derived growth factor 
0 NULL among the pathways involved in pericyte recruitment during embryonic development , the contribution of platelet-derived growth factor b and sphingosine 
16 pathways involved in pericyte recruitment during embryonic development , the contribution of platelet-derived growth factor b and sphingosine 1-phosphate is confirmed 
0 in pericyte recruitment during embryonic development , the contribution of derived growth factor b and sphingosine 1-phosphate is confirmed in tumour 
0 pericyte recruitment during embryonic development , the contribution of platelet-derived growth factor b and sphingosine 1-phosphate is confirmed in tumour angiogenesis 
3 growth factor b and sphingosine 1-phosphate is confirmed in tumour angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the effect of angiopoietin 1 depends on the tumour model . NULL 
0 NULL NULL NULL NULL NULL the effect of angiopoietin 1 depends on the tumour model . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL transforming growth factor-beta1 enhances tumour vascularization and microvessel maturation . NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL transforming growth factor-beta1 enhances tumour vascularization and microvessel maturation . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL transforming growth factor-beta1 enhances tumour vascularization and microvessel maturation . NULL NULL NULL NULL NULL NULL 
2 NULL NULL transforming growth factor-beta1 enhances tumour vascularization and microvessel maturation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL recent reports suggest a participation of matrix metalloproteinases ( mmp ) in tumour pericyte recruitment that is 
14 participation of matrix metalloproteinases ( mmp ) in tumour pericyte recruitment that is consistent with the effect of certain mmps in 
16 ) in tumour pericyte recruitment that is consistent with the effect of certain mmps in the development of microvasculature in embryonic 
2 is consistent with the effect of certain mmps in the development of microvasculature in embryonic development and in in vitro models 
0 of certain mmps in the development of microvasculature in embryonic development and in in vitro models of vascular remodelling . NULL 
17 NULL here , we discuss the possibility for mmps to contribute to pericyte recruitment at six levels : ( 1 ) 
14 we discuss the possibility for mmps to contribute to pericyte recruitment at six levels : ( 1 ) direct promotion of 
0 possibility for mmps to contribute to pericyte recruitment at six levels : ( 1 ) direct promotion of pericyte invasion by 
0 to pericyte recruitment at six levels : ( 1 ) direct promotion of pericyte invasion by extracellular matrix degradation ; ( 
17 pericyte recruitment at six levels : ( 1 ) direct promotion of pericyte invasion by extracellular matrix degradation ; ( 2 
14 six levels : ( 1 ) direct promotion of pericyte invasion by extracellular matrix degradation ; ( 2 ) stimulation of 
0 ( 1 ) direct promotion of pericyte invasion by extracellular matrix degradation ; ( 2 ) stimulation of pericyte proliferation and 
6 1 ) direct promotion of pericyte invasion by extracellular matrix degradation ; ( 2 ) stimulation of pericyte proliferation and protection 
17 pericyte invasion by extracellular matrix degradation ; ( 2 ) stimulation of pericyte proliferation and protection against apoptosis by modification of 
1 extracellular matrix degradation ; ( 2 ) stimulation of pericyte proliferation and protection against apoptosis by modification of the ecm ; 
0 degradation ; ( 2 ) stimulation of pericyte proliferation and protection against apoptosis by modification of the ecm ; ( 3 
0 ( 2 ) stimulation of pericyte proliferation and protection against apoptosis by modification of the ecm ; ( 3 ) activation 
17 apoptosis by modification of the ecm ; ( 3 ) activation of pericytes through the release of growth factor bound to 
0 ecm ; ( 3 ) activation of pericytes through the release of growth factor bound to the ecm ; ( 4 
0 ( 3 ) activation of pericytes through the release of growth factor bound to the ecm ; ( 4 ) transactivation 
15 ) activation of pericytes through the release of growth factor bound to the ecm ; ( 4 ) transactivation of angiogenic 
3 bound to the ecm ; ( 4 ) transactivation of angiogenic cell surface receptor ; ( 5 ) propagation of angiogenic 
3 angiogenic cell surface receptor ; ( 5 ) propagation of angiogenic signalling as cofactor ; and ( 6 ) recruitment of 
14 of angiogenic signalling as cofactor ; and ( 6 ) recruitment of bone marrow-derived stem cells . NULL NULL NULL NULL 
0 as cofactor ; and ( 6 ) recruitment of bone derived stem cells . NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL NULL ectopic localization of mitochondrial atp synthase : a target for anti-angiogenesis intervention 
16 NULL NULL ectopic localization of mitochondrial atp synthase : a target for anti-angiogenesis intervention ? NULL NULL NULL NULL NULL NULL 
3 ectopic localization of mitochondrial atp synthase : a target for angiogenesis intervention ? NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL this ectopic atp synthase catalyzes atp synthesis and is inhibited by angiostatin over a wide 
8 NULL NULL NULL NULL this ectopic atp synthase catalyzes atp synthesis and is inhibited by angiostatin over a wide ph range 
18 NULL this ectopic atp synthase catalyzes atp synthesis and is inhibited by angiostatin over a wide ph range . NULL NULL 
1 NULL NULL NULL NULL NULL NULL NULL NULL endothelial cells grown at normal ph suffer no ill effects from this angiostatin-mediated 
0 NULL endothelial cells grown at normal ph suffer no ill effects from this angiostatin-mediated inhibition of atp synthase , whereas endothelial 
0 grown at normal ph suffer no ill effects from this mediated inhibition of atp synthase , whereas endothelial cells grown at 
18 at normal ph suffer no ill effects from this angiostatin-mediated inhibition of atp synthase , whereas endothelial cells grown at low 
1 this angiostatin-mediated inhibition of atp synthase , whereas endothelial cells grown at low , tumor-like extracellular ph can not maintain a 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL angiostatin inhibits both atp synthesis and atp hydrolysis ( moser et al. 
8 NULL NULL NULL NULL NULL NULL angiostatin inhibits both atp synthesis and atp hydrolysis ( moser et al. , 2001 ) 
11 NULL NULL NULL angiostatin inhibits both atp synthesis and atp hydrolysis ( moser et al. , 2001 ) and interferes with 
0 et al. , 2001 ) and interferes with intracellular ph regulation ( wahl and grant , 2002 ; wahl et al. 
19 NULL NULL NULL NULL NULL NULL NULL NULL although angiostatin administered intravenously is cleared from the circulation in a matter of 
0 matter of minutes , angiostatin-mimetics that are more stable have potential for clinical application . NULL NULL NULL NULL NULL NULL 
0 minutes , angiostatin-mimetics that are more stable have potential for clinical application . NULL NULL NULL NULL NULL NULL NULL NULL 
0 , angiostatin-mimetics that are more stable have potential for clinical application . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL an angiostatin-mimetic activity has recently been observed using a polyclonal antibody against the 
0 NULL NULL NULL NULL an angiostatin-mimetic activity has recently been observed using a polyclonal antibody against the beta catalytic subunit of 
0 NULL NULL NULL NULL NULL in order to explore the mechanism of action of angiostatin and its mimetics , further work 
0 NULL NULL NULL in order to explore the mechanism of action of angiostatin and its mimetics , further work needs to 
0 mimetics , further work needs to be done to evaluate clinical applicability , specificity , and contraindications for this class of 
16 NULL NULL NULL NULL NULL NULL NULL prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction . NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction . NULL NULL NULL NULL 
16 NULL NULL NULL NULL prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction . NULL NULL NULL NULL NULL NULL 
17 transmembrane peptidase prostate-specific membrane antigen ( psma ) is universally upregulated in the vasculature of solid tumors , but its functional 
16 in the vasculature of solid tumors , but its functional role in tumor angiogenesis has not been investigated . NULL NULL 
0 vasculature of solid tumors , but its functional role in tumor angiogenesis has not been investigated . NULL NULL NULL NULL 
3 of solid tumors , but its functional role in tumor angiogenesis has not been investigated . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL here we show that angiogenesis is severely impaired in psma-null animals and that this angiogenic 
18 NULL NULL NULL here we show that angiogenesis is severely impaired in psma-null animals and that this angiogenic defect occurs at 
0 NULL here we show that angiogenesis is severely impaired in null animals and that this angiogenic defect occurs at the level 
3 angiogenesis is severely impaired in psma-null animals and that this angiogenic defect occurs at the level of endothelial cell invasion through 
14 this angiogenic defect occurs at the level of endothelial cell invasion through the extracellular matrix barrier . NULL NULL NULL NULL 
0 at the level of endothelial cell invasion through the extracellular matrix barrier . NULL NULL NULL NULL NULL NULL NULL NULL 
6 NULL NULL NULL NULL NULL NULL NULL NULL because proteolytic degradation of the extracellular matrix is a critical component of endothelial 
0 NULL NULL NULL NULL because proteolytic degradation of the extracellular matrix is a critical component of endothelial invasion in angiogenesis , 
0 NULL because proteolytic degradation of the extracellular matrix is a critical component of endothelial invasion in angiogenesis , it is logical 
14 of the extracellular matrix is a critical component of endothelial invasion in angiogenesis , it is logical to assume that psma 
3 extracellular matrix is a critical component of endothelial invasion in angiogenesis , it is logical to assume that psma participates in 
0 , it is logical to assume that psma participates in matrix degradation . NULL NULL NULL NULL NULL NULL NULL NULL 
6 it is logical to assume that psma participates in matrix degradation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL however , we demonstrate a novel and more complex role for psma in angiogenesis , where it is a principal 
3 demonstrate a novel and more complex role for psma in angiogenesis , where it is a principal component of a regulatory 
0 angiogenesis , where it is a principal component of a regulatory loop that is tightly modulating laminin-specific integrin signaling and gtpase-dependent 
16 a principal component of a regulatory loop that is tightly modulating laminin-specific integrin signaling and gtpase-dependent , p21-activated kinase 1 ( 
0 regulatory loop that is tightly modulating laminin-specific integrin signaling and dependent , p21-activated kinase 1 ( pak-1 ) activity . NULL 
0 that is tightly modulating laminin-specific integrin signaling and gtpase-dependent , activated kinase 1 ( pak-1 ) activity . NULL NULL NULL 
0 signaling and gtpase-dependent , p21-activated kinase 1 ( pak-1 ) activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL we show that psma inhibition , knockdown , or deficiency decreases endothelial cell invasion in 
19 NULL NULL NULL NULL we show that psma inhibition , knockdown , or deficiency decreases endothelial cell invasion in vitro via 
9 NULL we show that psma inhibition , knockdown , or deficiency decreases endothelial cell invasion in vitro via integrin and pak 
18 we show that psma inhibition , knockdown , or deficiency decreases endothelial cell invasion in vitro via integrin and pak , 
16 we show that psma inhibition , knockdown , or deficiency decreases endothelial cell invasion in vitro via integrin and pak , 
14 psma inhibition , knockdown , or deficiency decreases endothelial cell invasion in vitro via integrin and pak , thus abrogating angiogenesis 
3 invasion in vitro via integrin and pak , thus abrogating angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 , the neutralization of beta ( 1 ) or the inactivation of pak increases psma activity , suggesting that they negatively 
17 of beta ( 1 ) or the inactivation of pak increases psma activity , suggesting that they negatively regulate psma . 
0 ( 1 ) or the inactivation of pak increases psma activity , suggesting that they negatively regulate psma . NULL NULL 
18 inactivation of pak increases psma activity , suggesting that they negatively regulate psma . NULL NULL NULL NULL NULL NULL NULL 
18 of pak increases psma activity , suggesting that they negatively regulate psma . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL this negative regulation is mediated by the cytoskeleton as the disruption of 
18 NULL NULL NULL NULL NULL NULL NULL NULL this negative regulation is mediated by the cytoskeleton as the disruption of interactions 
16 NULL NULL NULL NULL NULL NULL this negative regulation is mediated by the cytoskeleton as the disruption of interactions between the 
18 this negative regulation is mediated by the cytoskeleton as the disruption of interactions between the psma cytoplasmic tail and the anchor 
15 regulation is mediated by the cytoskeleton as the disruption of interactions between the psma cytoplasmic tail and the anchor protein filamin 
0 of interactions between the psma cytoplasmic tail and the anchor protein filamin a decreases psma activity , integrin function , and 
18 the psma cytoplasmic tail and the anchor protein filamin a decreases psma activity , integrin function , and pak activation . 
0 cytoplasmic tail and the anchor protein filamin a decreases psma activity , integrin function , and pak activation . NULL NULL 
0 the anchor protein filamin a decreases psma activity , integrin function , and pak activation . NULL NULL NULL NULL NULL 
17 a decreases psma activity , integrin function , and pak activation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL finally , the inhibition of pak activation enhances the psma/filamin a interaction and , 
17 NULL NULL NULL NULL finally , the inhibition of pak activation enhances the psma/filamin a interaction and , thus , boosts 
17 NULL NULL NULL finally , the inhibition of pak activation enhances the psma/filamin a interaction and , thus , boosts psma 
15 , the inhibition of pak activation enhances the psma/filamin a interaction and , thus , boosts psma activity . NULL NULL 
0 the psma/filamin a interaction and , thus , boosts psma activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 imply that psma participates in an autoregulatory loop , wherein active psma facilitates integrin signaling and pak activation , leading to 
17 psma participates in an autoregulatory loop , wherein active psma facilitates integrin signaling and pak activation , leading to both productive 
17 loop , wherein active psma facilitates integrin signaling and pak activation , leading to both productive invasion and downregulation of integrin 
17 wherein active psma facilitates integrin signaling and pak activation , leading to both productive invasion and downregulation of integrin beta ( 
0 integrin signaling and pak activation , leading to both productive invasion and downregulation of integrin beta ( 1 ) signaling via 
18 and pak activation , leading to both productive invasion and downregulation of integrin beta ( 1 ) signaling via reduced psma 
18 and downregulation of integrin beta ( 1 ) signaling via reduced psma activity . NULL NULL NULL NULL NULL NULL NULL 
0 of integrin beta ( 1 ) signaling via reduced psma activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL therefore , we have identified a novel role for psma as a true molecular interface , integrating both 
0 a true molecular interface , integrating both extracellular and intracellular signals during angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 molecular interface , integrating both extracellular and intracellular signals during angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL heparin immobilized porous plga microspheres for angiogenic growth factor delivery . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL heparin immobilized porous plga microspheres for angiogenic growth factor delivery . NULL NULL NULL NULL NULL NULL NULL 
0 NULL heparin immobilized porous plga microspheres for angiogenic growth factor delivery . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 acid ) ( plga ) microspheres were prepared for sustained release of basic fibroblast growth factor ( bfgf ) to induce 
0 ) microspheres were prepared for sustained release of basic fibroblast growth factor ( bfgf ) to induce angiogenesis . NULL NULL 
17 release of basic fibroblast growth factor ( bfgf ) to induce angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 of basic fibroblast growth factor ( bfgf ) to induce angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 the bfgf loaded plga-heparin microspheres were tested for in vitro release and in vivo angiogenic activity . NULL NULL NULL NULL 
3 microspheres were tested for in vitro release and in vivo angiogenic activity . NULL NULL NULL NULL NULL NULL NULL NULL 
0 were tested for in vitro release and in vivo angiogenic activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : plga microspheres with an open-porous structure were formed . 
0 NULL results : plga microspheres with an open-porous structure were formed . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL plga-heparin microspheres released out bfgf in a more sustained manner with a smaller 
0 a more sustained manner with a smaller extent of initial burst than plga microspheres , indicating that surface immobilized heparin controlled 
16 burst than plga microspheres , indicating that surface immobilized heparin controlled the release rate of bfgf . NULL NULL NULL NULL 
14 plga microspheres , indicating that surface immobilized heparin controlled the release rate of bfgf . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL subcutaneous implantation of bfgf loaded plga-heparin microspheres in mice significantly induced the 
17 subcutaneous implantation of bfgf loaded plga-heparin microspheres in mice significantly induced the formation of new vascular microvessels . NULL NULL NULL 
2 of bfgf loaded plga-heparin microspheres in mice significantly induced the formation of new vascular microvessels . NULL NULL NULL NULL NULL 
0 conclusions : plga microspheres with an open porous structure allowed significant amount of heparin immobilization and bfgf loading . NULL NULL 
0 NULL NULL NULL NULL NULL NULL bfgf loaded plga-hp microspheres showed sustained release profiles of bfgf in vitro , demonstrating reversible 
14 NULL NULL NULL NULL bfgf loaded plga-hp microspheres showed sustained release profiles of bfgf in vitro , demonstrating reversible and specific 
15 profiles of bfgf in vitro , demonstrating reversible and specific binding of bfgf to immobilized heparin . NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL they also induced local angiogenesis in vivo in an animal model . NULL 
3 NULL NULL NULL NULL NULL NULL they also induced local angiogenesis in vivo in an animal model . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the role of syndecans in disease and wound healing . NULL NULL 
9 syndecans are a family of transmembrane heparan sulfate proteoglycans widely expressed in both developing and adult tissues . NULL NULL NULL 
0 family of transmembrane heparan sulfate proteoglycans widely expressed in both developing and adult tissues . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL until recently , their role in pathogenesis was largely unexplored . NULL NULL NULL NULL 
0 NULL NULL NULL NULL until recently , their role in pathogenesis was largely unexplored . NULL NULL NULL NULL NULL NULL 
0 NULL NULL in this review , we discuss the reported involvement of syndecans in human cancers , infectious diseases , obesity 
3 cancers , infectious diseases , obesity , wound healing and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL in some cancers , syndecan expression has been shown to regulate tumor cell function ( e.g. 
16 in some cancers , syndecan expression has been shown to regulate tumor cell function ( e.g. proliferation , adhesion , and 
0 some cancers , syndecan expression has been shown to regulate tumor cell function ( e.g. proliferation , adhesion , and motility 
0 , syndecan expression has been shown to regulate tumor cell function ( e.g. proliferation , adhesion , and motility ) and 
1 has been shown to regulate tumor cell function ( e.g. proliferation , adhesion , and motility ) and serve as a 
15 shown to regulate tumor cell function ( e.g. proliferation , adhesion , and motility ) and serve as a prognostic marker 
14 tumor cell function ( e.g. proliferation , adhesion , and motility ) and serve as a prognostic marker for tumor progression 
0 and motility ) and serve as a prognostic marker for tumor progression and patient survival . NULL NULL NULL NULL NULL 
2 motility ) and serve as a prognostic marker for tumor progression and patient survival . NULL NULL NULL NULL NULL NULL 
5 serve as a prognostic marker for tumor progression and patient survival . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 ectodomains and heparan sulfate glycosaminoglycan chains of syndecans can also act as receptors/co-receptors for some bacterial and viral pathogens , mediating 
0 act as receptors/co-receptors for some bacterial and viral pathogens , mediating infection . NULL NULL NULL NULL NULL NULL NULL NULL 
0 as receptors/co-receptors for some bacterial and viral pathogens , mediating infection . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , syndecans bind to obesity-related factors and regulate their signaling 
15 NULL NULL NULL NULL NULL NULL in addition , syndecans bind to obesity-related factors and regulate their signaling , in turn 
0 NULL in addition , syndecans bind to obesity-related factors and regulate their signaling , in turn modulating food consumption and weight 
0 to obesity-related factors and regulate their signaling , in turn modulating food consumption and weight balance . NULL NULL NULL NULL 
0 tissue injury and in vitro data also implicate syndecans in processes necessary for wound healing , including fibroblast and endothelial proliferation 
1 processes necessary for wound healing , including fibroblast and endothelial proliferation , cell motility , angiogenesis , and extracellular matrix organization 
14 wound healing , including fibroblast and endothelial proliferation , cell motility , angiogenesis , and extracellular matrix organization . NULL NULL 
3 , including fibroblast and endothelial proliferation , cell motility , angiogenesis , and extracellular matrix organization . NULL NULL NULL NULL 
0 endothelial proliferation , cell motility , angiogenesis , and extracellular matrix organization . NULL NULL NULL NULL NULL NULL NULL NULL 
2 proliferation , cell motility , angiogenesis , and extracellular matrix organization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL these new insights into the involvement of syndecans in disease and tissue repair coupled with the 
7 insights into the involvement of syndecans in disease and tissue repair coupled with the emergence of syndecan-specific molecular tools may lead 
0 into the involvement of syndecans in disease and tissue repair coupled with the emergence of syndecan-specific molecular tools may lead to 
0 repair coupled with the emergence of syndecan-specific molecular tools may lead to novel therapies for a variety of human diseases . 
0 the emergence of syndecan-specific molecular tools may lead to novel therapies for a variety of human diseases . NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL role of the fibrinolytic and matrix metalloproteinase systems in development of 
0 NULL NULL NULL NULL NULL role of the fibrinolytic and matrix metalloproteinase systems in development of adipose tissue . NULL NULL 
2 NULL role of the fibrinolytic and matrix metalloproteinase systems in development of adipose tissue . NULL NULL NULL NULL NULL NULL 
0 atherosclerosis , hypertension , cardiovascular disease and cancer are a major cause of mortality and morbidity in western-type societies . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL development of obesity is associated with extensive modifications in adipose tissue 
0 NULL NULL NULL NULL NULL NULL development of obesity is associated with extensive modifications in adipose tissue involving adipogenesis , angiogenesis 
0 of obesity is associated with extensive modifications in adipose tissue involving adipogenesis , angiogenesis and extracellular matrix proteolysis . NULL NULL 
3 associated with extensive modifications in adipose tissue involving adipogenesis , angiogenesis and extracellular matrix proteolysis . NULL NULL NULL NULL NULL 
0 modifications in adipose tissue involving adipogenesis , angiogenesis and extracellular matrix proteolysis . NULL NULL NULL NULL NULL NULL NULL NULL 
6 in adipose tissue involving adipogenesis , angiogenesis and extracellular matrix proteolysis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL the fibrinolytic ( plasminogen/plasmin ) and matrix metalloproteinase ( mmp ) systems cooperate in these processes . 
0 and matrix metalloproteinase ( mmp ) systems cooperate in these processes . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL a nutritionally induced obesity model in transgenic mice has been used extensively to 
19 NULL NULL NULL NULL a nutritionally induced obesity model in transgenic mice has been used extensively to study the role of 
0 a nutritionally induced obesity model in transgenic mice has been used extensively to study the role of the fibrinolytic and mmp 
0 in transgenic mice has been used extensively to study the role of the fibrinolytic and mmp systems in the development of 
0 the role of the fibrinolytic and mmp systems in the development of obesity . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL these studies support a role of both systems in adipogenesis and obesity ; 
0 NULL NULL NULL NULL NULL NULL these studies support a role of both systems in adipogenesis and obesity ; the role 
0 role of both systems in adipogenesis and obesity ; the role of specific members of these families , however , remains 
18 NULL NULL NULL NULL NULL NULL recombinant human prothrombin kringle-2 inhibits b16f10 melanoma metastasis through inhibition of neovascularization and reduction of 
14 NULL NULL NULL recombinant human prothrombin kringle-2 inhibits b16f10 melanoma metastasis through inhibition of neovascularization and reduction of matrix metalloproteinase expression 
18 NULL recombinant human prothrombin kringle-2 inhibits b16f10 melanoma metastasis through inhibition of neovascularization and reduction of matrix metalloproteinase expression . NULL 
3 human prothrombin kringle-2 inhibits b16f10 melanoma metastasis through inhibition of neovascularization and reduction of matrix metalloproteinase expression . NULL NULL NULL 
18 kringle-2 inhibits b16f10 melanoma metastasis through inhibition of neovascularization and reduction of matrix metalloproteinase expression . NULL NULL NULL NULL NULL 
0 b16f10 melanoma metastasis through inhibition of neovascularization and reduction of matrix metalloproteinase expression . NULL NULL NULL NULL NULL NULL NULL 
9 metastasis through inhibition of neovascularization and reduction of matrix metalloproteinase expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis , a multi-step process which involves endothelial cell proliferation , 
0 NULL NULL NULL NULL angiogenesis , a multi-step process which involves endothelial cell proliferation , adhesion , migration , and basement 
1 NULL angiogenesis , a multi-step process which involves endothelial cell proliferation , adhesion , migration , and basement membrane ( bm 
15 , a multi-step process which involves endothelial cell proliferation , adhesion , migration , and basement membrane ( bm ) degradation 
14 multi-step process which involves endothelial cell proliferation , adhesion , migration , and basement membrane ( bm ) degradation , is 
6 adhesion , migration , and basement membrane ( bm ) degradation , is essential for tumor metastasis . NULL NULL NULL 
17 , and basement membrane ( bm ) degradation , is essential for tumor metastasis . NULL NULL NULL NULL NULL NULL 
0 basement membrane ( bm ) degradation , is essential for tumor metastasis . NULL NULL NULL NULL NULL NULL NULL NULL 
14 membrane ( bm ) degradation , is essential for tumor metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 we show that recombinant human prothrombin kringle-2 ( rk-2 ) inhibited bovine capillary endothelial cell migration with an ic ( 50 
14 prothrombin kringle-2 ( rk-2 ) inhibited bovine capillary endothelial cell migration with an ic ( 50 ) ( concentration for half 
0 an ic ( 50 ) ( concentration for half maximal inhibition ) of 38 nm and inhibited adhesion to extracellular matrix 
0 concentration for half maximal inhibition ) of 38 nm and inhibited adhesion to extracellular matrix ( ecm ) proteins . NULL 
0 for half maximal inhibition ) of 38 nm and inhibited adhesion to extracellular matrix ( ecm ) proteins . NULL NULL 
0 inhibition ) of 38 nm and inhibited adhesion to extracellular matrix ( ecm ) proteins . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL because tumor metastasis requires angiogenesis , we examined whether rk-2 could inhibit 
14 NULL NULL NULL NULL NULL NULL NULL NULL because tumor metastasis requires angiogenesis , we examined whether rk-2 could inhibit metastases 
17 NULL NULL NULL NULL NULL NULL NULL because tumor metastasis requires angiogenesis , we examined whether rk-2 could inhibit metastases induced 
3 NULL NULL NULL NULL NULL NULL because tumor metastasis requires angiogenesis , we examined whether rk-2 could inhibit metastases induced by 
18 tumor metastasis requires angiogenesis , we examined whether rk-2 could inhibit metastases induced by injection of b16f10 melanoma cells into mice 
0 metastasis requires angiogenesis , we examined whether rk-2 could inhibit metastases induced by injection of b16f10 melanoma cells into mice . 
17 requires angiogenesis , we examined whether rk-2 could inhibit metastases induced by injection of b16f10 melanoma cells into mice . NULL 
19 , we examined whether rk-2 could inhibit metastases induced by injection of b16f10 melanoma cells into mice . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the results revealed that the metastatic tumors in mouse lung were markedly 
14 NULL NULL NULL NULL NULL the results revealed that the metastatic tumors in mouse lung were markedly decreased in a dose-dependent 
18 revealed that the metastatic tumors in mouse lung were markedly decreased in a dose-dependent manner and acute lung injury induced by 
0 metastatic tumors in mouse lung were markedly decreased in a dependent manner and acute lung injury induced by b16f10 melanoma metastasis 
0 markedly decreased in a dose-dependent manner and acute lung injury induced by b16f10 melanoma metastasis was diminished by systemic rk-2 treatment 
14 dose-dependent manner and acute lung injury induced by b16f10 melanoma metastasis was diminished by systemic rk-2 treatment . NULL NULL NULL 
0 and acute lung injury induced by b16f10 melanoma metastasis was diminished by systemic rk-2 treatment . NULL NULL NULL NULL NULL 
19 induced by b16f10 melanoma metastasis was diminished by systemic rk-2 treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in immunohistochemical analysis , rk-2 reduced expression of vascular endothelial growth factor 
18 NULL NULL NULL NULL NULL in immunohistochemical analysis , rk-2 reduced expression of vascular endothelial growth factor , which is a 
9 NULL NULL NULL NULL in immunohistochemical analysis , rk-2 reduced expression of vascular endothelial growth factor , which is a potent 
0 in immunohistochemical analysis , rk-2 reduced expression of vascular endothelial growth factor , which is a potent angiogenic activator and neovascularization 
3 of vascular endothelial growth factor , which is a potent angiogenic activator and neovascularization in the mouse lung . NULL NULL 
0 vascular endothelial growth factor , which is a potent angiogenic activator and neovascularization in the mouse lung . NULL NULL NULL 
3 growth factor , which is a potent angiogenic activator and neovascularization in the mouse lung . NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL also , rk-2 diminished the expression of matrix metalloproteinase-2 and -9 in the mouse 
9 NULL NULL NULL NULL NULL also , rk-2 diminished the expression of matrix metalloproteinase-2 and -9 in the mouse lung which 
0 NULL NULL NULL also , rk-2 diminished the expression of matrix metalloproteinase-2 and -9 in the mouse lung which induces tumor 
17 of matrix metalloproteinase-2 and -9 in the mouse lung which induces tumor metastasis and angiogenesis . NULL NULL NULL NULL NULL 
0 matrix metalloproteinase-2 and -9 in the mouse lung which induces tumor metastasis and angiogenesis . NULL NULL NULL NULL NULL NULL 
14 metalloproteinase-2 and -9 in the mouse lung which induces tumor metastasis and angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 -9 in the mouse lung which induces tumor metastasis and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL these data suggest that inhibition of b16f10 melanoma metastasis by rk-2 was caused by inhibition 
14 NULL NULL these data suggest that inhibition of b16f10 melanoma metastasis by rk-2 was caused by inhibition of neovascularization and reduction 
17 suggest that inhibition of b16f10 melanoma metastasis by rk-2 was caused by inhibition of neovascularization and reduction of matrix metalloproteinase expression 
18 inhibition of b16f10 melanoma metastasis by rk-2 was caused by inhibition of neovascularization and reduction of matrix metalloproteinase expression . NULL 
3 b16f10 melanoma metastasis by rk-2 was caused by inhibition of neovascularization and reduction of matrix metalloproteinase expression . NULL NULL NULL 
18 metastasis by rk-2 was caused by inhibition of neovascularization and reduction of matrix metalloproteinase expression . NULL NULL NULL NULL NULL 
0 rk-2 was caused by inhibition of neovascularization and reduction of matrix metalloproteinase expression . NULL NULL NULL NULL NULL NULL NULL 
9 caused by inhibition of neovascularization and reduction of matrix metalloproteinase expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL extracellular matrix as a bioactive material for soft tissue reconstruction . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the extracellular matrix ( ecm ) directs all phases of healing following trauma 
0 a natural source of prosthetic mesh material that can be used strategically to induce the repair and restoration of soft tissues 
17 of prosthetic mesh material that can be used strategically to induce the repair and restoration of soft tissues following surgery . 
2 mesh material that can be used strategically to induce the repair and restoration of soft tissues following surgery . NULL NULL 
19 to induce the repair and restoration of soft tissues following surgery . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 west lafayette , in , usa ) , which are derived from natural ecm , provide the extracellular components necessary to 
0 from natural ecm , provide the extracellular components necessary to direct the healing response , allow for the proliferation of new 
0 , provide the extracellular components necessary to direct the healing response , allow for the proliferation of new , healthy tissue 
4 necessary to direct the healing response , allow for the proliferation of new , healthy tissue and restore tissue integrity to 
0 new , healthy tissue and restore tissue integrity to the damaged site . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the 3-d organization of these extracellular components distinguishes the surgisis mesh from synthetic 
0 components distinguishes the surgisis mesh from synthetic materials and is associated with constructive tissue remodelling instead of scar tissue . NULL 
3 NULL NULL common features of this ecm-assisted tissue remodelling include angiogenesis , recruitment of circulating progenitor cells and constructive remodelling of 
14 common features of this ecm-assisted tissue remodelling include angiogenesis , recruitment of circulating progenitor cells and constructive remodelling of damaged tissue 
0 of this ecm-assisted tissue remodelling include angiogenesis , recruitment of circulating progenitor cells and constructive remodelling of damaged tissue structures . 
0 , recruitment of circulating progenitor cells and constructive remodelling of damaged tissue structures . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the tissue response to this biologic mesh is discussed in the context of 
0 mesh is discussed in the context of recent reports on clinical hernia repair . NULL NULL NULL NULL NULL NULL NULL 
0 discussed in the context of recent reports on clinical hernia repair . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL [ study on the expression of angiogenesis and spontaneous apoptosis and their relevance in laryngeal 
3 NULL NULL NULL NULL [ study on the expression of angiogenesis and spontaneous apoptosis and their relevance in laryngeal squamous cell 
0 NULL [ study on the expression of angiogenesis and spontaneous apoptosis and their relevance in laryngeal squamous cell carcinoma ] NULL 
3 NULL NULL NULL objective : to investigate the relationship among angiogenesis , spontaneous apoptosis and clinicopathological parameters in laryngeal squamous cell 
0 objective : to investigate the relationship among angiogenesis , spontaneous apoptosis and clinicopathological parameters in laryngeal squamous cell carcinoma ( lscc 
0 ) , apoptotic index ( ai ) and vascular endothelial growth factor ( vegf ) expression were detected by immunohistochemistry sabc 
9 ai ) and vascular endothelial growth factor ( vegf ) expression were detected by immunohistochemistry sabc and terminal uridine deoxynucleotidyl transferase 
0 and vascular endothelial growth factor ( vegf ) expression were detected by immunohistochemistry sabc and terminal uridine deoxynucleotidyl transferase mediated nick 
0 were detected by immunohistochemistry sabc and terminal uridine deoxynucleotidyl transferase mediated nick end labeling ( tunel ) methods in34 lscc patients 
0 NULL NULL NULL NULL NULL NULL the average imvd in positive and negative cervical lymphatic metastasis was ( 26.33 +/- 9.70 
0 NULL NULL NULL NULL the average imvd in positive and negative cervical lymphatic metastasis was ( 26.33 +/- 9.70 ) and 
0 NULL the average imvd in positive and negative cervical lymphatic metastasis was ( 26.33 +/- 9.70 ) and ( 17.68 +/- 
0 17.68 +/- 6.06 ) respectively , and the imvd with positive lymphatic metastasis tumors was statistical significantly higher than those with 
0 6.06 ) respectively , and the imvd with positive lymphatic metastasis tumors was statistical significantly higher than those with negative cervical 
0 lymphatic metastasis tumors was statistical significantly higher than those with negative cervical lymphatic metastasis tumors ( p less than 0.01 ) 
0 was statistical significantly higher than those with negative cervical lymphatic metastasis tumors ( p less than 0.01 ) . NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL expression of vegf had a significantly positive correlation with imvd ( 
0 NULL NULL NULL NULL expression of vegf had a significantly positive correlation with imvd ( r = 0.51 , p less 
0 we failed to find the statistical difference between imvd and tumor t-stage in lscc . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL conclusion : imvd may be an important indicator to predict cervical lymphatic metastasis in lscc . NULL 
0 imvd may be an important indicator to predict cervical lymphatic metastasis in lscc . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL vegf might be an important angiogenic factor , and could promote tumor angiogenesis in lscc 
3 NULL NULL NULL NULL NULL vegf might be an important angiogenic factor , and could promote tumor angiogenesis in lscc . 
17 vegf might be an important angiogenic factor , and could promote tumor angiogenesis in lscc . NULL NULL NULL NULL NULL 
0 might be an important angiogenic factor , and could promote tumor angiogenesis in lscc . NULL NULL NULL NULL NULL NULL 
3 be an important angiogenic factor , and could promote tumor angiogenesis in lscc . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor angiogenesis might contribute to tumor malignant progression by inhibiting spontaneous 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor angiogenesis might contribute to tumor malignant progression by inhibiting spontaneous apoptosis 
16 NULL NULL NULL NULL NULL NULL NULL tumor angiogenesis might contribute to tumor malignant progression by inhibiting spontaneous apoptosis in lscc 
0 NULL NULL NULL NULL NULL tumor angiogenesis might contribute to tumor malignant progression by inhibiting spontaneous apoptosis in lscc . NULL 
0 NULL NULL NULL NULL tumor angiogenesis might contribute to tumor malignant progression by inhibiting spontaneous apoptosis in lscc . NULL NULL 
2 NULL NULL NULL tumor angiogenesis might contribute to tumor malignant progression by inhibiting spontaneous apoptosis in lscc . NULL NULL NULL 
18 NULL tumor angiogenesis might contribute to tumor malignant progression by inhibiting spontaneous apoptosis in lscc . NULL NULL NULL NULL NULL 
5 angiogenesis might contribute to tumor malignant progression by inhibiting spontaneous apoptosis in lscc . NULL NULL NULL NULL NULL NULL NULL 
0 imaging ( mri ) , and in particular , dynamic enhanced mri ( dce-mri ) , in the assessment of tumour 
3 by means of animal tumour models evaluated before and after angiogenic treatment . NULL NULL NULL NULL NULL NULL NULL NULL 
19 means of animal tumour models evaluated before and after antiangiogenic treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 with intravascular contrast media in 21 rats : tumours were induced by subcutaneous injection of colon carcinoma cells in 7 rats 
19 media in 21 rats : tumours were induced by subcutaneous injection of colon carcinoma cells in 7 rats and mammary adenocarcinoma 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL perfusion and permeability parameters of the implanted tumours were evaluated by 
19 NULL NULL NULL NULL perfusion and permeability parameters of the implanted tumours were evaluated by using two contrast media ( b22956/1 
0 two contrast media ( b22956/1 and gd-dtpa37-albumin ) to establish response to treatment with two different antiangiogenic drugs ( tamoxifen and 
19 media ( b22956/1 and gd-dtpa37-albumin ) to establish response to treatment with two different antiangiogenic drugs ( tamoxifen and su6668 ) 
3 gd-dtpa37-albumin ) to establish response to treatment with two different angiogenic drugs ( tamoxifen and su6668 ) . NULL NULL NULL 
0 NULL NULL NULL these parameters were correlated with histology to obtain a radiological-histological map of tumour microvasculature . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : dce-mri revealed greater enhancement in the peripheral area than 
0 NULL NULL NULL NULL NULL results : dce-mri revealed greater enhancement in the peripheral area than in the central area in 
0 revealed greater enhancement in the peripheral area than in the central area in all the examined animal models . NULL NULL 
0 vascular permeability measured by means of b22956/1 in the animals treated with the antiangiogenic drug ( 0.0043317+/-0.0040418 ml/min ( -1 ) 
3 by means of b22956/1 in the animals treated with the angiogenic drug ( 0.0043317+/-0.0040418 ml/min ( -1 ) /ml ( -1 
0 /ml ( -1 ) ) was significantly less than in untreated animals ( 0.0090460+/-0.0043680 ml/min ( -1 ) /ml ( -1 
0 -1 ) /ml ( -1 ) ) , whereas no significant difference was observed with gd-dtpa-albumin ( 13.14+/-13.94 ml/min ( -1 
0 ( -1 ) ) , whereas no significant difference was observed with gd-dtpa-albumin ( 13.14+/-13.94 ml/min ( -1 ) /ml ( 
19 13.14+/-13.94 ml/min ( -1 ) /ml ( -1 ) in treated animals and 18.07+/-11.92 ml/min ( -1 ) /ml ( -1 
0 18.07+/-11.92 ml/min ( -1 ) /ml ( -1 ) in untreated animals ) . NULL NULL NULL NULL NULL NULL NULL 
0 NULL in the colon carcinoma experiment , mean permeability and perfusion decreased by 51 % ( from 5.2+/-1.1 to 2.5+/-0.8 ml/100 
0 in the colon carcinoma experiment , mean permeability and perfusion decreased by 51 % ( from 5.2+/-1.1 to 2.5+/-0.8 ml/100 ml 
3 of tissue ) , respectively , in all animals after angiogenic drug administration . NULL NULL NULL NULL NULL NULL NULL 
0 ) , respectively , in all animals after antiangiogenic drug administration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 particular of its dynamic characteristics and vascularity before and after angiogenic treatment . NULL NULL NULL NULL NULL NULL NULL NULL 
0 of its dynamic characteristics and vascularity before and after antiangiogenic treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis in the caprine caruncles in non-pregnant and pregnant normal and 
19 in the caprine caruncles in non-pregnant and pregnant normal and treated does . NULL NULL NULL NULL NULL NULL NULL NULL 
0 does was covered with capillary meshes of regular diameter and form , without crypts . NULL NULL NULL NULL NULL NULL 
0 NULL NULL as pregnancy advanced the complexity of the vasculature increased : at 4 weeks the surface showed a pattern of 
0 of the vasculature increased : at 4 weeks the surface showed a pattern of ridges separated by troughs . NULL NULL 
0 later stages , branches of radial arteries penetrated the periphery forming an extensive mesh of capillaries on the concave surface . 
2 NULL NULL NULL NULL NULL NULL NULL NULL capillary diameters increased significantly during pregnancy , especially after 4 weeks , when 
0 during pregnancy , especially after 4 weeks , when large flattened sinusoids formed . NULL NULL NULL NULL NULL NULL NULL 
0 , especially after 4 weeks , when large flattened sinusoids formed . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 these sinusoids had a great deal of surface area for potential contact with the fetal component . NULL NULL NULL NULL 
0 sinusoids had a great deal of surface area for potential contact with the fetal component . NULL NULL NULL NULL NULL 
0 NULL NULL the caprine placenta is usually considered to have increased interhemal distance compared with endotheliochorial and hemochorial types : our 
0 interhemal distance compared with endotheliochorial and hemochorial types : our results suggest that the very extensive development of sinusoids and crypts 
2 hemochorial types : our results suggest that the very extensive development of sinusoids and crypts may compensate for any negative consequences 
0 extensive development of sinusoids and crypts may compensate for any negative consequences of the placental architecture . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL placental angiogenesis , which is physiologically normal , may serve as a 
0 model of this process in other circumstances , such as tumor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL the effect of swainsonine ( active compound of locoweed and a potential 
0 NULL NULL NULL NULL NULL the effect of swainsonine ( active compound of locoweed and a potential anticancer drug ) on 
0 effect of swainsonine ( active compound of locoweed and a potential anticancer drug ) on vascular development showed no differences in 
2 of locoweed and a potential anticancer drug ) on vascular development showed no differences in sinusoidal diameters at 7 weeks , 
0 locoweed and a potential anticancer drug ) on vascular development showed no differences in sinusoidal diameters at 7 weeks , but 
18 differences in sinusoidal diameters at 7 weeks , but a decrease in capillary density was noted . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL swainsonine caused a great distortion to the vasculature at 18 weeks . 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL the effects of this compound on the vascular development lend credibility to 
2 NULL NULL the effects of this compound on the vascular development lend credibility to its potential as an anticancer agent . 
0 this compound on the vascular development lend credibility to its potential as an anticancer agent . NULL NULL NULL NULL NULL 
3 NULL high-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification 
0 high-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and 
0 low-grade renal cell carcinoma based on histomorphological quantification and qrt-pcr mrna expression profile . NULL NULL NULL NULL NULL NULL NULL 
0 renal cell carcinoma based on histomorphological quantification and qrt-pcr mrna expression profile . NULL NULL NULL NULL NULL NULL NULL NULL 
3 vascularised tumour and is therefore an attractive disease to study angiogenesis and to test novel angiogenesis inhibitors in early clinical development 
3 an attractive disease to study angiogenesis and to test novel angiogenesis inhibitors in early clinical development . NULL NULL NULL NULL 
0 study angiogenesis and to test novel angiogenesis inhibitors in early clinical development . NULL NULL NULL NULL NULL NULL NULL NULL 
0 angiogenesis and to test novel angiogenesis inhibitors in early clinical development . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
1 NULL NULL NULL NULL NULL NULL NULL NULL endothelial cell proliferation plays a pivotal role in the process of angiogenesis . 
16 NULL NULL NULL NULL NULL NULL NULL endothelial cell proliferation plays a pivotal role in the process of angiogenesis . NULL 
16 NULL NULL NULL NULL NULL endothelial cell proliferation plays a pivotal role in the process of angiogenesis . NULL NULL NULL 
16 NULL NULL NULL NULL endothelial cell proliferation plays a pivotal role in the process of angiogenesis . NULL NULL NULL NULL 
3 cell proliferation plays a pivotal role in the process of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL the aim of this study was to compare angiogenesis parameters in low nuclear grade ( n=87 ) vs high 
0 NULL NULL NULL NULL NULL a panel of antibodies was used for immunohistochemistry : cd34/ki-67 , carbonic anhydrase ix , hypoxia-inducible 
0 used for immunohistochemistry : cd34/ki-67 , carbonic anhydrase ix , inducible factor-1alpha ( hif-1alpha ) and vascular endothelial growth factor ( 
0 ix , hypoxia-inducible factor-1alpha ( hif-1alpha ) and vascular endothelial growth factor ( vegf ) . NULL NULL NULL NULL NULL 
1 density ( mvd - microvessel density ) , endothelial cell proliferation fraction ( ecp % ) and tumour cell proliferation fraction 
1 cell proliferation fraction ( ecp % ) and tumour cell proliferation fraction ( tcp % ) were assessed . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL mrna expression levels of angiogenesis stimulators and inhibitors were determined by 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL mrna expression levels of angiogenesis stimulators and inhibitors were determined by quantitative 
0 NULL NULL NULL NULL NULL NULL NULL NULL mrna expression levels of angiogenesis stimulators and inhibitors were determined by quantitative rt-pcr 
3 NULL NULL NULL NULL NULL NULL mrna expression levels of angiogenesis stimulators and inhibitors were determined by quantitative rt-pcr . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL high-grade cc-rcc showed a higher ecp % ( p=0.049 ) , a higher 
0 higher tcp % ( p=0.009 ) , a higher vegf protein expression ( p less than 0.001 ) , a lower 
9 tcp % ( p=0.009 ) , a higher vegf protein expression ( p less than 0.001 ) , a lower mvd 
0 ( p less than 0.001 ) and a lower hif-1alpha protein expression ( p=0.002 ) than low-grade cc-rcc . NULL NULL 
9 p less than 0.001 ) and a lower hif-1alpha protein expression ( p=0.002 ) than low-grade cc-rcc . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL growth factor mrna expression analyses revealed a higher expression of angiopoietin 
0 NULL NULL NULL NULL NULL NULL NULL NULL growth factor mrna expression analyses revealed a higher expression of angiopoietin 2 in 
0 NULL NULL NULL NULL NULL NULL NULL growth factor mrna expression analyses revealed a higher expression of angiopoietin 2 in low-grade 
10 NULL NULL growth factor mrna expression analyses revealed a higher expression of angiopoietin 2 in low-grade cc-rcc . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL because of the imperfect association of nuclear grade and ecp % or mvd , cc-rcc 
9 NULL NULL NULL NULL NULL this analysis revealed a higher expression of vessel maturation and stabilisation factors ( placental growth factor 
2 NULL NULL this analysis revealed a higher expression of vessel maturation and stabilisation factors ( placental growth factor , pdgfb1 , 
0 higher expression of vessel maturation and stabilisation factors ( placental growth factor , pdgfb1 , angiopoietin 1 ) in cc-rcc with 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL our results suggest heterogeneity in angiogenic activity and vessel maturation of cc-rcc 
3 NULL NULL NULL NULL NULL our results suggest heterogeneity in angiogenic activity and vessel maturation of cc-rcc , to a large 
0 NULL NULL NULL NULL our results suggest heterogeneity in angiogenic activity and vessel maturation of cc-rcc , to a large extent 
2 NULL our results suggest heterogeneity in angiogenic activity and vessel maturation of cc-rcc , to a large extent linked to nuclear 
0 and vessel maturation of cc-rcc , to a large extent linked to nuclear grade , and , with probable therapeutic implications 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the contribution of harold f . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL dvorak to the study of tumor angiogenesis and stroma generation mechanisms . NULL NULL NULL NULL 
3 NULL NULL NULL NULL dvorak to the study of tumor angiogenesis and stroma generation mechanisms . NULL NULL NULL NULL NULL 
2 NULL dvorak to the study of tumor angiogenesis and stroma generation mechanisms . NULL NULL NULL NULL NULL NULL NULL NULL 
0 dvorak and his colleagues were the first to show that tumor cells secreted vascular permeability factor ( vpf ) and that 
14 his colleagues were the first to show that tumor cells secreted vascular permeability factor ( vpf ) and that a blocking 
0 secreted vascular permeability factor ( vpf ) and that a blocking antibody to vpf could prevent the edema and fluid accumulation 
18 vpf ) and that a blocking antibody to vpf could prevent the edema and fluid accumulation that is characteristic of human 
0 blocking antibody to vpf could prevent the edema and fluid accumulation that is characteristic of human cancers . NULL NULL NULL 
14 1986 , dvorak went on to demonstrate that vpf was secreted by a variety of human tumor cell lines and proposed 
0 demonstrate that vpf was secreted by a variety of human tumor cell lines and proposed that vpf was in part responsible 
0 tumor cell lines and proposed that vpf was in part responsible for the abnormal vasculature seen in human tumors . NULL 
17 he and other investigators demonstrated that vpf was capable of stimulating endothelial cell growth and angiogenesis . NULL NULL NULL NULL 
1 investigators demonstrated that vpf was capable of stimulating endothelial cell growth and angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 that vpf was capable of stimulating endothelial cell growth and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL these fundamental discoveries led to additional research conducted by napoleone ferrara and his laboratory 
0 laboratory , confirming the cloning of vpf and renaming the protein vascular endothelial growth factor ( vegf ) . NULL NULL 
0 the cloning of vpf and renaming the protein vascular endothelial growth factor ( vegf ) . NULL NULL NULL NULL NULL 
17 1986 , dvorak proposed that by secreting vpf , tumors induce angiogenesis by turning on the wound healing response . NULL 
3 , dvorak proposed that by secreting vpf , tumors induce angiogenesis by turning on the wound healing response . NULL NULL 
0 , tumors induce angiogenesis by turning on the wound healing response . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 , causing blood vessels to leak plasma fibrinogen , which stimulates blood vessel growth and provides a matrix on which they 
4 vessels to leak plasma fibrinogen , which stimulates blood vessel growth and provides a matrix on which they can spread . 
0 fibrinogen , which stimulates blood vessel growth and provides a matrix on which they can spread . NULL NULL NULL NULL 
0 vessel growth and provides a matrix on which they can spread . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL unlike wounds , however , that turn off vpf production after healing , tumors did not turn off their vpf 
9 after healing , tumors did not turn off their vpf production and instead continued to make large amounts of vpf , 
0 instead continued to make large amounts of vpf , allowing malignant cells to continue to induce new blood vessels and so 
17 amounts of vpf , allowing malignant cells to continue to induce new blood vessels and so to grow and spread . 
2 amounts of vpf , allowing malignant cells to continue to induce new blood vessels and so to grow and spread . 
1 to continue to induce new blood vessels and so to grow and spread . NULL NULL NULL NULL NULL NULL NULL 
14 to induce new blood vessels and so to grow and spread . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL this work is again extremely significant for patients worldwide , as dvorak 's scientific research is 
0 for patients worldwide , as dvorak 's scientific research is leading his colleagues all over the world to examine how to 
19 his colleagues all over the world to examine how to treat a tumor through its blood supply . NULL NULL NULL 
0 all over the world to examine how to treat a tumor through its blood supply . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL the hedgehog intercellular signaling pathway regulates cell proliferation and differentiation . NULL NULL NULL NULL NULL 
1 NULL NULL NULL the hedgehog intercellular signaling pathway regulates cell proliferation and differentiation . NULL NULL NULL NULL NULL NULL NULL 
2 NULL the hedgehog intercellular signaling pathway regulates cell proliferation and differentiation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL this pathway has been implicated to play a role in the pathogenesis of cancer and 
0 NULL NULL NULL NULL this pathway has been implicated to play a role in the pathogenesis of cancer and in embryonic 
0 NULL NULL this pathway has been implicated to play a role in the pathogenesis of cancer and in embryonic blood vessel 
0 pathway has been implicated to play a role in the pathogenesis of cancer and in embryonic blood vessel development . NULL 
2 in the pathogenesis of cancer and in embryonic blood vessel development . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL in the current study , hedgehog signaling in tumor related vasculature and microenvironment was examined using human umbilical vein 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL use of exogenous sonic hedgehog ( shh ) peptide significantly increased 
17 use of exogenous sonic hedgehog ( shh ) peptide significantly increased brdu incorporation in endothelial cells in vitro by a factor 
14 exogenous sonic hedgehog ( shh ) peptide significantly increased brdu incorporation in endothelial cells in vitro by a factor of 2 
18 NULL NULL NULL NULL the hedgehog pathway antagonist cyclopamine effectively reduced shh-induced proliferation to control levels . NULL NULL NULL NULL 
17 NULL NULL NULL the hedgehog pathway antagonist cyclopamine effectively reduced induced proliferation to control levels . NULL NULL NULL NULL NULL 
1 NULL NULL the hedgehog pathway antagonist cyclopamine effectively reduced shh-induced proliferation to control levels . NULL NULL NULL NULL NULL NULL 
0 the hedgehog pathway antagonist cyclopamine effectively reduced shh-induced proliferation to control levels . NULL NULL NULL NULL NULL NULL NULL NULL 
0 hedgehog pathway antagonist cyclopamine effectively reduced shh-induced proliferation to control levels . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL to study hedgehog signaling in vivo a hind limb tumor model with the b16f0 cell line was used . NULL 
0 hind limb tumor model with the b16f0 cell line was used . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment with 25 mg/kg cyclopamine significantly attenuated brdu incorporation in tumor 
18 NULL NULL NULL NULL treatment with 25 mg/kg cyclopamine significantly attenuated brdu incorporation in tumor cells threefold ( p less than 
14 NULL NULL treatment with 25 mg/kg cyclopamine significantly attenuated brdu incorporation in tumor cells threefold ( p less than 0.001 ) 
0 treatment with 25 mg/kg cyclopamine significantly attenuated brdu incorporation in tumor cells threefold ( p less than 0.001 ) , in 
0 cells threefold ( p less than 0.001 ) , in tumor related endothelial cells threefold ( p = 0.004 ) , 
18 endothelial cells threefold ( p = 0.004 ) , and delayed tumor growth by 4 days . NULL NULL NULL NULL 
0 cells threefold ( p = 0.004 ) , and delayed tumor growth by 4 days . NULL NULL NULL NULL NULL 
4 threefold ( p = 0.004 ) , and delayed tumor growth by 4 days . NULL NULL NULL NULL NULL NULL 
14 NULL NULL immunohistochemistry revealed that the hedgehog receptor patched was localized to the tumor stroma and that b16f0 cells expressed shh 
0 revealed that the hedgehog receptor patched was localized to the tumor stroma and that b16f0 cells expressed shh peptide . NULL 
9 was localized to the tumor stroma and that b16f0 cells expressed shh peptide . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL furthermore , mouse embryonic fibroblasts required the presence of b16f0 cells to express patched in a 
0 NULL NULL NULL furthermore , mouse embryonic fibroblasts required the presence of b16f0 cells to express patched in a co-culture assay 
9 mouse embryonic fibroblasts required the presence of b16f0 cells to express patched in a co-culture assay system . NULL NULL NULL 
0 the presence of b16f0 cells to express patched in a culture assay system . NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL these studies indicate that shh peptide produced by melanoma cells induces patched expression in fibroblasts . NULL 
17 these studies indicate that shh peptide produced by melanoma cells induces patched expression in fibroblasts . NULL NULL NULL NULL NULL 
9 indicate that shh peptide produced by melanoma cells induces patched expression in fibroblasts . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL to study tumor related angiogenesis a vascular window model was used to monitor 
3 NULL NULL NULL NULL NULL NULL to study tumor related angiogenesis a vascular window model was used to monitor tumor vascularity 
0 to study tumor related angiogenesis a vascular window model was used to monitor tumor vascularity . NULL NULL NULL NULL NULL 
0 related angiogenesis a vascular window model was used to monitor tumor vascularity . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment with cyclopamine significantly attenuated vascular formation by a factor of 
18 NULL NULL NULL NULL NULL NULL treatment with cyclopamine significantly attenuated vascular formation by a factor of 2.5 ( p less 
2 NULL NULL NULL NULL treatment with cyclopamine significantly attenuated vascular formation by a factor of 2.5 ( p less than 0.001 
16 factor of 2.5 ( p less than 0.001 ) and altered vascular morphology . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL furthermore , cyclopamine reduced tumor blood vessel permeability to fitc labeled dextran while having 
0 NULL NULL NULL NULL NULL NULL furthermore , cyclopamine reduced tumor blood vessel permeability to fitc labeled dextran while having no 
19 furthermore , cyclopamine reduced tumor blood vessel permeability to fitc labeled dextran while having no effect on normal blood vessels . 
16 blood vessel permeability to fitc labeled dextran while having no effect on normal blood vessels . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL these studies suggest that hedgehog signaling regulates melanoma related vascular formation and function . NULL NULL NULL 
2 these studies suggest that hedgehog signaling regulates melanoma related vascular formation and function . NULL NULL NULL NULL NULL NULL NULL 
0 suggest that hedgehog signaling regulates melanoma related vascular formation and function . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL dependent subretinal microglia cell accumulation is associated with cardinal features of 
1 NULL NULL NULL NULL NULL NULL cx3cr1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration . 
16 NULL NULL NULL NULL cx3cr1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration . NULL NULL 
6 cell accumulation is associated with cardinal features of age-related macular degeneration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL the role of retinal microglial cells ( mcs ) in age-related macular 
6 of retinal microglial cells ( mcs ) in age-related macular degeneration ( amd ) is unclear . NULL NULL NULL NULL 
9 NULL NULL NULL here we demonstrated that all retinal mcs express cx3c chemokine receptor 1 ( cx3cr1 ) and that homozygosity 
0 that homozygosity for the cx3cr1 m280 allele , which is associated with impaired cell migration , increases the risk of amd 
18 for the cx3cr1 m280 allele , which is associated with impaired cell migration , increases the risk of amd . NULL 
14 cx3cr1 m280 allele , which is associated with impaired cell migration , increases the risk of amd . NULL NULL NULL 
0 allele , which is associated with impaired cell migration , increases the risk of amd . NULL NULL NULL NULL NULL 
1 NULL NULL NULL NULL in humans with amd , mcs accumulated in the subretinal space at sites of retinal degeneration and 
6 mcs accumulated in the subretinal space at sites of retinal degeneration and choroidal neovascularization ( cnv ) . NULL NULL NULL 
3 the subretinal space at sites of retinal degeneration and choroidal neovascularization ( cnv ) . NULL NULL NULL NULL NULL NULL 
3 space at sites of retinal degeneration and choroidal neovascularization ( cnv ) . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in deficient mice , mcs accumulated subretinally with age and albino background 
1 NULL NULL NULL NULL NULL in cx3cr1-deficient mice , mcs accumulated subretinally with age and albino background and after laser impact 
0 accumulated subretinally with age and albino background and after laser impact preceding retinal degeneration . NULL NULL NULL NULL NULL NULL 
6 age and albino background and after laser impact preceding retinal degeneration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL raising the albino mice in the dark prevented both events . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the appearance of lipid-bloated subretinal mcs was drusen-like on funduscopy of senescent 
17 mcs was drusen-like on funduscopy of senescent mice , and dependent mc accumulation was associated with an exacerbation of experimental cnv 
1 drusen-like on funduscopy of senescent mice , and cx3cr1-dependent mc accumulation was associated with an exacerbation of experimental cnv . NULL 
16 funduscopy of senescent mice , and cx3cr1-dependent mc accumulation was associated with an exacerbation of experimental cnv . NULL NULL NULL 
3 cx3cr1-dependent mc accumulation was associated with an exacerbation of experimental cnv . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results show that cx3cr1-dependent accumulation of subretinal mcs evokes cardinal features 
17 NULL NULL NULL NULL NULL NULL these results show that dependent accumulation of subretinal mcs evokes cardinal features of amd . 
1 NULL NULL NULL NULL NULL these results show that cx3cr1-dependent accumulation of subretinal mcs evokes cardinal features of amd . NULL 
0 what we believe to be a novel pathogenic process with important implications for the development of new therapies for amd . 
0 be a novel pathogenic process with important implications for the development of new therapies for amd . NULL NULL NULL NULL 
0 pathogenic process with important implications for the development of new therapies for amd . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL [ clinical significance of interleukin-6 ( il-6 ) as a prognostic factor 
0 NULL NULL interleukin-6 ( il-6 ) is proinflammatory cytokine that produces multifunctional effects . NULL NULL NULL NULL NULL NULL NULL 
0 interleukin-6 ( il-6 ) is proinflammatory cytokine that produces multifunctional effects . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL it is also involved in the regulation of immune reactions , hematopoiesis and inflammatory 
0 NULL NULL NULL NULL it is also involved in the regulation of immune reactions , hematopoiesis and inflammatory state . NULL 
16 NULL NULL NULL NULL interleukin-6 has been shown to be associated with tumor progression including inhibition of cancer cells apoptosis and 
0 NULL NULL interleukin-6 has been shown to be associated with tumor progression including inhibition of cancer cells apoptosis and stimulation of 
2 NULL interleukin-6 has been shown to be associated with tumor progression including inhibition of cancer cells apoptosis and stimulation of angiogenesis 
18 has been shown to be associated with tumor progression including inhibition of cancer cells apoptosis and stimulation of angiogenesis . NULL 
5 be associated with tumor progression including inhibition of cancer cells apoptosis and stimulation of angiogenesis . NULL NULL NULL NULL NULL 
17 with tumor progression including inhibition of cancer cells apoptosis and stimulation of angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 progression including inhibition of cancer cells apoptosis and stimulation of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL anti-il-6 therapy is a new strategy in the inflammatory autoimmune diseases and 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL clinical studies have shown elevated serum il-6 concentrations in patients with 
17 NULL NULL NULL NULL NULL NULL clinical studies have shown elevated serum il-6 concentrations in patients with endometrial cancer , non-small 
0 NULL NULL NULL NULL NULL NULL NULL NULL serum il-6 levels correlate with tumor stage , and survival of patients . 
0 NULL NULL NULL NULL NULL serum il-6 levels correlate with tumor stage , and survival of patients . NULL NULL NULL 
5 NULL serum il-6 levels correlate with tumor stage , and survival of patients . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL in this article we have focused on a role of il-6 as a prognostic factor in several malignancies such 
16 NULL functional significance of vegf-a in human ovarian carcinoma : role in vasculogenic mimicry . NULL NULL NULL NULL NULL NULL 
0 cancer is a silent killer , and shows early extensive tumor invasion and peritoneal metastasis . NULL NULL NULL NULL NULL 
14 is a silent killer , and shows early extensive tumor invasion and peritoneal metastasis . NULL NULL NULL NULL NULL NULL 
14 killer , and shows early extensive tumor invasion and peritoneal metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
4 most tumors includes cooperation of pre-existing vessels , intussusceptive microvascular growth , postnatal vasculogenesis , glomeruloid angiogenesis and vasculogenic mimicry ( 
3 cooperation of pre-existing vessels , intussusceptive microvascular growth , postnatal vasculogenesis , glomeruloid angiogenesis and vasculogenic mimicry ( vm ) . 
3 vessels , intussusceptive microvascular growth , postnatal vasculogenesis , glomeruloid angiogenesis and vasculogenic mimicry ( vm ) . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vm is critical for a tumor blood supply and is asscociated with aggressive 
0 NULL NULL NULL NULL NULL vm is critical for a tumor blood supply and is asscociated with aggressive features and metastasis 
0 tumor blood supply and is asscociated with aggressive features and metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 cells and call into question the underlying significance of their ability to form vm in vitro induced by vegf-a . NULL 
0 call into question the underlying significance of their ability to form vm in vitro induced by vegf-a . NULL NULL NULL 
17 underlying significance of their ability to form vm in vitro induced by vegf-a . NULL NULL NULL NULL NULL NULL NULL 
0 also show their clinicalpathological features of the cancers with human embedded tumor tissue samples . NULL NULL NULL NULL NULL NULL 
0 show their clinicalpathological features of the cancers with human paraffin-embedded tumor tissue samples . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results show that the process : vegf-a -- greater than epha2 
3 -- greater than vm is the main pathway for vm formation and vegf-a appears to play an important role in the 
16 the main pathway for vm formation and vegf-a appears to play an important role in the formation of vm based on 
16 pathway for vm formation and vegf-a appears to play an important role in the formation of vm based on our in 
16 for vm formation and vegf-a appears to play an important role in the formation of vm based on our in vitro 
3 and vegf-a appears to play an important role in the formation of vm based on our in vitro assays and clinical 
0 formation of vm based on our in vitro assays and clinical immunohistochemical analyses . NULL NULL NULL NULL NULL NULL NULL 
0 of vm based on our in vitro assays and clinical immunohistochemical analyses . NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL targeting strategies for ovarian cancer include anti-vegf-a treatment , knocking down 
19 NULL NULL NULL vm-targeting strategies for ovarian cancer include anti-vegf-a treatment , knocking down the epha2 gene and using antibodies against 
0 epha2 gene and using antibodies against human mmps if the tumor is vm positive . NULL NULL NULL NULL NULL NULL 
0 using antibodies against human mmps if the tumor is vm positive . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL this strategy may be of significant value in laying the foundation for a more explicit anti-tumor 
3 value in laying the foundation for a more explicit anti-tumor angiogenesis therapy . NULL NULL NULL NULL NULL NULL NULL NULL 
18 in laying the foundation for a more explicit anti-tumor angiogenesis therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL a novel role of thrombospondin-1 in cervical carcinogenesis : inhibit stroma reaction by 
0 NULL NULL NULL a novel role of thrombospondin-1 in cervical carcinogenesis : inhibit stroma reaction by inhibiting activated fibroblasts from invading 
18 NULL a novel role of thrombospondin-1 in cervical carcinogenesis : inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer . 
18 of thrombospondin-1 in cervical carcinogenesis : inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer . NULL NULL NULL NULL 
17 thrombospondin-1 in cervical carcinogenesis : inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer . NULL NULL NULL NULL NULL 
3 NULL NULL thrombospondin ( tsp ) -1 , a potent angiogenesis inhibitor , has been shown to exert different biological functions 
0 NULL thrombospondin ( tsp ) -1 , a potent angiogenesis inhibitor , has been shown to exert different biological functions on 
0 angiogenesis inhibitor , has been shown to exert different biological functions on various cell types . NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL here , we investigate the role of tsp-1 in tumor-stroma reaction , which is mainly characterized 
0 NULL here , we investigate the role of tsp-1 in tumor reaction , which is mainly characterized by fibroblast activation to 
17 in tumor-stroma reaction , which is mainly characterized by fibroblast activation to create a permissive microenvironment for tumor progression . NULL 
0 characterized by fibroblast activation to create a permissive microenvironment for tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL 
2 by fibroblast activation to create a permissive microenvironment for tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL immunohistochemistry examinations in the human surgical specimens have shown that a downregulation of tsp-1 during the 
18 examinations in the human surgical specimens have shown that a downregulation of tsp-1 during the progression of cervical carcinogenesis was accompanied 
0 specimens have shown that a downregulation of tsp-1 during the progression of cervical carcinogenesis was accompanied by an emergence in the 
0 that a downregulation of tsp-1 during the progression of cervical carcinogenesis was accompanied by an emergence in the upregulation of stroma 
17 of cervical carcinogenesis was accompanied by an emergence in the upregulation of stroma markers , alpha-smooth muscle actin ( alpha-sma ) 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL transfection of siha cervical cancer cells with a plasmid expressing the 
9 NULL transfection of siha cervical cancer cells with a plasmid expressing the tsp-1 protein exhibited antiangiogenic activity in vitro and resulted 
0 siha cervical cancer cells with a plasmid expressing the tsp-1 protein exhibited antiangiogenic activity in vitro and resulted in reduced tumor 
0 cervical cancer cells with a plasmid expressing the tsp-1 protein exhibited antiangiogenic activity in vitro and resulted in reduced tumor growth 
3 cancer cells with a plasmid expressing the tsp-1 protein exhibited angiogenic activity in vitro and resulted in reduced tumor growth in 
18 cells with a plasmid expressing the tsp-1 protein exhibited antiangiogenic activity in vitro and resulted in reduced tumor growth in severe 
17 expressing the tsp-1 protein exhibited antiangiogenic activity in vitro and resulted in reduced tumor growth in severe combined immunodeficiency ( scid 
18 tsp-1 protein exhibited antiangiogenic activity in vitro and resulted in reduced tumor growth in severe combined immunodeficiency ( scid ) mice 
0 protein exhibited antiangiogenic activity in vitro and resulted in reduced tumor growth in severe combined immunodeficiency ( scid ) mice , 
4 exhibited antiangiogenic activity in vitro and resulted in reduced tumor growth in severe combined immunodeficiency ( scid ) mice , which 
18 ( scid ) mice , which was accompanied by a decrease in tumor vascularization and lower expressions of alpha-sma and desmin 
0 ) mice , which was accompanied by a decrease in tumor vascularization and lower expressions of alpha-sma and desmin than those 
3 mice , which was accompanied by a decrease in tumor vascularization and lower expressions of alpha-sma and desmin than those in 
9 was accompanied by a decrease in tumor vascularization and lower expressions of alpha-sma and desmin than those in the vector controls 
0 expressions of alpha-sma and desmin than those in the vector controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL transfection with tsp-1 and purified tsp-1 added to nih3t3 cells did 
0 NULL NULL NULL NULL NULL NULL transfection with tsp-1 and purified tsp-1 added to nih3t3 cells did not alter the protein 
19 NULL NULL NULL NULL transfection with tsp-1 and purified tsp-1 added to nih3t3 cells did not alter the protein levels of 
16 tsp-1 and purified tsp-1 added to nih3t3 cells did not alter the protein levels of alpha-sma and desmin but significantly inhibited 
0 purified tsp-1 added to nih3t3 cells did not alter the protein levels of alpha-sma and desmin but significantly inhibited matrix metalloprotease-2 
0 tsp-1 added to nih3t3 cells did not alter the protein levels of alpha-sma and desmin but significantly inhibited matrix metalloprotease-2 activity 
18 alter the protein levels of alpha-sma and desmin but significantly inhibited matrix metalloprotease-2 activity . NULL NULL NULL NULL NULL NULL 
0 the protein levels of alpha-sma and desmin but significantly inhibited matrix metalloprotease-2 activity . NULL NULL NULL NULL NULL NULL NULL 
0 levels of alpha-sma and desmin but significantly inhibited matrix metalloprotease-2 activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL transforming growth factor-beta ( tgf-beta ) , a major factor in the 
0 NULL NULL transforming growth factor-beta ( tgf-beta ) , a major factor in the activation of fibroblasts , increased alpha-sma and 
17 factor-beta ( tgf-beta ) , a major factor in the activation of fibroblasts , increased alpha-sma and desmin expression and the 
17 , a major factor in the activation of fibroblasts , increased alpha-sma and desmin expression and the ability of cell migration 
9 in the activation of fibroblasts , increased alpha-sma and desmin expression and the ability of cell migration and invasion in nih3t3 
0 of fibroblasts , increased alpha-sma and desmin expression and the ability of cell migration and invasion in nih3t3 cells . NULL 
14 increased alpha-sma and desmin expression and the ability of cell migration and invasion in nih3t3 cells . NULL NULL NULL NULL 
14 and desmin expression and the ability of cell migration and invasion in nih3t3 cells . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL the increased migration ability and the invasive ability into tumor cluster of 
14 NULL NULL NULL NULL NULL NULL NULL NULL the increased migration ability and the invasive ability into tumor cluster of tgf-beta-treated 
0 NULL NULL NULL NULL NULL NULL NULL the increased migration ability and the invasive ability into tumor cluster of tgf-beta-treated nih3t3 
0 NULL NULL NULL the increased migration ability and the invasive ability into tumor cluster of tgf-beta-treated nih3t3 cells were dose dependently 
0 NULL the increased migration ability and the invasive ability into tumor cluster of tgf-beta-treated nih3t3 cells were dose dependently inhibited by 
19 migration ability and the invasive ability into tumor cluster of treated nih3t3 cells were dose dependently inhibited by tsp-1 . NULL 
18 into tumor cluster of tgf-beta-treated nih3t3 cells were dose dependently inhibited by tsp-1 . NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL in contrast , ectopic tsp-1 expression in siha cells has little effect on the invasive ability 
16 contrast , ectopic tsp-1 expression in siha cells has little effect on the invasive ability of the nih3t3 cells . NULL 
0 expression in siha cells has little effect on the invasive ability of the nih3t3 cells . NULL NULL NULL NULL NULL 
16 NULL NULL NULL together , our findings demonstrate a novel role of tsp-1 to inhibit tumor-stroma reaction that could be attributed 
18 , our findings demonstrate a novel role of tsp-1 to inhibit tumor-stroma reaction that could be attributed to the blockage of 
0 our findings demonstrate a novel role of tsp-1 to inhibit tumor reaction that could be attributed to the blockage of activated 
17 tumor-stroma reaction that could be attributed to the blockage of activated fibroblasts from invading cancer cells . NULL NULL NULL NULL 
0 NULL NULL summary : staging of colorectal cancer occurs after surgery and is based on the extent of disease invasiveness and 
0 after surgery and is based on the extent of disease invasiveness and dissemination . NULL NULL NULL NULL NULL NULL NULL 
0 and is based on the extent of disease invasiveness and dissemination . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL surgery is the primary treatment for stage i disease . NULL 
0 NULL NULL NULL NULL NULL NULL surgery is the primary treatment for stage i disease . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL adjuvant chemotherapy is recommended after resection in selected high-risk patients with stage 
0 NULL NULL NULL NULL NULL adjuvant chemotherapy is recommended after resection in selected high-risk patients with stage ii disease and in 
0 NULL NULL NULL NULL NULL NULL NULL NULL convenience of administration , tolerability , and patient factors not necessarily age may 
0 not necessarily age may be considerations in decisions about adjuvant therapy after resection . NULL NULL NULL NULL NULL NULL NULL 
0 age may be considerations in decisions about adjuvant therapy after resection . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment of stage iv colorectal cancer is based on the type 
0 iv colorectal cancer is based on the type of prior therapy and patient-specific factors . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL recently , significant improvements in survival have been achieved through the use of 
0 NULL NULL NULL NULL NULL recently , significant improvements in survival have been achieved through the use of combination chemotherapy and 
0 , significant improvements in survival have been achieved through the use of combination chemotherapy and monoclonal antibody regimens . NULL NULL 
0 in survival have been achieved through the use of combination chemotherapy and monoclonal antibody regimens . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL bevacizumab in combination with chemotherapy is first-line therapy for stage iv disease . NULL NULL 
0 NULL NULL NULL bevacizumab in combination with chemotherapy is first-line therapy for stage iv disease . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL age alone should not preclude the use of chemotherapy in stage iv colorectal cancer , although the 
19 NULL NULL age alone should not preclude the use of chemotherapy in stage iv colorectal cancer , although the ability to 
0 of chemotherapy in stage iv colorectal cancer , although the ability to tolerate drug-related toxicity may be a consideration . NULL 
19 NULL NULL NULL NULL NULL NULL the optimal duration of chemotherapy in patients with early and metastatic colorectal cancer is unclear 
0 the optimal duration of chemotherapy in patients with early and metastatic colorectal cancer is unclear . NULL NULL NULL NULL NULL 
19 NULL NULL NULL conclusion : the optimal approach to the treatment of colorectal cancer depends on several considerations , including patient-specific 
0 : the optimal approach to the treatment of colorectal cancer depends on several considerations , including patient-specific factors . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL serum and urine levels of interleukin-8 in patients with non-hodgkin 's lymphoma . NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis plays an important role in many types of cancer . 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis plays an important role in many types of cancer . NULL 
16 NULL NULL NULL NULL NULL NULL NULL angiogenesis plays an important role in many types of cancer . NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL angiogenesis plays an important role in many types of cancer . NULL NULL NULL NULL 
3 ( il-8 ) is known to be a pro-inflammatory and angiogenic cytokine , and il-8 has been reported to be associated 
16 pro-angiogenic cytokine , and il-8 has been reported to be associated with tumor progression , prognosis and survival in several types 
0 , and il-8 has been reported to be associated with tumor progression , prognosis and survival in several types of cancers 
2 and il-8 has been reported to be associated with tumor progression , prognosis and survival in several types of cancers . 
0 reported to be associated with tumor progression , prognosis and survival in several types of cancers . NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL however , the role of il-8 in non-hodgkin 's lymphoma ( nhl ) has 
0 we evaluated the usefulness of measuring serum and urine il-8 levels in patients with nhl . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL we developed reference intervals for serum and urine il-8 level in 131 
0 reference intervals for serum and urine il-8 level in 131 control individuals . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL we measured serum il-8 and urine il-8 levels in patients with nhl , and we compared the concentrations 
0 nhl , and we compared the concentrations with those of control individuals . NULL NULL NULL NULL NULL NULL NULL NULL 
0 of urine il-8/cr were significantly higher in patients than in controls ( 48.9+/-194.4 vs. 5.2+/-13.8 pg/mg cr , p less than 
0 NULL NULL NULL NULL NULL however , there were no significant differences in serum il-8 concentrations between nhl patients and controls 
0 significant differences in serum il-8 concentrations between nhl patients and controls ( 159.2+/-40.4 vs. 99.6+/-107.1 pg/ml ; p=0.099 ) . NULL 
0 correlation between the serum and urine concentrations of il-8 and clinical variables , the only exception being the international prognostic index 
0 being the international prognostic index ( ipi ) , which showed a marginal correlation with urine il-8/cr levels ( p=0.07 ) 
0 ) , which showed a marginal correlation with urine il-8/cr levels ( p=0.07 ) . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL this study indicated that urine il-8/cr levels might be useful as a diagnostic marker of nhl . 
17 NULL NULL NULL microscopic technique for the detection of nitric dependent angiogenesis in an animal model . NULL NULL NULL NULL 
3 NULL NULL microscopic technique for the detection of nitric oxide-dependent angiogenesis in an animal model . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL nitric oxide ( no ) plays an important role in maintaining vascular homeostasis . NULL NULL 
0 NULL NULL NULL nitric oxide ( no ) plays an important role in maintaining vascular homeostasis . NULL NULL NULL NULL 
0 NULL NULL nitric oxide ( no ) plays an important role in maintaining vascular homeostasis . NULL NULL NULL NULL NULL 
0 nitric oxide ( no ) plays an important role in maintaining vascular homeostasis . NULL NULL NULL NULL NULL NULL NULL 
0 demonstrated by several experimental conditions , such as vascular endothelial growth factor ( vegf ) -induced angiogenesis . NULL NULL NULL 
17 , such as vascular endothelial growth factor ( vegf ) induced angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 such as vascular endothelial growth factor ( vegf ) -induced angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 pathway in endothelial cells could be one of the main contributing factors for angiogenesis . NULL NULL NULL NULL NULL NULL 
3 cells could be one of the main contributing factors for angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL although several methods have been used for measuring in vitro angiogenesis , a proper technique has 
3 although several methods have been used for measuring in vitro angiogenesis , a proper technique has not been developed for identifying 
0 in vitro angiogenesis , a proper technique has not been developed for identifying in vivo no-dependent angiogenesis . NULL NULL NULL 
17 proper technique has not been developed for identifying in vivo dependent angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 technique has not been developed for identifying in vivo no-dependent angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 provides a new intravital microscopic method for detecting and measuring dependent angiogenesis in a mouse model . NULL NULL NULL NULL 
3 a new intravital microscopic method for detecting and measuring no-dependent angiogenesis in a mouse model . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL this technique showed strong abdominal neovascularization in wild-type mice , but not enos 
3 NULL NULL NULL NULL NULL this technique showed strong abdominal neovascularization in wild-type mice , but not enos knockout mice , 
19 wild-type mice , but not enos knockout mice , locally injected with vegf , as well as stimulation of angiogenesis in 
17 mice , locally injected with vegf , as well as stimulation of angiogenesis in no donor-injected mice . NULL NULL NULL 
3 locally injected with vegf , as well as stimulation of angiogenesis in no donor-injected mice . NULL NULL NULL NULL NULL 
19 vegf , as well as stimulation of angiogenesis in no injected mice . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL this technique also revealed the inhibitory effect of the nos inhibitor n ( g ) -iminoethyl-l-ornithine 
18 NULL NULL NULL NULL this technique also revealed the inhibitory effect of the nos inhibitor n ( g ) -iminoethyl-l-ornithine in 
0 this technique also revealed the inhibitory effect of the nos inhibitor n ( g ) -iminoethyl-l-ornithine in vegf-mediated in vivo angiogenesis 
17 of the nos inhibitor n ( g ) -iminoethyl-l-ornithine in mediated in vivo angiogenesis . NULL NULL NULL NULL NULL NULL 
3 inhibitor n ( g ) -iminoethyl-l-ornithine in vegf-mediated in vivo angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 describes intravital microscopy as a new imaging technique for detecting dependent angiogenesis in an animal model . NULL NULL NULL NULL 
3 intravital microscopy as a new imaging technique for detecting no-dependent angiogenesis in an animal model . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL neurotrophin p75 receptor ( p75ntr ) promotes endothelial cell apoptosis and inhibits angiogenesis : implications for diabetes-induced 
5 NULL neurotrophin p75 receptor ( p75ntr ) promotes endothelial cell apoptosis and inhibits angiogenesis : implications for diabetes-induced impaired neovascularization in 
18 p75 receptor ( p75ntr ) promotes endothelial cell apoptosis and inhibits angiogenesis : implications for diabetes-induced impaired neovascularization in ischemic limb 
3 receptor ( p75ntr ) promotes endothelial cell apoptosis and inhibits angiogenesis : implications for diabetes-induced impaired neovascularization in ischemic limb muscles 
0 promotes endothelial cell apoptosis and inhibits angiogenesis : implications for induced impaired neovascularization in ischemic limb muscles . NULL NULL NULL 
18 endothelial cell apoptosis and inhibits angiogenesis : implications for diabetes-induced impaired neovascularization in ischemic limb muscles . NULL NULL NULL NULL 
3 cell apoptosis and inhibits angiogenesis : implications for diabetes-induced impaired neovascularization in ischemic limb muscles . NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL diabetes impairs endothelial function and reparative neovascularization . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL diabetes impairs endothelial function and reparative neovascularization . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL diabetes impairs endothelial function and reparative neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 ( p75 ( ntr ) ) , which is scarcely present in healthy endothelial cells ( ecs ) , becomes strongly 
9 in healthy endothelial cells ( ecs ) , becomes strongly expressed by capillary ecs after induction of peripheral ischemia in type-1 
0 ecs ) , becomes strongly expressed by capillary ecs after induction of peripheral ischemia in type-1 diabetic mice . NULL NULL 
17 NULL NULL NULL NULL here , we show that gene induced p75 ( ntr ) expression impairs the survival , proliferation 
9 , we show that gene transfer-induced p75 ( ntr ) expression impairs the survival , proliferation , migration , and adhesion 
18 we show that gene transfer-induced p75 ( ntr ) expression impairs the survival , proliferation , migration , and adhesion capacities 
5 that gene transfer-induced p75 ( ntr ) expression impairs the survival , proliferation , migration , and adhesion capacities of cultured 
1 transfer-induced p75 ( ntr ) expression impairs the survival , proliferation , migration , and adhesion capacities of cultured ecs and 
14 ( ntr ) expression impairs the survival , proliferation , migration , and adhesion capacities of cultured ecs and endothelial progenitor 
15 expression impairs the survival , proliferation , migration , and adhesion capacities of cultured ecs and endothelial progenitor cells ( epcs 
19 survival , proliferation , migration , and adhesion capacities of cultured ecs and endothelial progenitor cells ( epcs ) and inhibits 
18 cultured ecs and endothelial progenitor cells ( epcs ) and inhibits angiogenesis in vitro . NULL NULL NULL NULL NULL NULL 
3 ecs and endothelial progenitor cells ( epcs ) and inhibits angiogenesis in vitro . NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL moreover , intramuscular p75 ( ntr ) gene delivery impairs neovascularization and blood flow recovery in a mouse model 
18 NULL moreover , intramuscular p75 ( ntr ) gene delivery impairs neovascularization and blood flow recovery in a mouse model of 
3 moreover , intramuscular p75 ( ntr ) gene delivery impairs neovascularization and blood flow recovery in a mouse model of limb 
0 NULL NULL NULL NULL NULL NULL NULL NULL these disturbed functions are associated with suppression of signaling mechanisms implicated in ec 
0 NULL NULL NULL NULL NULL NULL these disturbed functions are associated with suppression of signaling mechanisms implicated in ec survival and 
0 NULL NULL NULL NULL these disturbed functions are associated with suppression of signaling mechanisms implicated in ec survival and angiogenesis . 
0 these disturbed functions are associated with suppression of signaling mechanisms implicated in ec survival and angiogenesis . NULL NULL NULL NULL 
5 are associated with suppression of signaling mechanisms implicated in ec survival and angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 with suppression of signaling mechanisms implicated in ec survival and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 p75 ( ntr ) depresses the vegf-a/akt/enos/no pathway and additionally reduces the mrna levels of itgb1 [ beta ( 1 ) 
0 ntr ) depresses the vegf-a/akt/enos/no pathway and additionally reduces the mrna levels of itgb1 [ beta ( 1 ) integrin ] 
0 ) depresses the vegf-a/akt/enos/no pathway and additionally reduces the mrna levels of itgb1 [ beta ( 1 ) integrin ] , 
0 NULL NULL NULL NULL diabetic mice , which typically show impaired postischemic muscular neovascularization and blood perfusion recovery , have these 
3 NULL diabetic mice , which typically show impaired postischemic muscular neovascularization and blood perfusion recovery , have these defects corrected by 
0 , which typically show impaired postischemic muscular neovascularization and blood perfusion recovery , have these defects corrected by intramuscular gene transfer 
0 postischemic muscular neovascularization and blood perfusion recovery , have these defects corrected by intramuscular gene transfer of a dominant negative mutant 
0 these defects corrected by intramuscular gene transfer of a dominant negative mutant form of p75 ( ntr ) . NULL NULL 
0 corrected by intramuscular gene transfer of a dominant negative mutant form of p75 ( ntr ) . NULL NULL NULL NULL 
3 NULL NULL NULL collectively , our data newly demonstrate the angiogenic action of p75 ( ntr ) and open new avenues 
18 NULL NULL collectively , our data newly demonstrate the antiangiogenic action of p75 ( ntr ) and open new avenues for 
0 ( ntr ) and open new avenues for the therapeutic use of p75 ( ntr ) inhibition to combat diabetes-induced microvascular 
18 avenues for the therapeutic use of p75 ( ntr ) inhibition to combat diabetes-induced microvascular liabilities . NULL NULL NULL NULL 
17 therapeutic use of p75 ( ntr ) inhibition to combat induced microvascular liabilities . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor endothelial cell targeted cyclic rgd-modified heparin derivative : inhibition of 
19 NULL NULL NULL NULL NULL NULL NULL tumor endothelial cell targeted cyclic rgd-modified heparin derivative : inhibition of angiogenesis and tumor 
18 NULL tumor endothelial cell targeted cyclic rgd-modified heparin derivative : inhibition of angiogenesis and tumor growth . NULL NULL NULL NULL 
3 endothelial cell targeted cyclic rgd-modified heparin derivative : inhibition of angiogenesis and tumor growth . NULL NULL NULL NULL NULL NULL 
0 targeted cyclic rgd-modified heparin derivative : inhibition of angiogenesis and tumor growth . NULL NULL NULL NULL NULL NULL NULL NULL 
4 cyclic rgd-modified heparin derivative : inhibition of angiogenesis and tumor growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL purpose : we prepared tumor endothelium targeted crgd-modified heparin derivative ( crgd-hl ) by coupling 
19 NULL NULL NULL NULL purpose : we prepared tumor endothelium targeted crgd-modified heparin derivative ( crgd-hl ) by coupling heparin-lithocholic acid 
18 heparin-lithocholic acid ( hl ) with crgdyk , and evaluated inhibition effects of crgd-hl on angiogenesis and tumor growth . NULL 
0 acid ( hl ) with crgdyk , and evaluated inhibition effects of crgd-hl on angiogenesis and tumor growth . NULL NULL 
3 with crgdyk , and evaluated inhibition effects of crgd-hl on angiogenesis and tumor growth . NULL NULL NULL NULL NULL NULL 
0 , and evaluated inhibition effects of crgd-hl on angiogenesis and tumor growth . NULL NULL NULL NULL NULL NULL NULL NULL 
4 and evaluated inhibition effects of crgd-hl on angiogenesis and tumor growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL methods : to evaluate angiogenic activity of crgd-hl , we performed tests on endothelial cell 
18 NULL NULL NULL NULL NULL methods : to evaluate antiangiogenic activity of crgd-hl , we performed tests on endothelial cell adhesion 
15 activity of crgd-hl , we performed tests on endothelial cell adhesion and migration to vitronectin , tube formation , binding affinity 
14 crgd-hl , we performed tests on endothelial cell adhesion and migration to vitronectin , tube formation , binding affinity to purified 
2 on endothelial cell adhesion and migration to vitronectin , tube formation , binding affinity to purified alpha ( v ) beta 
15 cell adhesion and migration to vitronectin , tube formation , binding affinity to purified alpha ( v ) beta ( 3 
0 adhesion and migration to vitronectin , tube formation , binding affinity to purified alpha ( v ) beta ( 3 ) 
0 migration to vitronectin , tube formation , binding affinity to purified alpha ( v ) beta ( 3 ) integrin , 
18 NULL NULL NULL NULL NULL NULL NULL NULL the antitumor activity of crgd-hl was also evaluated by monitoring tumor growth and 
0 the antitumor activity of crgd-hl was also evaluated by monitoring tumor growth and microvessel formation in squamous cell carcinoma ( scc7 
4 antitumor activity of crgd-hl was also evaluated by monitoring tumor growth and microvessel formation in squamous cell carcinoma ( scc7 ) 
2 crgd-hl was also evaluated by monitoring tumor growth and microvessel formation in squamous cell carcinoma ( scc7 ) tumor . NULL 
0 and microvessel formation in squamous cell carcinoma ( scc7 ) tumor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : the crgd-hl significantly inhibited adhesion and migration of endothelial 
18 NULL NULL NULL NULL NULL results : the crgd-hl significantly inhibited adhesion and migration of endothelial cells to vitronectin , and 
15 NULL NULL NULL NULL results : the crgd-hl significantly inhibited adhesion and migration of endothelial cells to vitronectin , and tubular 
14 NULL NULL results : the crgd-hl significantly inhibited adhesion and migration of endothelial cells to vitronectin , and tubular structures of 
15 NULL compared to crgdyk and hl , crgd-hl has high binding affinity to purified alpha ( v ) beta ( 3 
0 compared to crgdyk and hl , crgd-hl has high binding affinity to purified alpha ( v ) beta ( 3 ) 
0 crgdyk and hl , crgd-hl has high binding affinity to purified alpha ( v ) beta ( 3 ) integrin . 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL the enhanced antiangiogenic effect of crgd-hl was confirmed in matrigel assay by 
3 NULL NULL NULL NULL NULL NULL NULL NULL the enhanced angiogenic effect of crgd-hl was confirmed in matrigel assay by showing 
18 NULL NULL NULL NULL NULL NULL NULL the enhanced antiangiogenic effect of crgd-hl was confirmed in matrigel assay by showing the 
0 of crgd-hl was confirmed in matrigel assay by showing the significant inhibition of bfgf-driven angiogenesis and blood vessel formation . NULL 
18 crgd-hl was confirmed in matrigel assay by showing the significant inhibition of bfgf-driven angiogenesis and blood vessel formation . NULL NULL 
3 in matrigel assay by showing the significant inhibition of bfgf-driven angiogenesis and blood vessel formation . NULL NULL NULL NULL NULL 
2 showing the significant inhibition of bfgf-driven angiogenesis and blood vessel formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL it was thought that potent angiogenic effect of crgd-hl was probably due to the interference of 
18 NULL NULL NULL NULL it was thought that potent antiangiogenic effect of crgd-hl was probably due to the interference of alpha 
18 potent antiangiogenic effect of crgd-hl was probably due to the interference of alpha ( v ) beta ( 3 ) -mediated 
0 interference of alpha ( v ) beta ( 3 ) mediated interaction , resulting in the enhanced antitumoral activity against scc7 
15 of alpha ( v ) beta ( 3 ) -mediated interaction , resulting in the enhanced antitumoral activity against scc7 tumor 
0 ( v ) beta ( 3 ) -mediated interaction , resulting in the enhanced antitumoral activity against scc7 tumor . NULL 
17 beta ( 3 ) -mediated interaction , resulting in the enhanced antitumoral activity against scc7 tumor . NULL NULL NULL NULL 
0 3 ) -mediated interaction , resulting in the enhanced antitumoral activity against scc7 tumor . NULL NULL NULL NULL NULL NULL 
0 interaction , resulting in the enhanced antitumoral activity against scc7 tumor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL conclusion : these results demonstrated that crgd-modified heparin derivative enhanced anti-angiotherapeutic effects against solid 
17 NULL conclusion : these results demonstrated that crgd-modified heparin derivative enhanced anti-angiotherapeutic effects against solid tumor , and therefore , it 
18 : these results demonstrated that crgd-modified heparin derivative enhanced anti-angiotherapeutic effects against solid tumor , and therefore , it could be 
0 demonstrated that crgd-modified heparin derivative enhanced anti-angiotherapeutic effects against solid tumor , and therefore , it could be applied to treat 
19 tumor , and therefore , it could be applied to treat various cancers and angiogenic diseases as a potent angiogenesis inhibitor 
3 , it could be applied to treat various cancers and angiogenic diseases as a potent angiogenesis inhibitor . NULL NULL NULL 
3 to treat various cancers and angiogenic diseases as a potent angiogenesis inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL 
0 treat various cancers and angiogenic diseases as a potent angiogenesis inhibitor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL [ inhibitory effect of adenovirus-mediated endostatin gene transfer on transplanted lung carcinoma 
0 NULL NULL NULL NULL NULL NULL NULL NULL [ inhibitory effect of adenovirus-mediated endostatin gene transfer on transplanted lung carcinoma in 
17 NULL NULL NULL NULL NULL NULL [ inhibitory effect of mediated endostatin gene transfer on transplanted lung carcinoma in mice ] 
19 NULL [ inhibitory effect of adenovirus-mediated endostatin gene transfer on transplanted lung carcinoma in mice ] NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL objective : to investigate the effect of adenovirus-mediated endostatin gene transfer on transplanted lung cancer in 
17 NULL NULL NULL objective : to investigate the effect of mediated endostatin gene transfer on transplanted lung cancer in mice and 
19 to investigate the effect of adenovirus-mediated endostatin gene transfer on transplanted lung cancer in mice and its mechanism of action . 
0 gene transfer on transplanted lung cancer in mice and its mechanism of action . NULL NULL NULL NULL NULL NULL NULL 
0 on transplanted lung cancer in mice and its mechanism of action . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL methods : transplant tumor model was induced by subcutaneous inoculation of 2 x 
0 NULL NULL NULL NULL NULL NULL NULL methods : transplant tumor model was induced by subcutaneous inoculation of 2 x 10 
0 NULL NULL NULL NULL methods : transplant tumor model was induced by subcutaneous inoculation of 2 x 10 ( 6 ) 
19 NULL methods : transplant tumor model was induced by subcutaneous inoculation of 2 x 10 ( 6 ) lewis lung cancer 
0 NULL NULL NULL NULL NULL NULL NULL the mice were treated by intratumoral injection of 2 x 10 ( 9 ) 
19 NULL NULL NULL NULL the mice were treated by intratumoral injection of 2 x 10 ( 9 ) pfu ad-mendostatin . 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL the expression of endostatin in situ and its maintaining time were detected 
0 NULL NULL the expression of endostatin in situ and its maintaining time were detected by immunohistochemistry and western blot , respectively 
0 expression of endostatin in situ and its maintaining time were detected by immunohistochemistry and western blot , respectively . NULL NULL 
18 endostatin level in serum was determined by elisa . the inhibition of tumor growth and changes of survival were recorded and 
0 in serum was determined by elisa . the inhibition of tumor growth and changes of survival were recorded and the microvessel 
4 serum was determined by elisa . the inhibition of tumor growth and changes of survival were recorded and the microvessel density 
0 determined by elisa . the inhibition of tumor growth and changes of survival were recorded and the microvessel density ( mvd 
0 elisa . the inhibition of tumor growth and changes of survival were recorded and the microvessel density ( mvd ) was 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the tumor apoptosis was observed by electron microscopy . NULL NULL NULL 
5 NULL NULL NULL NULL NULL NULL NULL NULL the tumor apoptosis was observed by electron microscopy . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL the tumor apoptosis was observed by electron microscopy . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : in comparison with controls , intratumoral injection of ad-mendostatin 
0 NULL NULL NULL NULL NULL results : in comparison with controls , intratumoral injection of ad-mendostatin significantly inhibited the tumor growth 
19 NULL NULL results : in comparison with controls , intratumoral injection of ad-mendostatin significantly inhibited the tumor growth and metastasis , 
18 in comparison with controls , intratumoral injection of ad-mendostatin significantly inhibited the tumor growth and metastasis , and prolonged the survival 
0 with controls , intratumoral injection of ad-mendostatin significantly inhibited the tumor growth and metastasis , and prolonged the survival rate of 
4 controls , intratumoral injection of ad-mendostatin significantly inhibited the tumor growth and metastasis , and prolonged the survival rate of mice 
14 intratumoral injection of ad-mendostatin significantly inhibited the tumor growth and metastasis , and prolonged the survival rate of mice ( p 
17 ad-mendostatin significantly inhibited the tumor growth and metastasis , and prolonged the survival rate of mice ( p less than 0.05 
5 inhibited the tumor growth and metastasis , and prolonged the survival rate of mice ( p less than 0.05 ) . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL strong positive expression of mendostatin was seen in the tumor tissue after 
9 NULL NULL NULL NULL NULL NULL NULL NULL strong positive expression of mendostatin was seen in the tumor tissue after injection 
0 NULL strong positive expression of mendostatin was seen in the tumor tissue after injection of ad-mendostatin , immunhistochemically ostained by mouse 
19 expression of mendostatin was seen in the tumor tissue after injection of ad-mendostatin , immunhistochemically ostained by mouse endostatin monoclonal antibody 
0 immunhistochemically ostained by mouse endostatin monoclonal antibody , while the control groups showed only very low expression or absence . NULL 
0 by mouse endostatin monoclonal antibody , while the control groups showed only very low expression or absence . NULL NULL NULL 
9 antibody , while the control groups showed only very low expression or absence . NULL NULL NULL NULL NULL NULL NULL 
19 was 1540 +/- 560 ng/ml at the second week of administration , the expression of endostatin diminished a month later . 
9 560 ng/ml at the second week of administration , the expression of endostatin diminished a month later . NULL NULL NULL 
18 the second week of administration , the expression of endostatin diminished a month later . NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL the microvessel density ( mvd ) ) decreased from 42.4 +/- 4.8 to 10.5 +/- 3.2 per x 
0 +/- 3.2 per x 200 magnificetion microscopic field by cd10 staining and from 68.5 +/- 4.5 to 37.5 +/- 4.6 by 
0 from 68.5 +/- 4.5 to 37.5 +/- 4.6 by cd31 staining , respectively ( p less than 0.05 ) . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL more apoptotic tumor cells were seen under the transmission electron microscope . NULL 
19 NULL NULL NULL NULL NULL NULL conclusion : endostatin gene therapy mediated by adenoviral vector efficiently induces expression of endostatin in 
17 NULL NULL NULL NULL NULL conclusion : endostatin gene therapy mediated by adenoviral vector efficiently induces expression of endostatin in vivo 
17 conclusion : endostatin gene therapy mediated by adenoviral vector efficiently induces expression of endostatin in vivo , and inhibits the growth 
9 : endostatin gene therapy mediated by adenoviral vector efficiently induces expression of endostatin in vivo , and inhibits the growth and 
18 vector efficiently induces expression of endostatin in vivo , and inhibits the growth and metastasis of tumor . NULL NULL NULL 
4 induces expression of endostatin in vivo , and inhibits the growth and metastasis of tumor . NULL NULL NULL NULL NULL 
14 of endostatin in vivo , and inhibits the growth and metastasis of tumor . NULL NULL NULL NULL NULL NULL NULL 
0 in vivo , and inhibits the growth and metastasis of tumor . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL it is concluded that its action is targeted to tumor neovasculature and the mechanism is inhibition 
0 NULL NULL NULL it is concluded that its action is targeted to tumor neovasculature and the mechanism is inhibition of tumor 
0 NULL it is concluded that its action is targeted to tumor neovasculature and the mechanism is inhibition of tumor angiogenesis . 
0 that its action is targeted to tumor neovasculature and the mechanism is inhibition of tumor angiogenesis . NULL NULL NULL NULL 
18 action is targeted to tumor neovasculature and the mechanism is inhibition of tumor angiogenesis . NULL NULL NULL NULL NULL NULL 
0 targeted to tumor neovasculature and the mechanism is inhibition of tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 to tumor neovasculature and the mechanism is inhibition of tumor angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL diverse cell signaling events modulated by perlecan . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL perlecan is a ubiquitous pericellular proteoglycan ideally placed to mediate cell signaling events controlling migration , proliferation , 
0 NULL perlecan is a ubiquitous pericellular proteoglycan ideally placed to mediate cell signaling events controlling migration , proliferation , and differentiation 
0 ubiquitous pericellular proteoglycan ideally placed to mediate cell signaling events controlling migration , proliferation , and differentiation . NULL NULL NULL 
0 pericellular proteoglycan ideally placed to mediate cell signaling events controlling migration , proliferation , and differentiation . NULL NULL NULL NULL 
0 ideally placed to mediate cell signaling events controlling migration , proliferation , and differentiation . NULL NULL NULL NULL NULL NULL 
0 mediate cell signaling events controlling migration , proliferation , and differentiation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL its control of growth factor signaling usually involves interactions with the heparan 
0 NULL NULL NULL NULL NULL NULL NULL its control of growth factor signaling usually involves interactions with the heparan sulfate chains 
0 NULL NULL NULL its control of growth factor signaling usually involves interactions with the heparan sulfate chains covalently coupled to the 
0 NULL NULL its control of growth factor signaling usually involves interactions with the heparan sulfate chains covalently coupled to the protein 
0 signaling usually involves interactions with the heparan sulfate chains covalently coupled to the protein core 's n-terminus . NULL NULL NULL 
0 interactions with the heparan sulfate chains covalently coupled to the protein core 's n-terminus . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL however , this modular protein core also binds with relatively high affinity to a number 
0 NULL NULL NULL however , this modular protein core also binds with relatively high affinity to a number of growth factors 
0 , this modular protein core also binds with relatively high affinity to a number of growth factors and surface receptors , 
0 also binds with relatively high affinity to a number of growth factors and surface receptors , thereby stabilizing cell-matrix links . 
0 a number of growth factors and surface receptors , thereby stabilizing cell-matrix links . NULL NULL NULL NULL NULL NULL NULL 
0 number of growth factors and surface receptors , thereby stabilizing matrix links . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL this review will focus on growth factor interactions and describe recent advances in our understanding of 
15 NULL NULL NULL this review will focus on perlecan-growth factor interactions and describe recent advances in our understanding of this highly 
0 advances in our understanding of this highly conserved proteoglycan during development , cancer growth , and angiogenesis . NULL NULL NULL 
4 understanding of this highly conserved proteoglycan during development , cancer growth , and angiogenesis . NULL NULL NULL NULL NULL NULL 
3 highly conserved proteoglycan during development , cancer growth , and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL the angiogenic capacities of perlecan that involve proliferative and migratory signals in 
0 NULL NULL NULL NULL the pro-angiogenic capacities of perlecan that involve proliferative and migratory signals in response to bound growth factors 
0 NULL NULL NULL the pro-angiogenic capacities of perlecan that involve proliferative and migratory signals in response to bound growth factors will 
0 the pro-angiogenic capacities of perlecan that involve proliferative and migratory signals in response to bound growth factors will be explored , 
0 capacities of perlecan that involve proliferative and migratory signals in response to bound growth factors will be explored , as well 
15 perlecan that involve proliferative and migratory signals in response to bound growth factors will be explored , as well as the 
0 that involve proliferative and migratory signals in response to bound growth factors will be explored , as well as the anti-angiogenic 
3 growth factors will be explored , as well as the angiogenic signals resulting from interactions between the c-terminal domain known as 
18 factors will be explored , as well as the anti-angiogenic signals resulting from interactions between the c-terminal domain known as endorepellin 
17 will be explored , as well as the anti-angiogenic signals resulting from interactions between the c-terminal domain known as endorepellin and 
15 explored , as well as the anti-angiogenic signals resulting from interactions between the c-terminal domain known as endorepellin and integrins that 
16 between the c-terminal domain known as endorepellin and integrins that control adhesion of cells to the extracellular matrix . NULL NULL 
15 the c-terminal domain known as endorepellin and integrins that control adhesion of cells to the extracellular matrix . NULL NULL NULL 
0 and integrins that control adhesion of cells to the extracellular matrix . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL these two somewhat diametrically opposed roles will be discussed in light of new data emerging from 
0 emerging from various fields which converge on perlecan as a key regulator of cell growth and angiogenesis . NULL NULL NULL 
0 from various fields which converge on perlecan as a key regulator of cell growth and angiogenesis . NULL NULL NULL NULL 
1 which converge on perlecan as a key regulator of cell growth and angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 on perlecan as a key regulator of cell growth and angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL [ retinochoroidopathy after intravitreal anti-vegf treatment ] NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL [ retinochoroidopathy after intravitreal anti-vegf treatment ] NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 with persistent metamorphopsias of the right eye 2 weeks after intravitreal injection of bevacizumab to treat choroidal neovascularization due to exudative 
19 persistent metamorphopsias of the right eye 2 weeks after intravitreal injection of bevacizumab to treat choroidal neovascularization due to exudative age-related 
19 right eye 2 weeks after intravitreal injection of bevacizumab to treat choroidal neovascularization due to exudative age-related macular degeneration . NULL 
3 2 weeks after intravitreal injection of bevacizumab to treat choroidal neovascularization due to exudative age-related macular degeneration . NULL NULL NULL 
6 bevacizumab to treat choroidal neovascularization due to exudative age-related macular degeneration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 was retinochoroiditis as an occult manifestation of sarcoidosis , possibly resulting from an intravitreal injection of bevacizumab . NULL NULL NULL 
19 an occult manifestation of sarcoidosis , possibly resulting from an intravitreal injection of bevacizumab . NULL NULL NULL NULL NULL NULL 
19 occult manifestation of sarcoidosis , possibly resulting from an intravitreal injection of bevacizumab . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL the patient received a prescription for 100 mg ultralan to be taken daily 
0 during the further course no deterioration of the condition was observed . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL silencing of directional migration in roundabout4 knockdown endothelial cells . NULL NULL NULL NULL 
0 NULL NULL NULL NULL silencing of directional migration in roundabout4 knockdown endothelial cells . NULL NULL NULL NULL NULL NULL NULL 
16 are axon guidance molecules that have recently been identified to play a role in vascular guidance as well . NULL NULL 
16 guidance molecules that have recently been identified to play a role in vascular guidance as well . NULL NULL NULL NULL 
19 NULL NULL in this study , we have investigated gene knockdown analysis of endothelial robos , in particular roundabout 4 ( 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : robo1 and robo4 knockdown cells display distinct activity in 
0 NULL NULL NULL NULL NULL results : robo1 and robo4 knockdown cells display distinct activity in endothelial cell migration assay . 
0 NULL results : robo1 and robo4 knockdown cells display distinct activity in endothelial cell migration assay . NULL NULL NULL NULL 
14 and robo4 knockdown cells display distinct activity in endothelial cell migration assay . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL the knockdown of robo4 abrogated the chemotactic response of endothelial cells to 
18 NULL NULL NULL NULL NULL NULL the knockdown of robo4 abrogated the chemotactic response of endothelial cells to serum but enhanced 
16 NULL NULL NULL the knockdown of robo4 abrogated the chemotactic response of endothelial cells to serum but enhanced a chemokinetic response 
17 abrogated the chemotactic response of endothelial cells to serum but enhanced a chemokinetic response to slit2 , while robo1 knockdown cells 
16 response of endothelial cells to serum but enhanced a chemokinetic response to slit2 , while robo1 knockdown cells do not display 
0 but enhanced a chemokinetic response to slit2 , while robo1 knockdown cells do not display chemotactic response to serum or vegf 
16 slit2 , while robo1 knockdown cells do not display chemotactic response to serum or vegf . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL robo4 knockdown endothelial cells unexpectedly show up regulation of rho gtpases . 
17 NULL NULL NULL robo4 knockdown endothelial cells unexpectedly show up regulation of rho gtpases . NULL NULL NULL NULL NULL NULL 
18 NULL zebrafish robo4 rescues both rho gtpase homeostasis and serum reduced chemotaxis in robo4 knockdown cells . NULL NULL NULL NULL 
14 zebrafish robo4 rescues both rho gtpase homeostasis and serum reduced chemotaxis in robo4 knockdown cells . NULL NULL NULL NULL NULL 
0 both rho gtpase homeostasis and serum reduced chemotaxis in robo4 knockdown cells . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , this study mechanistically implicates irsp53 in the signaling nexus 
17 this study mechanistically implicates irsp53 in the signaling nexus between activated cdc42 and mena , both of which have previously been 
0 , both of which have previously been shown to be involved with robo4 signaling in endothelial cells . NULL NULL NULL 
14 the robo signaling apparatus that work together to guide directional migration of endothelial cells . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL p53 hot-spot mutants increase tumor vascularization via ros-mediated activation of the hif1/vegf-a pathway . 
0 NULL NULL NULL NULL NULL NULL p53 hot-spot mutants increase tumor vascularization via ros-mediated activation of the hif1/vegf-a pathway . NULL 
3 NULL NULL NULL NULL NULL p53 hot-spot mutants increase tumor vascularization via ros-mediated activation of the hif1/vegf-a pathway . NULL NULL 
17 NULL NULL NULL p53 hot-spot mutants increase tumor vascularization via mediated activation of the hif1/vegf-a pathway . NULL NULL NULL NULL 
17 NULL NULL p53 hot-spot mutants increase tumor vascularization via ros-mediated activation of the hif1/vegf-a pathway . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the function of p53 tumor suppressor is often altered in various human 
0 NULL NULL NULL NULL NULL NULL the function of p53 tumor suppressor is often altered in various human tumors predominantly through 
0 NULL NULL NULL NULL NULL the function of p53 tumor suppressor is often altered in various human tumors predominantly through missense-mutations 
0 NULL NULL the function of p53 tumor suppressor is often altered in various human tumors predominantly through missense-mutations resulting in accumulation 
0 is often altered in various human tumors predominantly through missense-mutations resulting in accumulation of mutant proteins . NULL NULL NULL NULL 
0 altered in various human tumors predominantly through missense-mutations resulting in accumulation of mutant proteins . NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL we revealed that expression of p53 proteins with amino-acid substitutions at codons 175 ( 
17 representing the hot-spots of mutations in various human tumors , increased the number of vessels in hct116 human colon carcinoma xenografts 
17 human colon carcinoma xenografts and , as a result , accelerated their growth . NULL NULL NULL NULL NULL NULL NULL 
4 carcinoma xenografts and , as a result , accelerated their growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL stimulation of tumor angiogenesis was connected with about 2-fold increase in 
0 NULL NULL NULL NULL NULL NULL NULL NULL stimulation of tumor angiogenesis was connected with about 2-fold increase in intracellular level 
3 NULL NULL NULL NULL NULL NULL NULL stimulation of tumor angiogenesis was connected with about 2-fold increase in intracellular level of 
17 NULL stimulation of tumor angiogenesis was connected with about 2-fold increase in intracellular level of reactive oxygen species ( ros ) 
18 NULL NULL NULL NULL NULL antioxidant n-acetyl-l-aspartate ( nac ) decreased vessels number in tumors formed by cells with inactivated p53 
2 antioxidant n-acetyl-l-aspartate ( nac ) decreased vessels number in tumors formed by cells with inactivated p53 and inhibited their growth . 
18 number in tumors formed by cells with inactivated p53 and inhibited their growth . NULL NULL NULL NULL NULL NULL NULL 
4 tumors formed by cells with inactivated p53 and inhibited their growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL effect of ros on angiogenesis in tumors expressing hot-spot p53 mutants 
3 NULL NULL NULL NULL NULL NULL effect of ros on angiogenesis in tumors expressing hot-spot p53 mutants was correlated with their 
9 NULL NULL NULL effect of ros on angiogenesis in tumors expressing hot-spot p53 mutants was correlated with their ability to increase 
0 in tumors expressing hot-spot p53 mutants was correlated with their ability to increase a content of hif1 transcriptional factor responsible for 
17 expressing hot-spot p53 mutants was correlated with their ability to increase a content of hif1 transcriptional factor responsible for up-regulation of 
0 correlated with their ability to increase a content of hif1 transcriptional factor responsible for up-regulation of vegf-a mrnas . NULL NULL 
16 their ability to increase a content of hif1 transcriptional factor responsible for up-regulation of vegf-a mrnas . NULL NULL NULL NULL 
17 to increase a content of hif1 transcriptional factor responsible for up-regulation of vegf-a mrnas . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL estradiol increases il-8 secretion of normal human breast tissue and breast cancer 
14 NULL NULL NULL NULL NULL NULL NULL estradiol increases il-8 secretion of normal human breast tissue and breast cancer in vivo 
16 NULL NULL NULL NULL NULL il-8 or cxcl8 has been associated with tumor angiogenesis , metastasis , and poor prognosis in 
0 NULL NULL NULL il-8 or cxcl8 has been associated with tumor angiogenesis , metastasis , and poor prognosis in breast cancer 
3 NULL NULL il-8 or cxcl8 has been associated with tumor angiogenesis , metastasis , and poor prognosis in breast cancer . 
14 il-8 or cxcl8 has been associated with tumor angiogenesis , metastasis , and poor prognosis in breast cancer . NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL estrogen is crucial in breast carcinogenesis and tumor progression . NULL NULL NULL 
0 NULL NULL NULL NULL NULL estrogen is crucial in breast carcinogenesis and tumor progression . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL estrogen is crucial in breast carcinogenesis and tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL 
2 NULL NULL estrogen is crucial in breast carcinogenesis and tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL whether sex steroids affect il-8 secretion of normal breast tissue or breast cancer is 
14 NULL NULL NULL NULL NULL whether sex steroids affect il-8 secretion of normal breast tissue or breast cancer is not known 
16 NULL NULL NULL NULL NULL NULL NULL NULL hence , regulatory mechanisms of il-8 need to be investigated in whole tissue 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL we used microdialysis to sample il-8 in normal human breast tissue in 
0 NULL NULL NULL NULL NULL NULL NULL we found a significant positive correlation between il-8 and estradiol in normal breast tissue 
0 NULL NULL NULL NULL NULL NULL we found a significant positive correlation between il-8 and estradiol in normal breast tissue and 
0 correlation between il-8 and estradiol in normal breast tissue and dependent breast cancer in vivo . NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL ex vivo , estradiol exposure increased the il-8 secretion of normal whole breast tissue in 
17 NULL NULL NULL NULL NULL ex vivo , estradiol exposure increased the il-8 secretion of normal whole breast tissue in culture 
14 NULL NULL ex vivo , estradiol exposure increased the il-8 secretion of normal whole breast tissue in culture . NULL NULL 
19 increased the il-8 secretion of normal whole breast tissue in culture . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL in experimental breast cancer , estradiol increased il-8 whereas the anti-estrogen tamoxifen inhibited the secretion of il-8 
18 breast cancer , estradiol increased il-8 whereas the anti-estrogen tamoxifen inhibited the secretion of il-8 both in vitro and extracellularly in 
14 , estradiol increased il-8 whereas the anti-estrogen tamoxifen inhibited the secretion of il-8 both in vitro and extracellularly in vivo in 
18 NULL NULL NULL NULL NULL NULL NULL an anti-il-8 ab inhibited endothelial cell proliferation induced by cancer cell produced il-8 and 
1 NULL NULL NULL NULL an anti-il-8 ab inhibited endothelial cell proliferation induced by cancer cell produced il-8 and tumors with low 
17 NULL NULL NULL an anti-il-8 ab inhibited endothelial cell proliferation induced by cancer cell produced il-8 and tumors with low il-8 
9 anti-il-8 ab inhibited endothelial cell proliferation induced by cancer cell produced il-8 and tumors with low il-8 levels exhibited decreased angiogenesis 
0 by cancer cell produced il-8 and tumors with low il-8 levels exhibited decreased angiogenesis . NULL NULL NULL NULL NULL NULL 
0 cancer cell produced il-8 and tumors with low il-8 levels exhibited decreased angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
18 cell produced il-8 and tumors with low il-8 levels exhibited decreased angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 produced il-8 and tumors with low il-8 levels exhibited decreased angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL our results strongly suggest that estradiol has a critical role in the 
16 NULL NULL our results strongly suggest that estradiol has a critical role in the regulation of il-8 in normal human breast 
16 NULL our results strongly suggest that estradiol has a critical role in the regulation of il-8 in normal human breast tissue 
16 strongly suggest that estradiol has a critical role in the regulation of il-8 in normal human breast tissue and human breast 
0 NULL NULL NULL NULL NULL NULL NULL NULL il-8 may present a novel therapeutic target for estrogen driven breast carcinogenesis and 
0 NULL NULL NULL NULL il-8 may present a novel therapeutic target for estrogen driven breast carcinogenesis and tumor progression . NULL 
0 may present a novel therapeutic target for estrogen driven breast carcinogenesis and tumor progression . NULL NULL NULL NULL NULL NULL 
0 a novel therapeutic target for estrogen driven breast carcinogenesis and tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL 
2 novel therapeutic target for estrogen driven breast carcinogenesis and tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL effect of estrogen and progesterone on macrophage activation during wound healing 
17 NULL NULL NULL effect of estrogen and progesterone on macrophage activation during wound healing . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL age-related impaired wound healing leads to substantial morbidity and mortality along with 
0 NULL NULL NULL NULL NULL NULL age-related impaired wound healing leads to substantial morbidity and mortality along with a large financial 
6 NULL NULL NULL there is accumulating evidence that the tissue damage associated with chronic wounds is initiated and propagated by an 
0 NULL NULL there is accumulating evidence that the tissue damage associated with chronic wounds is initiated and propagated by an inappropriately 
17 evidence that the tissue damage associated with chronic wounds is initiated and propagated by an inappropriately excessive inflammatory response . NULL 
0 wounds is initiated and propagated by an inappropriately excessive inflammatory response . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL research on age-related impaired wound healing suggests that the decline in sex steroid hormones 
0 NULL research on age-related impaired wound healing suggests that the decline in sex steroid hormones with age may have a substantial 
0 in sex steroid hormones with age may have a substantial influence on the inflammatory response in vivo . NULL NULL NULL 
0 with age may have a substantial influence on the inflammatory response in vivo . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL topical and systemic estrogen treatments have shown an increased rate of healing by reducing inflammation 
0 NULL NULL topical and systemic estrogen treatments have shown an increased rate of healing by reducing inflammation , however the underlying 
0 estrogen treatments have shown an increased rate of healing by reducing inflammation , however the underlying mechanisms are little understood . 
0 NULL NULL NULL in vitro studies also suggest progesterone may play a role in modulating inflammation . NULL NULL NULL NULL 
0 NULL in vitro studies also suggest progesterone may play a role in modulating inflammation . NULL NULL NULL NULL NULL NULL 
0 vitro studies also suggest progesterone may play a role in modulating inflammation . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL macrophages are essential mediators of inflammation and wound healing . NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL macrophages can be activated in a classical or alternative manner in parallel with the 
16 healing model this study was carried out to investigate the roles of estrogen and progesterone on macrophage activation during the wound 
17 to investigate the roles of estrogen and progesterone on macrophage activation during the wound healing response . NULL NULL NULL NULL 
0 estrogen and progesterone on macrophage activation during the wound healing response . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL our findings suggest with a reduction of steroid hormones following ovariectomy , alternatively activated macrophage markers 
17 with a reduction of steroid hormones following ovariectomy , alternatively activated macrophage markers ( fizz1 and ym1 ) were reduced , 
18 alternatively activated macrophage markers ( fizz1 and ym1 ) were reduced , with this effect being reversed with the administration of 
0 ( fizz1 and ym1 ) were reduced , with this effect being reversed with the administration of estrogen or progesterone ; 
18 and ym1 ) were reduced , with this effect being reversed with the administration of estrogen or progesterone ; suggesting that 
19 were reduced , with this effect being reversed with the administration of estrogen or progesterone ; suggesting that with the reduction 
18 administration of estrogen or progesterone ; suggesting that with the reduction of steroid hormones macrophages are activated in a classical manner 
17 suggesting that with the reduction of steroid hormones macrophages are activated in a classical manner , promoting inflammation , whereas estrogen 
0 steroid hormones macrophages are activated in a classical manner , promoting inflammation , whereas estrogen or progesterone are contributing toward macrophage 
16 manner , promoting inflammation , whereas estrogen or progesterone are contributing toward macrophage activation in an alternative manner , driving wound 
17 inflammation , whereas estrogen or progesterone are contributing toward macrophage activation in an alternative manner , driving wound repair , angiogenesis 
0 toward macrophage activation in an alternative manner , driving wound repair , angiogenesis , and remodeling . NULL NULL NULL NULL 
3 activation in an alternative manner , driving wound repair , angiogenesis , and remodeling . NULL NULL NULL NULL NULL NULL 
0 alternative manner , driving wound repair , angiogenesis , and remodeling . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL effect of platelet-rich plasma and fibrin glue on healing of critical-size 
0 effect of platelet-rich plasma and fibrin glue on healing of critical calvarial bone defects . NULL NULL NULL NULL NULL NULL 
0 plasma and fibrin glue on healing of critical-size calvarial bone defects . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 , platelet-rich plasma ( prp ) including high amounts of growth factors is introduced to clinical use rapidly . NULL NULL 
0 ) including high amounts of growth factors is introduced to clinical use rapidly . NULL NULL NULL NULL NULL NULL NULL 
0 including high amounts of growth factors is introduced to clinical use rapidly . NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL the aim of this study was to compare the effects of prp and platelet-poor plasma ( ppp ) on healing 
0 prp and platelet-poor plasma ( ppp ) on healing of critical bone defects.bilateral full-thickness , critical-size bone defects were created in 
0 ppp ) on healing of critical-size bone defects.bilateral full-thickness , critical bone defects were created in the parietal bones of 32 
0 on healing of critical-size bone defects.bilateral full-thickness , critical-size bone defects were created in the parietal bones of 32 rabbits , 
0 , ppp , and prp were applied to the created defects before closure . NULL NULL NULL NULL NULL NULL NULL 
0 , and prp were applied to the created defects before closure . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL radiologic defect area measurement results at 0 , 4 , and 16 weeks were compared 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , densities of the newly formed bones at 16th week 
2 NULL NULL NULL in addition , densities of the newly formed bones at 16th week were studied . NULL NULL NULL 
3 NULL histologic parameters ( primary and secondary bone trabecula , neovascularization , and bone marrow and connective tissue formation ) were 
2 trabecula , neovascularization , and bone marrow and connective tissue formation ) were compared between 4- and 16-week groups.more rapid decrease 
0 formation ) were compared between 4- and 16-week groups.more rapid decrease in defect size was observed in groups 3 and 4 
0 4- and 16-week groups.more rapid decrease in defect size was observed in groups 3 and 4 than in groups 1 and 
2 NULL NULL NULL NULL NULL NULL NULL NULL NULL newly formed bone densities were also found to be higher in these 
2 NULL NULL NULL NULL NULL NULL NULL NULL new bone formation was detected to be more rapid considering histologic parameters , 
0 NULL NULL NULL NULL NULL NULL new bone formation was detected to be more rapid considering histologic parameters , in groups 
16 16th weeks.study demonstrates that prp and ppp might have favorable effects on bone healing . NULL NULL NULL NULL NULL NULL 
0 reveal any statistical difference between these 2 substances considering osteoinductive potential , prp group has demonstrated superior results compared with fibrin 
0 substances considering osteoinductive potential , prp group has demonstrated superior results compared with fibrin glue group . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL higher platelet concentrations may expose beneficial effects of prp . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL higher platelet concentrations may expose beneficial effects of prp . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL derived angiopoietin-2 affects early stages of tumor development and vessel maturation 
16 NULL NULL NULL NULL NULL NULL NULL NULL host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is 
0 NULL NULL NULL NULL host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages 
2 NULL NULL NULL host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of 
2 host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth . 
0 and vessel maturation but is dispensable for later stages of tumor growth . NULL NULL NULL NULL NULL NULL NULL NULL 
4 vessel maturation but is dispensable for later stages of tumor growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 been identified as the second vascular-specific receptor tyrosine kinase system controlling vessel assembly , maturation , and quiescence . NULL NULL 
2 as the second vascular-specific receptor tyrosine kinase system controlling vessel assembly , maturation , and quiescence . NULL NULL NULL NULL 
2 second vascular-specific receptor tyrosine kinase system controlling vessel assembly , maturation , and quiescence . NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL angiopoietin-2 ( ang-2 ) is prominently up-regulated in the host-derived vasculature of most tumors , making it 
0 NULL angiopoietin-2 ( ang-2 ) is prominently up-regulated in the derived vasculature of most tumors , making it an attractive candidate 
3 of most tumors , making it an attractive candidate for angiogenic intervention . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL yet , the net outcome of ang-2 functions on tumor angiogenesis is believed to be contextual depending on 
0 NULL yet , the net outcome of ang-2 functions on tumor angiogenesis is believed to be contextual depending on the local 
3 yet , the net outcome of ang-2 functions on tumor angiogenesis is believed to be contextual depending on the local cytokine 
0 NULL NULL NULL NULL NULL NULL correspondingly , ang-2 manipulatory therapies have been shown to exert protumorigenic as well as antitumorigenic 
0 have been shown to exert protumorigenic as well as antitumorigenic effects . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL to clarify the role of ang-2 for angiogenesis and tumor growth in a definite 
3 NULL NULL NULL to clarify the role of ang-2 for angiogenesis and tumor growth in a definite genetic experimental setting , 
0 NULL to clarify the role of ang-2 for angiogenesis and tumor growth in a definite genetic experimental setting , the present 
4 to clarify the role of ang-2 for angiogenesis and tumor growth in a definite genetic experimental setting , the present study 
0 tumor growth in a definite genetic experimental setting , the present study was aimed at comparatively studying the growth of different 
4 , the present study was aimed at comparatively studying the growth of different tumors in wild-type and ang-2-deficient mice . NULL 
9 comparatively studying the growth of different tumors in wild-type and deficient mice . NULL NULL NULL NULL NULL NULL NULL NULL 
4 lung carcinomas , mt-ret melanomas , and b16f10 melanomas all grew slower in ang-2-deficient mice . NULL NULL NULL NULL NULL 
9 mt-ret melanomas , and b16f10 melanomas all grew slower in deficient mice . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL yet , tumor growth in wild-type and ang-2-deficient mice dissociated during early stages 
4 NULL NULL NULL NULL NULL NULL NULL yet , tumor growth in wild-type and ang-2-deficient mice dissociated during early stages of 
9 NULL NULL NULL yet , tumor growth in wild-type and deficient mice dissociated during early stages of tumor development , whereas 
0 in wild-type and ang-2-deficient mice dissociated during early stages of tumor development , whereas tumor growth rates during later stages of 
2 wild-type and ang-2-deficient mice dissociated during early stages of tumor development , whereas tumor growth rates during later stages of primary 
0 mice dissociated during early stages of tumor development , whereas tumor growth rates during later stages of primary tumor progression were 
4 dissociated during early stages of tumor development , whereas tumor growth rates during later stages of primary tumor progression were similar 
0 , whereas tumor growth rates during later stages of primary tumor progression were similar . NULL NULL NULL NULL NULL NULL 
2 whereas tumor growth rates during later stages of primary tumor progression were similar . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL analysis of the intratumoral vascular architecture revealed no major differences in microvessel density and perfusion characteristics . NULL NULL 
14 vascular architecture revealed no major differences in microvessel density and perfusion characteristics . NULL NULL NULL NULL NULL NULL NULL NULL 
4 however , diameters of intratumoral microvessels were smaller in tumors grown in ang-2-deficient mice , and the vasculature had an altered 
9 diameters of intratumoral microvessels were smaller in tumors grown in deficient mice , and the vasculature had an altered pattern of 
0 grown in ang-2-deficient mice , and the vasculature had an altered pattern of pericyte recruitment and maturation . NULL NULL NULL 
14 , and the vasculature had an altered pattern of pericyte recruitment and maturation . NULL NULL NULL NULL NULL NULL NULL 
2 the vasculature had an altered pattern of pericyte recruitment and maturation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL deficient tumor vessels had higher pericyte coverage indices . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL ang-2-deficient tumor vessels had higher pericyte coverage indices . NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL recruited pericytes were desmin and ng2 positive and predominately alpha-smooth muscle 
0 NULL NULL NULL NULL recruited pericytes were desmin and ng2 positive and predominately alpha-smooth muscle actin negative , indicative of a 
0 were desmin and ng2 positive and predominately alpha-smooth muscle actin negative , indicative of a more mature pericyte phenotype . NULL 
16 NULL NULL NULL NULL collectively , the experiments define the role of ang-2 during tumor angiogenesis and establish a better rationale 
0 collectively , the experiments define the role of ang-2 during tumor angiogenesis and establish a better rationale for combination therapies involving 
3 , the experiments define the role of ang-2 during tumor angiogenesis and establish a better rationale for combination therapies involving ang-2 
0 during tumor angiogenesis and establish a better rationale for combination therapies involving ang-2 manipulatory therapies . NULL NULL NULL NULL NULL 
0 tumor angiogenesis and establish a better rationale for combination therapies involving ang-2 manipulatory therapies . NULL NULL NULL NULL NULL NULL 
0 establish a better rationale for combination therapies involving ang-2 manipulatory therapies . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL short pigment derived factor-derived peptide inhibits angiogenesis and tumor growth . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL short pigment epithelial-derived derived peptide inhibits angiogenesis and tumor growth . NULL NULL NULL 
18 NULL NULL NULL NULL NULL short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth . NULL NULL NULL NULL NULL NULL 
0 NULL NULL short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth . NULL NULL NULL NULL NULL NULL NULL NULL 
4 NULL short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL purpose : pigment derived factor ( pedf ) is a potent angiogenesis inhibitor with 
3 : pigment epithelial-derived factor ( pedf ) is a potent angiogenesis inhibitor with multiple other functions , some of which enhance 
0 pigment epithelial-derived factor ( pedf ) is a potent angiogenesis inhibitor with multiple other functions , some of which enhance tumor 
0 pedf ) is a potent angiogenesis inhibitor with multiple other functions , some of which enhance tumor growth . NULL NULL 
17 angiogenesis inhibitor with multiple other functions , some of which enhance tumor growth . NULL NULL NULL NULL NULL NULL NULL 
0 inhibitor with multiple other functions , some of which enhance tumor growth . NULL NULL NULL NULL NULL NULL NULL NULL 
4 with multiple other functions , some of which enhance tumor growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL our previous studies mapped pedf angiogenic and prosurvival activities to distinct epitopes . NULL NULL NULL 
18 NULL NULL our previous studies mapped pedf antiangiogenic and prosurvival activities to distinct epitopes . NULL NULL NULL NULL NULL NULL 
3 to determine the minimal fragment of pedf , which maintains angiogenic and antitumor efficacy . NULL NULL NULL NULL NULL NULL 
18 minimal fragment of pedf , which maintains antiangiogenic and antitumor efficacy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 design : we analyzed antigenicity , hydrophilicity , and charge distribution of the angioinhibitory epitope ( the 34-mer ) and designed 
0 NULL NULL NULL NULL NULL NULL NULL we analyzed their ability to block endothelial cell chemotaxis and induce apoptosis in vitro 
18 NULL NULL NULL NULL NULL we analyzed their ability to block endothelial cell chemotaxis and induce apoptosis in vitro and their 
14 NULL NULL we analyzed their ability to block endothelial cell chemotaxis and induce apoptosis in vitro and their antiangiogenic activity in 
17 we analyzed their ability to block endothelial cell chemotaxis and induce apoptosis in vitro and their antiangiogenic activity in vivo . 
5 analyzed their ability to block endothelial cell chemotaxis and induce apoptosis in vitro and their antiangiogenic activity in vivo . NULL 
3 endothelial cell chemotaxis and induce apoptosis in vitro and their angiogenic activity in vivo . NULL NULL NULL NULL NULL NULL 
18 cell chemotaxis and induce apoptosis in vitro and their antiangiogenic activity in vivo . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL the selected peptide was tested for the antitumor activity against mildly aggressive xenografted prostate carcinoma and highly aggressive renal 
0 p18 acts in the same manner as pedf , we used immunohistochemistry to measure pedf targets , vascular endothelial growth factor 
0 manner as pedf , we used immunohistochemistry to measure pedf targets , vascular endothelial growth factor receptor 2 , and cd95 
0 we used immunohistochemistry to measure pedf targets , vascular endothelial growth factor receptor 2 , and cd95 ligand expression in p18-treated 
9 vascular endothelial growth factor receptor 2 , and cd95 ligand expression in p18-treated vasculature . NULL NULL NULL NULL NULL NULL 
19 growth factor receptor 2 , and cd95 ligand expression in treated vasculature . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : p14 and p18 blocked endothelial cell chemotaxis ; p18 
18 NULL NULL NULL NULL NULL results : p14 and p18 blocked endothelial cell chemotaxis ; p18 and p23 induced apoptosis . 
14 NULL NULL results : p14 and p18 blocked endothelial cell chemotaxis ; p18 and p23 induced apoptosis . NULL NULL NULL 
17 and p18 blocked endothelial cell chemotaxis ; p18 and p23 induced apoptosis . NULL NULL NULL NULL NULL NULL NULL NULL 
5 p18 blocked endothelial cell chemotaxis ; p18 and p23 induced apoptosis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL p18 showed the highest ic50 and blocked angiogenesis in vivo : p23 
18 NULL NULL NULL NULL p18 showed the highest ic50 and blocked angiogenesis in vivo : p23 was inactive and p14 was 
3 NULL NULL NULL p18 showed the highest ic50 and blocked angiogenesis in vivo : p23 was inactive and p14 was proangiogenic 
3 angiogenesis in vivo : p23 was inactive and p14 was angiogenic . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL p18 increased the production of cd95 ligand and reduced the expression of 
9 NULL NULL NULL NULL NULL NULL NULL p18 increased the production of cd95 ligand and reduced the expression of vascular endothelial 
18 NULL NULL p18 increased the production of cd95 ligand and reduced the expression of vascular endothelial growth factor receptor 2 by 
9 p18 increased the production of cd95 ligand and reduced the expression of vascular endothelial growth factor receptor 2 by the endothelial 
0 of cd95 ligand and reduced the expression of vascular endothelial growth factor receptor 2 by the endothelial cells in vivo . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in tumor studies , p18 was more effective in blocking the angiogenesis 
0 NULL NULL NULL in tumor studies , p18 was more effective in blocking the angiogenesis and growth of the prostate cancer 
18 NULL in tumor studies , p18 was more effective in blocking the angiogenesis and growth of the prostate cancer than parental 
3 tumor studies , p18 was more effective in blocking the angiogenesis and growth of the prostate cancer than parental 34-mer ; 
4 , p18 was more effective in blocking the angiogenesis and growth of the prostate cancer than parental 34-mer ; in the 
18 34-mer ; in the renal cell carcinoma , p18 strongly decreased angiogenesis and halted the progression of established tumors . NULL 
3 ; in the renal cell carcinoma , p18 strongly decreased angiogenesis and halted the progression of established tumors . NULL NULL 
17 cell carcinoma , p18 strongly decreased angiogenesis and halted the progression of established tumors . NULL NULL NULL NULL NULL NULL 
0 , p18 strongly decreased angiogenesis and halted the progression of established tumors . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL conclusions : p18 is a novel and potent angiogenic biotherapeutic agent that has potential to be developed for the 
0 is a novel and potent antiangiogenic biotherapeutic agent that has potential to be developed for the treatment of prostate and renal 
0 and potent antiangiogenic biotherapeutic agent that has potential to be developed for the treatment of prostate and renal cancer . NULL 
19 biotherapeutic agent that has potential to be developed for the treatment of prostate and renal cancer . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL distinct role of plcbeta3 in vegf-mediated directional migration and vascular sprouting . 
16 NULL NULL NULL NULL NULL distinct role of plcbeta3 in mediated directional migration and vascular sprouting . NULL NULL NULL NULL 
0 NULL NULL NULL distinct role of plcbeta3 in vegf-mediated directional migration and vascular sprouting . NULL NULL NULL NULL NULL NULL 
2 distinct role of plcbeta3 in vegf-mediated directional migration and vascular sprouting . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
1 NULL NULL NULL NULL NULL NULL NULL NULL endothelial cell proliferation and migration is essential to angiogenesis . NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL endothelial cell proliferation and migration is essential to angiogenesis . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL endothelial cell proliferation and migration is essential to angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL endothelial cell proliferation and migration is essential to angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
1 NULL NULL NULL NULL NULL NULL NULL NULL typically , proliferation and chemotaxis of endothelial cells is driven by growth factors 
14 NULL NULL NULL NULL NULL NULL typically , proliferation and chemotaxis of endothelial cells is driven by growth factors such as 
0 , proliferation and chemotaxis of endothelial cells is driven by growth factors such as vascular endothelial growth factor ( vegf ) 
0 cells is driven by growth factors such as vascular endothelial growth factor ( vegf ) and basic fibroblast growth factor ( 
0 vascular endothelial growth factor ( vegf ) and basic fibroblast growth factor ( bfgf ) . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL vegf activates phospholipases ( plcs ) - specifically plcgamma1 - that are 
17 phospholipases ( plcs ) - specifically plcgamma1 - that are important for tubulogenesis , differentiation and dna synthesis . NULL NULL 
0 - specifically plcgamma1 - that are important for tubulogenesis , differentiation and dna synthesis . NULL NULL NULL NULL NULL NULL 
0 - that are important for tubulogenesis , differentiation and dna synthesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 we show here that vegf , specifically through vegfr2 , induces phosphorylation of two serine residues on plcbeta3 , and this 
16 we show here that vegf , specifically through vegfr2 , induces phosphorylation of two serine residues on plcbeta3 , and this 
12 show here that vegf , specifically through vegfr2 , induces phosphorylation of two serine residues on plcbeta3 , and this was 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL knockdown of plcbeta3 in huvec cells affects ip3 production , actin 
16 NULL NULL NULL NULL knockdown of plcbeta3 in huvec cells affects ip3 production , actin reorganization , migration and proliferation ; 
9 NULL NULL knockdown of plcbeta3 in huvec cells affects ip3 production , actin reorganization , migration and proliferation ; whereas migration 
16 of plcbeta3 in huvec cells affects ip3 production , actin reorganization , migration and proliferation ; whereas migration is inhibited , 
14 in huvec cells affects ip3 production , actin reorganization , migration and proliferation ; whereas migration is inhibited , proliferation is 
1 cells affects ip3 production , actin reorganization , migration and proliferation ; whereas migration is inhibited , proliferation is enhanced . 
14 production , actin reorganization , migration and proliferation ; whereas migration is inhibited , proliferation is enhanced . NULL NULL NULL 
18 actin reorganization , migration and proliferation ; whereas migration is inhibited , proliferation is enhanced . NULL NULL NULL NULL NULL 
1 , migration and proliferation ; whereas migration is inhibited , proliferation is enhanced . NULL NULL NULL NULL NULL NULL NULL 
17 and proliferation ; whereas migration is inhibited , proliferation is enhanced . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL our data suggest that enhanced proliferation is precipitated by an accelerated cell cycle , and 
0 NULL NULL NULL NULL NULL our data suggest that enhanced proliferation is precipitated by an accelerated cell cycle , and decreased 
0 our data suggest that enhanced proliferation is precipitated by an accelerated cell cycle , and decreased migration by an inability to 
0 proliferation is precipitated by an accelerated cell cycle , and decreased migration by an inability to activate cdc42 . NULL NULL 
0 is precipitated by an accelerated cell cycle , and decreased migration by an inability to activate cdc42 . NULL NULL NULL 
17 cell cycle , and decreased migration by an inability to activate cdc42 . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL given that plcbeta3 is typically known as an effector of heterotrimeric 
0 g-proteins , our data demonstrate a unique crosstalk between the protein and receptor tyrosine kinase ( rtk ) axes and reveal 
0 kinase ( rtk ) axes and reveal a novel molecular mechanism of vegf signaling and , thus , angiogenesis . NULL 
3 novel molecular mechanism of vegf signaling and , thus , angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL antivascular actions of binding drugs . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL binding drugs ( mbd ) are widely used in cancer chemotherapy 
0 NULL NULL NULL microtubule-binding drugs ( mbd ) are widely used in cancer chemotherapy and also have clinically relevant antiangiogenic and 
19 microtubule-binding drugs ( mbd ) are widely used in cancer chemotherapy and also have clinically relevant antiangiogenic and vascular-disrupting properties . 
3 widely used in cancer chemotherapy and also have clinically relevant angiogenic and vascular-disrupting properties . NULL NULL NULL NULL NULL NULL 
6 in cancer chemotherapy and also have clinically relevant antiangiogenic and disrupting properties . NULL NULL NULL NULL NULL NULL NULL NULL 
18 cancer chemotherapy and also have clinically relevant antiangiogenic and vascular-disrupting properties . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL these antivascular actions are due in part to direct effects on endothelial cells , and all mbds ( both 
16 NULL these antivascular actions are due in part to direct effects on endothelial cells , and all mbds ( both microtubule-stabilizing 
0 effects on endothelial cells , and all mbds ( both stabilizing and microtubule-destabilizing ) inhibit endothelial cell proliferation , migration , 
18 , and all mbds ( both microtubule-stabilizing and microtubule-destabilizing ) inhibit endothelial cell proliferation , migration , and tube formation in 
1 mbds ( both microtubule-stabilizing and microtubule-destabilizing ) inhibit endothelial cell proliferation , migration , and tube formation in vitro , actions 
14 both microtubule-stabilizing and microtubule-destabilizing ) inhibit endothelial cell proliferation , migration , and tube formation in vitro , actions that are 
2 ) inhibit endothelial cell proliferation , migration , and tube formation in vitro , actions that are thought to correspond to 
3 vitro , actions that are thought to correspond to therapeutic angiogenic actions . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , the microtubule-destabilizing agents cause prominent changes in endothelial cell 
16 NULL NULL in addition , the microtubule-destabilizing agents cause prominent changes in endothelial cell morphology , an action associated with rapid 
0 agents cause prominent changes in endothelial cell morphology , an action associated with rapid vascular collapse in vivo . NULL NULL 
16 cause prominent changes in endothelial cell morphology , an action associated with rapid vascular collapse in vivo . NULL NULL NULL 
6 endothelial cell morphology , an action associated with rapid vascular collapse in vivo . NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL the effects on endothelial cells occur in vitro at low drug concentrations 
16 in vitro at low drug concentrations , which do not affect microtubule gross morphology , do not cause microtubule bundling or 
6 gross morphology , do not cause microtubule bundling or microtubule loss and do not induce cell cycle arrest , apoptosis , 
0 not cause microtubule bundling or microtubule loss and do not induce cell cycle arrest , apoptosis , or cell death . 
0 bundling or microtubule loss and do not induce cell cycle arrest , apoptosis , or cell death . NULL NULL NULL 
5 microtubule loss and do not induce cell cycle arrest , apoptosis , or cell death . NULL NULL NULL NULL NULL 
5 not induce cell cycle arrest , apoptosis , or cell death . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 has been hypothesized that , at low concentrations , mbds produce more subtle effects on microtubule dynamics , block critical cell 
16 that , at low concentrations , mbds produce more subtle effects on microtubule dynamics , block critical cell signaling pathways , 
0 , mbds produce more subtle effects on microtubule dynamics , block critical cell signaling pathways , and prevent the microtubules from 
0 mbds produce more subtle effects on microtubule dynamics , block critical cell signaling pathways , and prevent the microtubules from properly 
0 subtle effects on microtubule dynamics , block critical cell signaling pathways , and prevent the microtubules from properly interacting with transient 
18 microtubule dynamics , block critical cell signaling pathways , and prevent the microtubules from properly interacting with transient subcellular assemblies ( 
15 cell signaling pathways , and prevent the microtubules from properly interacting with transient subcellular assemblies ( focal adhesions and adherens junctions 
6 assemblies ( focal adhesions and adherens junctions ) whose subsequent stabilization and/or maturation are required for cell motility and cell-cell interactions 
2 focal adhesions and adherens junctions ) whose subsequent stabilization and/or maturation are required for cell motility and cell-cell interactions . NULL 
17 and adherens junctions ) whose subsequent stabilization and/or maturation are required for cell motility and cell-cell interactions . NULL NULL NULL 
14 ) whose subsequent stabilization and/or maturation are required for cell motility and cell-cell interactions . NULL NULL NULL NULL NULL NULL 
0 subsequent stabilization and/or maturation are required for cell motility and cell-cell interactions . NULL NULL NULL NULL NULL NULL NULL NULL 
15 stabilization and/or maturation are required for cell motility and cell-cell interactions . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 the identification or design of agents whose actions more selectively target the tumor vasculature . NULL NULL NULL NULL NULL NULL 
0 or design of agents whose actions more selectively target the tumor vasculature . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL neurovascular effects of cd47 signaling : promotion of cell death , inflammation 
17 NULL NULL NULL NULL neurovascular effects of cd47 signaling : promotion of cell death , inflammation , and suppression of angiogenesis 
5 NULL neurovascular effects of cd47 signaling : promotion of cell death , inflammation , and suppression of angiogenesis in brain endothelial 
18 signaling : promotion of cell death , inflammation , and suppression of angiogenesis in brain endothelial cells in vitro . NULL 
3 promotion of cell death , inflammation , and suppression of angiogenesis in brain endothelial cells in vitro . NULL NULL NULL 
0 NULL the concept of the neurovascular unit emphasizes that common signals and substrates underlie the physiology and pathophysiology of neuronal and 
17 NULL NULL NULL NULL NULL NULL recent data suggest that activation of the integrin-associated protein cd47 promotes neuronal cell death . 
15 NULL NULL NULL recent data suggest that activation of the associated protein cd47 promotes neuronal cell death . NULL NULL NULL 
0 NULL NULL recent data suggest that activation of the integrin-associated protein cd47 promotes neuronal cell death . NULL NULL NULL NULL 
17 recent data suggest that activation of the integrin-associated protein cd47 promotes neuronal cell death . NULL NULL NULL NULL NULL NULL 
5 that activation of the integrin-associated protein cd47 promotes neuronal cell death . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL is it possible that cd47 may also negatively affect cerebral endothelial cells ? exposure of wild-type primary mouse 
18 NULL NULL is it possible that cd47 may also negatively affect cerebral endothelial cells ? exposure of wild-type primary mouse cerebral 
19 that cd47 may also negatively affect cerebral endothelial cells ? exposure of wild-type primary mouse cerebral endothelial cells to the cd47 
17 cells to the cd47 ligand thrombospondin 1 ( tsp-1 ) induced an increasing amount of cell death , whereas cytotoxicity was 
0 the cd47 ligand thrombospondin 1 ( tsp-1 ) induced an increasing amount of cell death , whereas cytotoxicity was significantly decreased 
5 1 ( tsp-1 ) induced an increasing amount of cell death , whereas cytotoxicity was significantly decreased in cerebral endothelial cells 
0 increasing amount of cell death , whereas cytotoxicity was significantly decreased in cerebral endothelial cells derived from cd47 knockout mice . 
0 , whereas cytotoxicity was significantly decreased in cerebral endothelial cells derived from cd47 knockout mice . NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL the specific activating peptide , 4n1k , similarly induced cell death in human 
17 NULL NULL the specific cd47-activating peptide , 4n1k , similarly induced cell death in human brain microvascular endothelial cells . NULL 
5 the specific cd47-activating peptide , 4n1k , similarly induced cell death in human brain microvascular endothelial cells . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL promotion of inflammation was also involved because lower tsp-1 was able 
0 NULL NULL NULL NULL NULL promotion of inflammation was also involved because lower tsp-1 was able to up-regulate the adhesion molecules 
17 inflammation was also involved because lower tsp-1 was able to up-regulate the adhesion molecules intercellular adhesion molecule-1 and vascular cell adhesion 
0 also involved because lower tsp-1 was able to up-regulate the adhesion molecules intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 . 
0 lower tsp-1 was able to up-regulate the adhesion molecules intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 . NULL NULL NULL 
0 up-regulate the adhesion molecules intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 . NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL finally , cd47 signaling may suppress angiogenesis because 4n1k significantly inhibited endothelial cell migration and tube 
3 NULL NULL NULL NULL finally , cd47 signaling may suppress angiogenesis because 4n1k significantly inhibited endothelial cell migration and tube formation 
18 finally , cd47 signaling may suppress angiogenesis because 4n1k significantly inhibited endothelial cell migration and tube formation in vitro . NULL 
14 signaling may suppress angiogenesis because 4n1k significantly inhibited endothelial cell migration and tube formation in vitro . NULL NULL NULL NULL 
2 angiogenesis because 4n1k significantly inhibited endothelial cell migration and tube formation in vitro . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL we conclude that cd47 signaling can negatively affect the viability and function of cerebral endothelial cells , 
18 NULL NULL NULL we conclude that cd47 signaling can negatively affect the viability and function of cerebral endothelial cells , further 
0 conclude that cd47 signaling can negatively affect the viability and function of cerebral endothelial cells , further supporting the notion that 
0 the viability and function of cerebral endothelial cells , further supporting the notion that cd47 may be a potential neurovascular target 
0 , further supporting the notion that cd47 may be a potential neurovascular target for stroke and brain injury . NULL NULL 
0 supporting the notion that cd47 may be a potential neurovascular target for stroke and brain injury . NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL cisplatin reduces endothelial cell migration via regulation of type 2-matrix metalloproteinase activity 
14 NULL NULL NULL NULL NULL NULL cisplatin reduces endothelial cell migration via regulation of type 2-matrix metalloproteinase activity . NULL NULL 
16 NULL NULL NULL NULL cisplatin reduces endothelial cell migration via regulation of type 2-matrix metalloproteinase activity . NULL NULL NULL NULL 
0 NULL cisplatin reduces endothelial cell migration via regulation of type matrix metalloproteinase activity . NULL NULL NULL NULL NULL NULL NULL 
0 reduces endothelial cell migration via regulation of type 2-matrix metalloproteinase activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL aims : in this study we investigated the effect of cisplatin on endothelial cell migration , an essential process 
14 study we investigated the effect of cisplatin on endothelial cell migration , an essential process for vascular remodeling and regeneration in 
17 the effect of cisplatin on endothelial cell migration , an essential process for vascular remodeling and regeneration in several physiological and 
7 on endothelial cell migration , an essential process for vascular remodeling and regeneration in several physiological and pathological situations . NULL 
2 cell migration , an essential process for vascular remodeling and regeneration in several physiological and pathological situations . NULL NULL NULL 
19 : human umbilical vein endothelial cells ( huvec ) were treated with cisplatin and endothelial cell migration analyzed by fluorescence and 
14 ( huvec ) were treated with cisplatin and endothelial cell migration analyzed by fluorescence and scratch-wound migration assay . NULL NULL 
0 cisplatin and endothelial cell migration analyzed by fluorescence and scratch-wound migration assay . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL mmp2 and mmp9 activity were determined by zymographic assay , and mapk activation by 
17 mmp9 activity were determined by zymographic assay , and mapk activation by western blotting analysis . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : we demonstrated that cisplatin provoked a time- and dose-dependent 
0 results : we demonstrated that cisplatin provoked a time- and dependent decrease of huvec migration ; this effect was clearly independent 
18 : we demonstrated that cisplatin provoked a time- and dose-dependent decrease of huvec migration ; this effect was clearly independent from 
14 that cisplatin provoked a time- and dose-dependent decrease of huvec migration ; this effect was clearly independent from its well known 
0 a time- and dose-dependent decrease of huvec migration ; this effect was clearly independent from its well known cytotoxic activity . 
0 dose-dependent decrease of huvec migration ; this effect was clearly independent from its well known cytotoxic activity . NULL NULL NULL 
0 this effect was clearly independent from its well known cytotoxic activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL in addition , cisplatin markedly reduced mmp2 activity in both conditioned media 
18 NULL NULL NULL NULL NULL in addition , cisplatin markedly reduced mmp2 activity in both conditioned media and cell lysates , 
0 NULL NULL NULL in addition , cisplatin markedly reduced mmp2 activity in both conditioned media and cell lysates , increased p38 
17 mmp2 activity in both conditioned media and cell lysates , increased p38 mapk and jnk phosphorylation , but did not affect 
12 media and cell lysates , increased p38 mapk and jnk phosphorylation , but did not affect erk phosphorylation . NULL NULL 
16 increased p38 mapk and jnk phosphorylation , but did not affect erk phosphorylation . NULL NULL NULL NULL NULL NULL NULL 
12 mapk and jnk phosphorylation , but did not affect erk phosphorylation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL endothelial cell migration was attenuated by treatment of cells with gm6001 , a 
18 NULL NULL NULL NULL NULL NULL endothelial cell migration was attenuated by treatment of cells with gm6001 , a non-specific inhibitor 
19 NULL NULL NULL NULL endothelial cell migration was attenuated by treatment of cells with gm6001 , a non-specific inhibitor of mmps 
0 attenuated by treatment of cells with gm6001 , a non-specific inhibitor of mmps , or by a selective anti-mmp2 antibody . 
19 NULL NULL NULL NULL NULL NULL NULL NULL however , treatment of cells with sb202190 or sp600125 , inhibitors of p38 
16 inhibitors of p38 mapk and jnk respectively , did not affect huvec migration . NULL NULL NULL NULL NULL NULL NULL 
14 p38 mapk and jnk respectively , did not affect huvec migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL conclusion : these results suggested that cisplatin induced a reduction of endothelial cell migration 
17 NULL NULL NULL conclusion : these results suggested that cisplatin induced a reduction of endothelial cell migration through an inhibition of 
18 NULL conclusion : these results suggested that cisplatin induced a reduction of endothelial cell migration through an inhibition of mmp2 activity 
14 results suggested that cisplatin induced a reduction of endothelial cell migration through an inhibition of mmp2 activity by downstream signal transduction 
18 cisplatin induced a reduction of endothelial cell migration through an inhibition of mmp2 activity by downstream signal transduction pathways independent of 
0 reduction of endothelial cell migration through an inhibition of mmp2 activity by downstream signal transduction pathways independent of jnk and p38 
0 endothelial cell migration through an inhibition of mmp2 activity by downstream signal transduction pathways independent of jnk and p38 mapk activation 
0 through an inhibition of mmp2 activity by downstream signal transduction pathways independent of jnk and p38 mapk activation . NULL NULL 
16 an inhibition of mmp2 activity by downstream signal transduction pathways independent of jnk and p38 mapk activation . NULL NULL NULL 
17 downstream signal transduction pathways independent of jnk and p38 mapk activation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL the modulation of platelet and endothelial cell adhesion to vascular graft materials 
15 NULL NULL NULL the modulation of platelet and endothelial cell adhesion to vascular graft materials by perlecan . NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL controlled neo-endothelialisation is critical to the patency of small diameter vascular 
0 NULL NULL NULL NULL NULL NULL NULL controlled neo-endothelialisation is critical to the patency of small diameter vascular grafts . NULL 
15 NULL NULL NULL NULL NULL NULL NULL endothelialisation and platelet adhesion to purified endothelial cell-derived perlecan , the major heparan sulfate 
0 NULL NULL NULL NULL NULL endothelialisation and platelet adhesion to purified endothelial cell-derived perlecan , the major heparan sulfate ( hs 
0 NULL NULL NULL endothelialisation and platelet adhesion to purified endothelial derived perlecan , the major heparan sulfate ( hs ) proteoglycan 
0 and platelet adhesion to purified endothelial cell-derived perlecan , the major heparan sulfate ( hs ) proteoglycan in basement membranes , 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL enhanced endothelial cell growth and reduced platelet adhesion were observed on 
1 NULL NULL NULL NULL NULL NULL NULL enhanced endothelial cell growth and reduced platelet adhesion were observed on the perlecan coated 
18 NULL NULL NULL NULL NULL enhanced endothelial cell growth and reduced platelet adhesion were observed on the perlecan coated grafts when 
15 NULL NULL NULL enhanced endothelial cell growth and reduced platelet adhesion were observed on the perlecan coated grafts when compared to 
0 NULL enhanced endothelial cell growth and reduced platelet adhesion were observed on the perlecan coated grafts when compared to uncoated controls 
0 observed on the perlecan coated grafts when compared to uncoated controls implanted in the same sheep ( n=5 ) . NULL 
19 on the perlecan coated grafts when compared to uncoated controls implanted in the same sheep ( n=5 ) . NULL NULL 
17 NULL NULL NULL NULL NULL perlecan was also found to stimulate endothelial cell proliferation in vitro over a period of 6 
1 NULL NULL perlecan was also found to stimulate endothelial cell proliferation in vitro over a period of 6 days in the 
14 in vitro over a period of 6 days in the presence of plasma proteins and fibroblastic growth factor 2 ( fgf-2 
0 6 days in the presence of plasma proteins and fibroblastic growth factor 2 ( fgf-2 ) , however in the absence 
1 ) , however in the absence of fgf-2 endothelial cell growth could not be maintained during this period . NULL NULL 
0 the absence of fgf-2 endothelial cell growth could not be maintained during this period . NULL NULL NULL NULL NULL NULL 
15 NULL NULL NULL NULL NULL perlecan was found to be adhesive for platelets , however after removal of the hs chains 
0 was found to be anti-adhesive for platelets , however after removal of the hs chains attached to perlecan , platelet adhesion 
15 removal of the hs chains attached to perlecan , platelet adhesion and aggregation were supported . NULL NULL NULL NULL NULL 
15 the hs chains attached to perlecan , platelet adhesion and aggregation were supported . NULL NULL NULL NULL NULL NULL NULL 
0 chains attached to perlecan , platelet adhesion and aggregation were supported . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results suggest a role for hs chains of perlecan in improving 
0 NULL NULL NULL NULL NULL NULL these results suggest a role for hs chains of perlecan in improving graft patency by 
17 hs chains of perlecan in improving graft patency by selectively promoting endothelial cell proliferation while modulating platelet adhesion . NULL NULL 
1 perlecan in improving graft patency by selectively promoting endothelial cell proliferation while modulating platelet adhesion . NULL NULL NULL NULL NULL 
16 improving graft patency by selectively promoting endothelial cell proliferation while modulating platelet adhesion . NULL NULL NULL NULL NULL NULL NULL 
15 patency by selectively promoting endothelial cell proliferation while modulating platelet adhesion . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL tumour angiogenesis : its mechanism and therapeutic implications in malignant gliomas . 
0 NULL NULL NULL NULL NULL NULL tumour angiogenesis : its mechanism and therapeutic implications in malignant gliomas . NULL NULL NULL 
0 NULL tumour angiogenesis : its mechanism and therapeutic implications in malignant gliomas . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis is a key event in the progression of malignant gliomas 
0 NULL NULL NULL NULL NULL NULL NULL angiogenesis is a key event in the progression of malignant gliomas . NULL NULL 
2 NULL NULL NULL angiogenesis is a key event in the progression of malignant gliomas . NULL NULL NULL NULL NULL NULL 
0 NULL angiogenesis is a key event in the progression of malignant gliomas . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the presence of microvascular proliferation leads to the histological diagnosis of glioblastoma 
2 NULL NULL NULL NULL NULL NULL the presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme . NULL 
0 NULL NULL NULL NULL NULL the presence of microvascular proliferation leads to the histological diagnosis of glioblastoma multiforme . NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL tumour angiogenesis involves multiple cellular processes including endothelial cell proliferation , migration 
16 NULL NULL NULL NULL NULL NULL NULL NULL tumour angiogenesis involves multiple cellular processes including endothelial cell proliferation , migration , 
0 NULL NULL NULL NULL NULL tumour angiogenesis involves multiple cellular processes including endothelial cell proliferation , migration , reorganisation of extracellular 
1 NULL tumour angiogenesis involves multiple cellular processes including endothelial cell proliferation , migration , reorganisation of extracellular matrix and tube formation 
14 angiogenesis involves multiple cellular processes including endothelial cell proliferation , migration , reorganisation of extracellular matrix and tube formation . NULL 
0 including endothelial cell proliferation , migration , reorganisation of extracellular matrix and tube formation . NULL NULL NULL NULL NULL NULL 
2 proliferation , migration , reorganisation of extracellular matrix and tube formation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these processes are regulated by numerous pro-angiogenic and anti-angiogenic growth factors . 
0 NULL NULL NULL NULL NULL NULL NULL these processes are regulated by numerous pro-angiogenic and anti-angiogenic growth factors . NULL NULL 
3 NULL NULL NULL NULL these processes are regulated by numerous angiogenic and anti-angiogenic growth factors . NULL NULL NULL NULL NULL 
3 NULL NULL these processes are regulated by numerous pro-angiogenic and angiogenic growth factors . NULL NULL NULL NULL NULL NULL NULL 
0 NULL these processes are regulated by numerous pro-angiogenic and anti-angiogenic growth factors . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis inhibitors have been developed to interrupt the angiogenic process at 
0 NULL NULL NULL NULL NULL NULL angiogenesis inhibitors have been developed to interrupt the angiogenic process at the growth factor , 
3 NULL NULL angiogenesis inhibitors have been developed to interrupt the angiogenic process at the growth factor , receptor tyrosine kinase and 
0 have been developed to interrupt the angiogenic process at the growth factor , receptor tyrosine kinase and intracellular kinase levels . 
0 the growth factor , receptor tyrosine kinase and intracellular kinase levels . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL other angiogenic therapies alter the immune response and endogeneous angiogenesis inhibitor levels 
18 NULL NULL NULL NULL NULL NULL NULL NULL other anti-angiogenic therapies alter the immune response and endogeneous angiogenesis inhibitor levels . 
0 NULL NULL NULL NULL NULL NULL NULL other anti-angiogenic therapies alter the immune response and endogeneous angiogenesis inhibitor levels . NULL 
0 NULL NULL NULL NULL other anti-angiogenic therapies alter the immune response and endogeneous angiogenesis inhibitor levels . NULL NULL NULL NULL 
3 NULL other anti-angiogenic therapies alter the immune response and endogeneous angiogenesis inhibitor levels . NULL NULL NULL NULL NULL NULL NULL 
0 other anti-angiogenic therapies alter the immune response and endogeneous angiogenesis inhibitor levels . NULL NULL NULL NULL NULL NULL NULL NULL 
0 anti-angiogenic therapies alter the immune response and endogeneous angiogenesis inhibitor levels . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL most angiogenic therapies for malignant gliomas are in phase i/ii trials and 
18 NULL NULL NULL NULL NULL NULL NULL NULL most anti-angiogenic therapies for malignant gliomas are in phase i/ii trials and only 
0 NULL NULL NULL NULL NULL NULL most anti-angiogenic therapies for malignant gliomas are in phase i/ii trials and only modest efficacies 
0 most anti-angiogenic therapies for malignant gliomas are in phase i/ii trials and only modest efficacies are reported for monotherapies . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the greatest potential for angiogenesis inhibitors may lie in their ability to combine 
3 NULL NULL NULL NULL NULL NULL the greatest potential for angiogenesis inhibitors may lie in their ability to combine safely with 
0 the greatest potential for angiogenesis inhibitors may lie in their ability to combine safely with chemotherapy and radiotherapy . NULL NULL 
0 inhibitors may lie in their ability to combine safely with chemotherapy and radiotherapy . NULL NULL NULL NULL NULL NULL NULL 
0 lie in their ability to combine safely with chemotherapy and radiotherapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL regulation of thrombospondin-1 by natural and synthetic progestins in human breast 
17 NULL NULL NULL NULL our recent studies show that progestins induce vascular endothelial growth factor ( vegf ) in breast cancer 
0 NULL our recent studies show that progestins induce vascular endothelial growth factor ( vegf ) in breast cancer cells that express 
9 growth factor ( vegf ) in breast cancer cells that express mutant p53 protein . NULL NULL NULL NULL NULL NULL 
0 vegf ) in breast cancer cells that express mutant p53 protein . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 here , we show that natural and synthetic progestins also induce thrombospondin-1 ( tsp-1 ) mrna and protein in t47-d and 
0 natural and synthetic progestins also induce thrombospondin-1 ( tsp-1 ) mrna and protein in t47-d and bt-474 breast cancer cells . 
0 synthetic progestins also induce thrombospondin-1 ( tsp-1 ) mrna and protein in t47-d and bt-474 breast cancer cells . NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL antiprogestin ru-486 inhibits the induction of vegf and tsp-1 by progestins , suggesting 
17 NULL NULL NULL NULL NULL NULL antiprogestin ru-486 inhibits the induction of vegf and tsp-1 by progestins , suggesting that this 
0 of vegf and tsp-1 by progestins , suggesting that this effect of progestin is mediated by the progesterone receptor ( pr 
16 by progestins , suggesting that this effect of progestin is mediated by the progesterone receptor ( pr ) . NULL NULL 
18 NULL NULL NULL actinomycin-d , but not puromycin , also blocks progestin-dependent induction of tsp-1 . NULL NULL NULL NULL NULL 
17 NULL NULL actinomycin-d , but not puromycin , also blocks dependent induction of tsp-1 . NULL NULL NULL NULL NULL NULL 
17 NULL actinomycin-d , but not puromycin , also blocks progestin-dependent induction of tsp-1 . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL a putative response element was identified in the human tsp-1 promoter , which 
16 consistent with the hypothesis that a progestin-pr complex might directly regulate transcription of the tsp-1 gene in human cells . NULL 
10 with the hypothesis that a progestin-pr complex might directly regulate transcription of the tsp-1 gene in human cells . NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL conditioned medium from treated breast cancer cells stimulates endothelial cell proliferation in the absence 
17 NULL NULL NULL conditioned medium from progestin-treated breast cancer cells stimulates endothelial cell proliferation in the absence though not in the 
1 conditioned medium from progestin-treated breast cancer cells stimulates endothelial cell proliferation in the absence though not in the presence of antibody 
0 endothelial cell proliferation in the absence though not in the presence of antibody to tsp-1 , indicating that tsp-1 secreted by 
14 the presence of antibody to tsp-1 , indicating that tsp-1 secreted by breast cancer cells could be pro-angiogenic . NULL NULL 
3 indicating that tsp-1 secreted by breast cancer cells could be angiogenic . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL since tumor cell-derived tsp-1 has the potential to promote angiogenesis in the 
0 NULL NULL NULL NULL NULL NULL NULL NULL since tumor derived tsp-1 has the potential to promote angiogenesis in the tumor 
0 NULL NULL NULL NULL since tumor cell-derived tsp-1 has the potential to promote angiogenesis in the tumor microenvironment , it could 
17 NULL NULL since tumor cell-derived tsp-1 has the potential to promote angiogenesis in the tumor microenvironment , it could be a 
3 NULL since tumor cell-derived tsp-1 has the potential to promote angiogenesis in the tumor microenvironment , it could be a potential 
0 cell-derived tsp-1 has the potential to promote angiogenesis in the tumor microenvironment , it could be a potential target for breast 
0 angiogenesis in the tumor microenvironment , it could be a potential target for breast cancer therapy . NULL NULL NULL NULL 
0 in the tumor microenvironment , it could be a potential target for breast cancer therapy . NULL NULL NULL NULL NULL 
19 , it could be a potential target for breast cancer therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL c-ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth 
17 NULL NULL NULL NULL NULL NULL NULL NULL c-ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta 
0 NULL NULL NULL NULL NULL NULL NULL c-ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling 
4 NULL NULL NULL NULL NULL NULL c-ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in 
3 NULL NULL NULL NULL c-ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric 
18 NULL NULL c-ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma . 
0 overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma . NULL NULL NULL 
0 , originally identified as a proto-oncogene product , is an important negative regulator of transforming growth factor ( tgf ) -beta 
0 originally identified as a proto-oncogene product , is an important negative regulator of transforming growth factor ( tgf ) -beta family 
0 identified as a proto-oncogene product , is an important negative regulator of transforming growth factor ( tgf ) -beta family signaling 
0 proto-oncogene product , is an important negative regulator of transforming growth factor ( tgf ) -beta family signaling through interaction with 
15 transforming growth factor ( tgf ) -beta family signaling through interaction with smad2 , smad3 , and smad4 . NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL high expression of c-ski has been found in some cancers , including 
0 NULL NULL NULL NULL NULL NULL NULL NULL we previously showed that disruption of tgf-beta signaling by dominant-negative tgf-beta type ii 
18 NULL NULL NULL NULL NULL NULL we previously showed that disruption of tgf-beta signaling by dominant-negative tgf-beta type ii receptor in 
0 NULL we previously showed that disruption of tgf-beta signaling by negative tgf-beta type ii receptor in a diffuse-type gastric carcinoma model 
17 tgf-beta type ii receptor in a diffuse-type gastric carcinoma model accelerated tumor growth through induction of tumor angiogenesis by decreased expression 
0 type ii receptor in a diffuse-type gastric carcinoma model accelerated tumor growth through induction of tumor angiogenesis by decreased expression of 
4 ii receptor in a diffuse-type gastric carcinoma model accelerated tumor growth through induction of tumor angiogenesis by decreased expression of the 
17 in a diffuse-type gastric carcinoma model accelerated tumor growth through induction of tumor angiogenesis by decreased expression of the anti-angiogenic factor 
0 diffuse-type gastric carcinoma model accelerated tumor growth through induction of tumor angiogenesis by decreased expression of the anti-angiogenic factor thrombospondin ( 
3 gastric carcinoma model accelerated tumor growth through induction of tumor angiogenesis by decreased expression of the anti-angiogenic factor thrombospondin ( tsp 
18 model accelerated tumor growth through induction of tumor angiogenesis by decreased expression of the anti-angiogenic factor thrombospondin ( tsp ) -1 
9 accelerated tumor growth through induction of tumor angiogenesis by decreased expression of the anti-angiogenic factor thrombospondin ( tsp ) -1 . 
3 through induction of tumor angiogenesis by decreased expression of the angiogenic factor thrombospondin ( tsp ) -1 . NULL NULL NULL 
0 NULL NULL NULL NULL NULL here , we examined the function of c-ski in human diffuse-type gastric carcinoma ocum-2mln cells . 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL overexpression of c-ski inhibited tgf-beta signaling in ocum-2mln cells . NULL 
18 NULL NULL NULL NULL NULL NULL NULL overexpression of c-ski inhibited tgf-beta signaling in ocum-2mln cells . NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL NULL NULL interestingly , c-ski overexpression resulted in extensive acceleration of the growth of subcutaneous xenografts 
0 NULL NULL NULL NULL NULL NULL interestingly , c-ski overexpression resulted in extensive acceleration of the growth of subcutaneous xenografts in 
4 interestingly , c-ski overexpression resulted in extensive acceleration of the growth of subcutaneous xenografts in balb/c nu/nu female mice ( 6 
9 NULL NULL NULL NULL NULL NULL NULL similar to tumors expressing dominant-negative tgf-beta type ii receptor , histochemical studies revealed less 
0 NULL NULL NULL NULL NULL NULL similar to tumors expressing negative tgf-beta type ii receptor , histochemical studies revealed less fibrosis 
17 type ii receptor , histochemical studies revealed less fibrosis and increased angiogenesis in xenografted tumors expressing c-ski compared to control tumors 
3 ii receptor , histochemical studies revealed less fibrosis and increased angiogenesis in xenografted tumors expressing c-ski compared to control tumors . 
9 studies revealed less fibrosis and increased angiogenesis in xenografted tumors expressing c-ski compared to control tumors . NULL NULL NULL NULL 
0 and increased angiogenesis in xenografted tumors expressing c-ski compared to control tumors . NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL induction of tsp-1 mrna by tgf-beta was attenuated by c-ski in 
0 NULL NULL NULL NULL NULL NULL NULL induction of tsp-1 mrna by tgf-beta was attenuated by c-ski in vitro , and 
18 NULL NULL NULL induction of tsp-1 mrna by tgf-beta was attenuated by c-ski in vitro , and expression of tsp-1 mrna 
10 by tgf-beta was attenuated by c-ski in vitro , and expression of tsp-1 mrna was decreased in tumors expressing c-ski in 
0 attenuated by c-ski in vitro , and expression of tsp-1 mrna was decreased in tumors expressing c-ski in vivo . NULL 
18 c-ski in vitro , and expression of tsp-1 mrna was decreased in tumors expressing c-ski in vivo . NULL NULL NULL 
9 , and expression of tsp-1 mrna was decreased in tumors expressing c-ski in vivo . NULL NULL NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL these findings suggest that c-ski overexpression promotes the growth of diffuse-type gastric carcinoma through induction of 
17 NULL NULL NULL NULL these findings suggest that c-ski overexpression promotes the growth of diffuse-type gastric carcinoma through induction of angiogenesis 
4 NULL NULL these findings suggest that c-ski overexpression promotes the growth of diffuse-type gastric carcinoma through induction of angiogenesis . NULL 
17 c-ski overexpression promotes the growth of diffuse-type gastric carcinoma through induction of angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 promotes the growth of diffuse-type gastric carcinoma through induction of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis novel therapeutic approach for ischemic heart disease . NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis is the biologic process of forming new blood vessels . 
2 NULL NULL NULL NULL angiogenesis is the biologic process of forming new blood vessels . NULL NULL NULL NULL NULL NULL 
4 NULL NULL NULL NULL NULL NULL undoubtedly , blood vessels growth regulation is a vital aspect in health and disease . 
16 NULL NULL NULL NULL NULL undoubtedly , blood vessels growth regulation is a vital aspect in health and disease . NULL 
3 NULL NULL NULL NULL NULL NULL under physiological conditions , angiogenesis is regulated by local balance between endogenous stimulators and inhibitors 
16 NULL NULL NULL NULL under physiological conditions , angiogenesis is regulated by local balance between endogenous stimulators and inhibitors of this 
16 NULL NULL NULL NULL in many diseases state body loses control over angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL in many diseases state body loses control over angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis diseases result when new blood vessels either grow excessively or 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL dependent diseases result when new blood vessels either grow excessively or 
4 NULL NULL angiogenesis-dependent diseases result when new blood vessels either grow excessively or insufficiently . NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL insufficient angiogenesis occurs in diseases such as coronary artery disease , stroke 
17 ischemia both acute and chronic has been clearly shown to stimulate angiogenesis in many experimental models . NULL NULL NULL NULL 
3 both acute and chronic has been clearly shown to stimulate angiogenesis in many experimental models . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL therapeutic angiogenesis is the biological agents or bioactive material to stimulate the 
17 therapeutic angiogenesis is the biological agents or bioactive material to stimulate the growth of new blood vessels . NULL NULL NULL 
4 is the biological agents or bioactive material to stimulate the growth of new blood vessels . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL traditional coronary revascularization therapies such as coronary angioplasty or bypass graft surgery , 
0 NULL NULL NULL NULL NULL NULL NULL traditional coronary revascularization therapies such as coronary angioplasty or bypass graft surgery , act 
0 coronary revascularization therapies such as coronary angioplasty or bypass graft surgery , act by restoring blood flow through the preexisting coronary 
0 therapies such as coronary angioplasty or bypass graft surgery , act by restoring blood flow through the preexisting coronary vessels . 
0 , however , may be the failure to normalize myocardial perfusion , due to the concomitant presence or small of resistance 
0 failure to normalize myocardial perfusion , due to the concomitant presence or small of resistance vessel disease . NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL in contrast , therapeutic angiogenesis is based on the concept that coronary collateral development may 
2 therapeutic angiogenesis is based on the concept that coronary collateral development may be stimulated by pharmacological or molecular means and can 
17 based on the concept that coronary collateral development may be stimulated by pharmacological or molecular means and can limit myocardial ischemia 
0 may be stimulated by pharmacological or molecular means and can limit myocardial ischemia . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL studies , both in human and animal models support the notion that , various angiogenic growth factors and progenitor 
3 human and animal models support the notion that , various angiogenic growth factors and progenitor cells can enhance new blood vessels 
0 and animal models support the notion that , various angiogenic growth factors and progenitor cells can enhance new blood vessels . 
17 that , various angiogenic growth factors and progenitor cells can enhance new blood vessels . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) , fibroblast growth factor ( fgf 
0 NULL vascular endothelial growth factor ( vegf ) , fibroblast growth factor ( fgf ) , recombinant proteins and bone marrow 
0 , recombinant proteins and bone marrow stem cells are currently used therapeutic stimulators for angiogenesis . NULL NULL NULL NULL NULL 
3 bone marrow stem cells are currently used therapeutic stimulators for angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL as coronary artery disease is the major cause of death in the developed societies and also an 
0 NULL as coronary artery disease is the major cause of death in the developed societies and also an emerging health problem 
0 artery disease is the major cause of death in the developed societies and also an emerging health problem in developing countries 
0 the developed societies and also an emerging health problem in developing countries like bangladesh therapeutic angiogenesis may provide hope as a 
3 an emerging health problem in developing countries like bangladesh therapeutic angiogenesis may provide hope as a new treatment modality for ischemic 
0 like bangladesh therapeutic angiogenesis may provide hope as a new treatment modality for ischemic heart disease with or in place of 
0 for ischemic heart disease with or in place of current therapies . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL use of uteroglobin for the engineering of polyvalent , polyspecific fusion 
0 use of uteroglobin for the engineering of polyvalent , polyspecific fusion proteins . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL we report a novel strategy to engineer and express stable and soluble human recombinant polyvalent/polyspecific fusion proteins . NULL 
0 to engineer and express stable and soluble human recombinant polyvalent/polyspecific fusion proteins . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL the procedure is based on the use of a central skeleton of uteroglobin , a small and 
0 NULL the procedure is based on the use of a central skeleton of uteroglobin , a small and very soluble covalently 
0 skeleton of uteroglobin , a small and very soluble covalently linked homodimeric protein that is very resistant to proteolytic enzymes and 
0 uteroglobin , a small and very soluble covalently linked homodimeric protein that is very resistant to proteolytic enzymes and to ph 
3 a human recombinant antibody ( scfv ) specific for the angiogenesis marker domain b of fibronectin , interleukin 2 , and 
18 fibronectin , interleukin 2 , and an scfv able to neutralize tumor necrosis factor-alpha , we expressed various biologically active uteroglobin 
0 , interleukin 2 , and an scfv able to neutralize tumor necrosis factor-alpha , we expressed various biologically active uteroglobin fusion 
0 interleukin 2 , and an scfv able to neutralize tumor necrosis factor-alpha , we expressed various biologically active uteroglobin fusion proteins 
0 an scfv able to neutralize tumor necrosis factor-alpha , we expressed various biologically active uteroglobin fusion proteins . NULL NULL NULL 
0 to neutralize tumor necrosis factor-alpha , we expressed various biologically active uteroglobin fusion proteins . NULL NULL NULL NULL NULL NULL 
0 tumor necrosis factor-alpha , we expressed various biologically active uteroglobin fusion proteins . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the results demonstrate the possibility to generate monospecific divalent and tetravalent antibodies 
0 NULL NULL NULL NULL NULL furthermore , compared with similar fusion proteins in which uteroglobin was not used , the use 
0 compared with similar fusion proteins in which uteroglobin was not used , the use of uteroglobin improved properties of solubility and 
0 fusion proteins in which uteroglobin was not used , the use of uteroglobin improved properties of solubility and stability . NULL 
0 which uteroglobin was not used , the use of uteroglobin improved properties of solubility and stability . NULL NULL NULL NULL 
0 uteroglobin was not used , the use of uteroglobin improved properties of solubility and stability . NULL NULL NULL NULL NULL 
0 possible to vacuum dry and reconstitute the proteins without any aggregation or loss in protein and biological activity . NULL NULL 
0 vacuum dry and reconstitute the proteins without any aggregation or loss in protein and biological activity . NULL NULL NULL NULL 
0 and reconstitute the proteins without any aggregation or loss in protein and biological activity . NULL NULL NULL NULL NULL NULL 
0 proteins without any aggregation or loss in protein and biological activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL [ prognostic significance of cellular vascular endothelial growth factor ( vegf ) expression in the course of chronic 
9 significance of cellular vascular endothelial growth factor ( vegf ) expression in the course of chronic myeloid leukaemia ] NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL introduction : increased angiogenesis in bone marrow is one of the 
17 NULL NULL NULL NULL NULL NULL NULL NULL introduction : increased angiogenesis in bone marrow is one of the characteristics of 
3 NULL NULL NULL NULL NULL NULL NULL introduction : increased angiogenesis in bone marrow is one of the characteristics of chronic 
0 , a clonal myeloproliferative disorder that expresses a chimeric bcr/abl protein . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL vascular endothelial growth factor ( vegf ) is one of the most potent 
16 ) is one of the most potent and a specific regulator of angiogenesis which principally targets endothelial cells and regulates several 
3 one of the most potent and a specific regulator of angiogenesis which principally targets endothelial cells and regulates several of their 
0 most potent and a specific regulator of angiogenesis which principally targets endothelial cells and regulates several of their functions , including 
16 specific regulator of angiogenesis which principally targets endothelial cells and regulates several of their functions , including mitogenesis , permeability and 
0 which principally targets endothelial cells and regulates several of their functions , including mitogenesis , permeability and migration . NULL NULL 
0 several of their functions , including mitogenesis , permeability and migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the impact of elevated vegf expression on the course of chronic myeloid 
17 NULL NULL NULL NULL NULL NULL NULL the impact of elevated vegf expression on the course of chronic myeloid leukaemia is 
9 NULL NULL NULL NULL NULL the impact of elevated vegf expression on the course of chronic myeloid leukaemia is unknown . 
9 the aim of this study was the follow-up of vegf expression during the course of cml . NULL NULL NULL NULL 
9 NULL NULL NULL NULL NULL methods : we studied vegf expression of 85 cml patients ( median age 50 years , 
0 in chronic phase ( cp ) , 25 in an accelerated phase ( ap ) , and 31 in the blast 
9 NULL NULL NULL NULL NULL NULL NULL NULL the temporal expression ( percentage positivity per 1000 analysed cells ) vegf proteins 
0 proteins over the course of cml were studied using the immunohistochemical technique utilizing relevant monoclonal antibodies . NULL NULL NULL NULL 
0 platelet counts , and the percentage of blasts ) and clinical parameters ( organomegaly , duration of cp , ap , 
0 of cp , ap , and bc ) of disease progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : the expression ofvegf protein was most pronounced in ap 
9 NULL NULL NULL NULL NULL NULL NULL results : the expression ofvegf protein was most pronounced in ap ( anova , 
0 NULL NULL NULL NULL NULL results : the expression ofvegf protein was most pronounced in ap ( anova , p=0.033 ) 
9 NULL NULL NULL NULL NULL NULL the level of vegf expression correlated inversely with the degree of splenomegaly ( pearson , 
9 NULL NULL NULL NULL NULL NULL NULL NULL NULL high expression of vegf correlated with a shorter overall survival ( log 
0 NULL high expression of vegf correlated with a shorter overall survival ( log rank , p=0.042 ) . NULL NULL NULL 
9 NULL NULL NULL conclusion : immunohistochemically confirmed significance of the expression of vegf in dependence of the cml stage could be 
0 vegf in dependence of the cml stage could be of clinical importance in deciding on the timing therapy . NULL NULL 
0 could be of clinical importance in deciding on the timing therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL these data suggest that vegf plays a role in the biology of cml and that vegf 
0 NULL NULL NULL these data suggest that vegf plays a role in the biology of cml and that vegf inhibitors should 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor angiogenesis : initiation and targeting - therapeutic targeting of an 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor angiogenesis : initiation and targeting - therapeutic targeting of an fgf-binding 
0 NULL NULL NULL NULL NULL NULL NULL tumor angiogenesis : initiation and targeting - therapeutic targeting of an fgf-binding protein , 
0 NULL NULL NULL NULL NULL tumor angiogenesis : initiation and targeting - therapeutic targeting of an fgf-binding protein , an angiogenic 
19 NULL NULL tumor angiogenesis : initiation and targeting - therapeutic targeting of an fgf-binding protein , an angiogenic switch molecule , 
0 angiogenesis : initiation and targeting - therapeutic targeting of an binding protein , an angiogenic switch molecule , and indicator of 
0 : initiation and targeting - therapeutic targeting of an fgf-binding protein , an angiogenic switch molecule , and indicator of early 
3 targeting - therapeutic targeting of an fgf-binding protein , an angiogenic switch molecule , and indicator of early stages of gastrointestinal 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor angiogenesis has been related to the initiation as well as 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL tumor angiogenesis has been related to the initiation as well as progression 
17 NULL NULL NULL tumor angiogenesis has been related to the initiation as well as progression toward more aggressive behavior of human 
17 angiogenesis has been related to the initiation as well as progression toward more aggressive behavior of human tumors . NULL NULL 
0 NULL NULL NULL NULL NULL NULL in particular , the activity of angiogenic factors is crucial for tumor progression . NULL 
3 NULL NULL NULL NULL in particular , the activity of angiogenic factors is crucial for tumor progression . NULL NULL NULL 
0 NULL in particular , the activity of angiogenic factors is crucial for tumor progression . NULL NULL NULL NULL NULL NULL 
0 particular , the activity of angiogenic factors is crucial for tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL 
2 , the activity of angiogenic factors is crucial for tumor progression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL we previously characterized a secreted fibroblast growth factor-binding protein ( fgf-bp ) as a chaperone 
0 NULL NULL NULL NULL we previously characterized a secreted fibroblast growth factor-binding protein ( fgf-bp ) as a chaperone molecule , 
0 NULL NULL NULL we previously characterized a secreted fibroblast growth binding protein ( fgf-bp ) as a chaperone molecule , which 
0 NULL NULL we previously characterized a secreted fibroblast growth factor-binding protein ( fgf-bp ) as a chaperone molecule , which binds 
0 protein ( fgf-bp ) as a chaperone molecule , which binds to various fgfs , enhances fgf-mediated biochemical and biologic events 
0 a chaperone molecule , which binds to various fgfs , enhances fgf-mediated biochemical and biologic events and importantly is a crucial 
0 chaperone molecule , which binds to various fgfs , enhances mediated biochemical and biologic events and importantly is a crucial rate-limiting 
17 enhances fgf-mediated biochemical and biologic events and importantly is a crucial rate-limiting factor for tumor-dependent angiogenesis . NULL NULL NULL NULL 
0 fgf-mediated biochemical and biologic events and importantly is a crucial limiting factor for tumor-dependent angiogenesis . NULL NULL NULL NULL NULL 
17 biologic events and importantly is a crucial rate-limiting factor for dependent angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL 
3 events and importantly is a crucial rate-limiting factor for tumor-dependent angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL we generated monoclonal antibodies that target fgf-bp protein and used them as a tool to evaluate 
0 NULL NULL NULL we generated monoclonal antibodies that target fgf-bp protein and used them as a tool to evaluate frequency and 
0 NULL we generated monoclonal antibodies that target fgf-bp protein and used them as a tool to evaluate frequency and pattern of 
9 as a tool to evaluate frequency and pattern of fgf-bp expression during the malignant progression of pancreas and colorectal carcinoma in 
0 to evaluate frequency and pattern of fgf-bp expression during the malignant progression of pancreas and colorectal carcinoma in archival tissue samples 
2 evaluate frequency and pattern of fgf-bp expression during the malignant progression of pancreas and colorectal carcinoma in archival tissue samples . 
17 NULL NULL NULL NULL we found that fgf-bp is dramatically upregulated during the initiation of colorectal and pancreatic adenocarcinoma . NULL 
2 NULL we found that fgf-bp is dramatically upregulated during the initiation of colorectal and pancreatic adenocarcinoma . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL crucial genetic events underlying the initiation and progression of colorectal and 
2 NULL NULL NULL NULL NULL crucial genetic events underlying the initiation and progression of colorectal and pancreatic adenocarcinoma with a particular 
2 NULL NULL NULL crucial genetic events underlying the initiation and progression of colorectal and pancreatic adenocarcinoma with a particular focus on 
16 colorectal and pancreatic adenocarcinoma with a particular focus on the modulation of angiogenesis and antiangiogenic therapies are discussed . NULL NULL 
3 pancreatic adenocarcinoma with a particular focus on the modulation of angiogenesis and antiangiogenic therapies are discussed . NULL NULL NULL NULL 
3 with a particular focus on the modulation of angiogenesis and angiogenic therapies are discussed . NULL NULL NULL NULL NULL NULL 
19 a particular focus on the modulation of angiogenesis and antiangiogenic therapies are discussed . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL we propose that the upregulation of the secreted fgf-bp protein during early phases of pancreas 
14 NULL NULL NULL we propose that the upregulation of the secreted fgf-bp protein during early phases of pancreas and colon cancer 
0 NULL we propose that the upregulation of the secreted fgf-bp protein during early phases of pancreas and colon cancer could make 
0 early phases of pancreas and colon cancer could make this protein a possible serum marker indicating the presence of high-risk premalignant 
0 could make this protein a possible serum marker indicating the presence of high-risk premalignant lesions . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL furthermore , the biological activity of fgf-bp is neutralized by monoclonal antibodies suggesting the potential 
0 activity of fgf-bp is neutralized by monoclonal antibodies suggesting the potential for antibody-based therapeutic targeting . NULL NULL NULL NULL NULL 
0 neutralized by monoclonal antibodies suggesting the potential for antibody-based therapeutic targeting . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL experimental drug therapy of peritumoral brain edema . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL four drugs with potential anti-peritumoral brain edema activity were studied using the vx2 rabbit 
18 NULL NULL NULL four drugs with potential anti-peritumoral brain edema activity were studied using the vx2 rabbit brain tumor model . 
0 brain edema activity were studied using the vx2 rabbit brain tumor model . NULL NULL NULL NULL NULL NULL NULL NULL 
18 tested in an attempt to confirm recent reports of anti-edema activity in non steroidal anti-inflammatory drugs ( nsaid 's ) . 
0 were tested because of their lack of glucocorticoid and mineralocorticoid effects and their structural similarity to glucocorticoids . NULL NULL NULL 
0 of their lack of glucocorticoid and mineralocorticoid effects and their structural similarity to glucocorticoids . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the protein and water component of brain edema were indirectly quantitated . 
0 NULL NULL NULL NULL none of the test drugs demonstrated significant anti-edema activity . NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL none of the test drugs demonstrated significant anti-edema activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 work does not confirm reports that nsaid 's have anti-edema activity and suggests that there may be no correlation between 'angiostatic 
18 there may be no correlation between 'angiostatic ' and anti-edema activity in certain steroid compounds . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL low-level radiation effects on functional vascular changes in syrian hamster cheek pouch 
16 NULL NULL NULL NULL NULL NULL NULL NULL low-level x-radiation effects on functional vascular changes in syrian hamster cheek pouch epithelium 
16 NULL NULL NULL NULL low-level x-radiation effects on functional vascular changes in syrian hamster cheek pouch epithelium during hydrocarbon carcinogenesis . 
0 vascular changes in syrian hamster cheek pouch epithelium during hydrocarbon carcinogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL effects of repeated low-level x radiation on functional microvascular changes in 
0 NULL NULL NULL NULL NULL effects of repeated low-level x radiation on functional microvascular changes in hamster cheek pouch epithelium during 
16 NULL effects of repeated low-level x radiation on functional microvascular changes in hamster cheek pouch epithelium during and following carcinogenesis by 
0 microvascular changes in hamster cheek pouch epithelium during and following carcinogenesis by 7 , 12-dimethylbenz [ a ] anthracene ( dmba 
0 NULL NULL NULL NULL NULL NULL NULL NULL prior studies showed enhancement of such carcinogenesis by repeated 20 rad head and 
0 NULL NULL NULL NULL NULL NULL NULL prior studies showed enhancement of such carcinogenesis by repeated 20 rad head and neck 
0 NULL NULL NULL NULL prior studies showed enhancement of such carcinogenesis by repeated 20 rad head and neck x-radiation exposures , 
19 of such carcinogenesis by repeated 20 rad head and neck radiation exposures , and it was proposed that one possible mechanism 
0 x-radiation exposures , and it was proposed that one possible mechanism was radiogenic alteration of the functional microvasculature in a manner 
0 of the functional microvasculature in a manner which favored subsequent tumor development . NULL NULL NULL NULL NULL NULL NULL NULL 
2 the functional microvasculature in a manner which favored subsequent tumor development . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL hamsters were treated with either radiation , dmba , radiation + dmba , 
0 NULL NULL NULL NULL NULL hamsters were treated with either radiation , dmba , radiation + dmba , or no treatment 
0 NULL hamsters were treated with either radiation , dmba , radiation + dmba , or no treatment . NULL NULL NULL 
19 radiation , dmba , radiation + dmba , or no treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL animals were sacrificed at 3-week intervals from 0 to 39 weeks after treatments 
0 sacrificed at 3-week intervals from 0 to 39 weeks after treatments began . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL pouch vascular volume and permeability changes were studied by fractional distributions of radiotracers and were analyzed 
0 variety of statistical methods which explored the vascular parameters , treatment types , elapsed time , presence of the carcinogen , 
0 the vascular parameters , treatment types , elapsed time , presence of the carcinogen , and histopathologic changes . NULL NULL 
0 elapsed time , presence of the carcinogen , and histopathologic changes . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL all treatments resulted in significant changes in vascular volume with time , 
0 NULL NULL NULL NULL NULL NULL NULL NULL all treatments resulted in significant changes in vascular volume with time , while 
0 NULL NULL NULL NULL NULL NULL all treatments resulted in significant changes in vascular volume with time , while only dmba 
16 NULL NULL NULL NULL NULL all treatments resulted in significant changes in vascular volume with time , while only dmba treatments 
0 changes in vascular volume with time , while only dmba treatments alone resulted in significant changes in vascular permeability with time 
0 vascular volume with time , while only dmba treatments alone resulted in significant changes in vascular permeability with time . NULL 
0 with time , while only dmba treatments alone resulted in significant changes in vascular permeability with time . NULL NULL NULL 
16 time , while only dmba treatments alone resulted in significant changes in vascular permeability with time . NULL NULL NULL NULL 
16 NULL prior to the appearances of frank neoplasms , volumetric changes in dmba only and radiation only groups were similar , 
0 of frank neoplasms , volumetric changes in dmba only and radiation only groups were similar , while volume changes in dmba 
16 only and radiation only groups were similar , while volume changes in dmba + radiation groups increased slowly to a peak 
0 groups were similar , while volume changes in dmba + radiation groups increased slowly to a peak later than in other 
17 similar , while volume changes in dmba + radiation groups increased slowly to a peak later than in other groups and 
0 to a peak later than in other groups and then declined steadily to levels similar to the radiation only group . 
0 later than in other groups and then declined steadily to levels similar to the radiation only group . NULL NULL NULL 
0 groups and then declined steadily to levels similar to the radiation only group . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL as in prior studies , there were significant vascular volume differences between dmba and dmba + radiation groups 
0 were significant vascular volume differences between dmba and dmba + radiation groups of tumor-bearing cheek pouches . NULL NULL NULL NULL 
0 dmba maxima were significantly higher than those of dmba + radiation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL radiation significantly affected dmba-associated vascular volume and permeability changes during carcinogenesis 
16 NULL NULL NULL NULL NULL NULL NULL NULL radiation significantly affected dmba-associated vascular volume and permeability changes during carcinogenesis . NULL 
16 NULL NULL NULL NULL NULL NULL NULL radiation significantly affected associated vascular volume and permeability changes during carcinogenesis . NULL NULL 
0 NULL NULL radiation significantly affected dmba-associated vascular volume and permeability changes during carcinogenesis . NULL NULL NULL NULL NULL NULL NULL 
0 radiation significantly affected dmba-associated vascular volume and permeability changes during carcinogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL several possible explanations for the relationship of these changes to the enhancement of dmba carcinogenesis include : radiation blocking 
17 possible explanations for the relationship of these changes to the enhancement of dmba carcinogenesis include : radiation blocking normal capillary proliferative 
0 the relationship of these changes to the enhancement of dmba carcinogenesis include : radiation blocking normal capillary proliferative and/or dilatory responses 
0 these changes to the enhancement of dmba carcinogenesis include : radiation blocking normal capillary proliferative and/or dilatory responses to inflammation secondary 
0 changes to the enhancement of dmba carcinogenesis include : radiation blocking normal capillary proliferative and/or dilatory responses to inflammation secondary to 
4 enhancement of dmba carcinogenesis include : radiation blocking normal capillary proliferative and/or dilatory responses to inflammation secondary to neoplastic changes ; 
0 capillary proliferative and/or dilatory responses to inflammation secondary to neoplastic changes ; radiation-induced focal increases in the pericapillary connective tissue histohematic 
0 and/or dilatory responses to inflammation secondary to neoplastic changes ; radiation focal increases in the pericapillary connective tissue histohematic barrier , 
0 and/or dilatory responses to inflammation secondary to neoplastic changes ; induced focal increases in the pericapillary connective tissue histohematic barrier , 
0 responses to inflammation secondary to neoplastic changes ; radiation-induced focal increases in the pericapillary connective tissue histohematic barrier , stimulating angiogenesis 
17 focal increases in the pericapillary connective tissue histohematic barrier , stimulating angiogenesis but reducing nutrient diffusion ; radiation exposures sensitizing vascular 
3 increases in the pericapillary connective tissue histohematic barrier , stimulating angiogenesis but reducing nutrient diffusion ; radiation exposures sensitizing vascular endothelium 
0 the pericapillary connective tissue histohematic barrier , stimulating angiogenesis but reducing nutrient diffusion ; radiation exposures sensitizing vascular endothelium to subsequent 
0 histohematic barrier , stimulating angiogenesis but reducing nutrient diffusion ; radiation exposures sensitizing vascular endothelium to subsequent angiogenic stimulation from premalignant 
3 nutrient diffusion ; radiation exposures sensitizing vascular endothelium to subsequent angiogenic stimulation from premalignant tissues ; dmba vascular and epithelial effects 
17 diffusion ; radiation exposures sensitizing vascular endothelium to subsequent angiogenic stimulation from premalignant tissues ; dmba vascular and epithelial effects partially 
0 angiogenic stimulation from premalignant tissues ; dmba vascular and epithelial effects partially or completely blocking radiation effects on epithelial and/or endothelial 
18 tissues ; dmba vascular and epithelial effects partially or completely blocking radiation effects on epithelial and/or endothelial cells ; and radiation 
0 ; dmba vascular and epithelial effects partially or completely blocking radiation effects on epithelial and/or endothelial cells ; and radiation damage 
16 dmba vascular and epithelial effects partially or completely blocking radiation effects on epithelial and/or endothelial cells ; and radiation damage to 
0 blocking radiation effects on epithelial and/or endothelial cells ; and radiation damage to vessel walls partially or fully inhibiting normal physiologic 
6 radiation effects on epithelial and/or endothelial cells ; and radiation damage to vessel walls partially or fully inhibiting normal physiologic mechanisms 
0 ; and radiation damage to vessel walls partially or fully inhibiting normal physiologic mechanisms of repairing dmba damage to the vessels 
6 partially or fully inhibiting normal physiologic mechanisms of repairing dmba damage to the vessels . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL scanning electron microscopy of vascular casts was used to investigate three experimental models of neovascularization . NULL NULL 
3 vascular casts was used to investigate three experimental models of neovascularization . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
2 casts provided a valuable three dimensional representation of the newly formed blood vessels and permitted subclassification of the vessels within normal 
4 vessels and permitted subclassification of the vessels within normal and proliferating vascular networks . NULL NULL NULL NULL NULL NULL NULL 
4 from venules and capillaries , and enabled the evolution of proliferating vessels into arterioles and venules to be documented . NULL 
17 NULL NULL NULL NULL NULL NULL NULL mast cell heparin stimulates migration of capillary endothelial cells in vitro . NULL NULL 
14 NULL NULL NULL NULL NULL NULL mast cell heparin stimulates migration of capillary endothelial cells in vitro . NULL NULL NULL 
14 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL migration of capillary endothelial cells is an important component of angiogenesis 
0 NULL NULL NULL migration of capillary endothelial cells is an important component of angiogenesis in vivo . NULL NULL NULL NULL 
3 migration of capillary endothelial cells is an important component of angiogenesis in vivo . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL increased numbers of mast cells have been associated with several types 
16 NULL NULL NULL increased numbers of mast cells have been associated with several types of angiogenesis . NULL NULL NULL NULL 
3 of mast cells have been associated with several types of angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL we have used a quantitative assay in vitro to demonstrate that mast cells 
0 a quantitative assay in vitro to demonstrate that mast cells release a factor that significantly increases bovine capillary endothelial cell migration 
17 to demonstrate that mast cells release a factor that significantly increases bovine capillary endothelial cell migration . NULL NULL NULL NULL 
14 release a factor that significantly increases bovine capillary endothelial cell migration . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL the factor is present in medium conditioned by mast cells as well as lysates 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL the stimulatory effect of mast cells on migration is specific for capillary 
17 NULL NULL NULL NULL NULL NULL NULL NULL the stimulatory effect of mast cells on migration is specific for capillary endothelial 
14 NULL NULL NULL the stimulatory effect of mast cells on migration is specific for capillary endothelial cells . NULL NULL NULL 
16 NULL NULL NULL furthermore , mast cells have no mitogenic activity for capillary endothelial cells . NULL NULL NULL NULL NULL 
17 the secretory products of mast cells tested , only heparin stimulated capillary endothelial cell migration in vitro . NULL NULL NULL 
14 mast cells tested , only heparin stimulated capillary endothelial cell migration in vitro . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL heparin preparations from a variety of sources stimulated capillary endothelial cell migration to the same degree but did 
14 preparations from a variety of sources stimulated capillary endothelial cell migration to the same degree but did not stimulate migration of 
17 endothelial cell migration to the same degree but did not stimulate migration of several other cell types . NULL NULL NULL 
14 cell migration to the same degree but did not stimulate migration of several other cell types . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the migration activity of heparin and mast cell conditioned medium was blocked 
0 NULL NULL NULL NULL NULL NULL NULL NULL the migration activity of heparin and mast cell conditioned medium was blocked by 
18 migration activity of heparin and mast cell conditioned medium was blocked by specific antagonists of heparin ( protamine and heparinase ) 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the migration activity of mast cell conditioned medium was resistant to heat 
0 NULL NULL NULL NULL NULL NULL NULL NULL the migration activity of mast cell conditioned medium was resistant to heat ( 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results suggest that the role of mast cells in angiogenesis may 
16 NULL NULL NULL NULL NULL these results suggest that the role of mast cells in angiogenesis may be to enhance migration 
3 these results suggest that the role of mast cells in angiogenesis may be to enhance migration of the endothelial cells of 
17 the role of mast cells in angiogenesis may be to enhance migration of the endothelial cells of growing capillaries . NULL 
14 role of mast cells in angiogenesis may be to enhance migration of the endothelial cells of growing capillaries . NULL NULL 
4 may be to enhance migration of the endothelial cells of growing capillaries . NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL heparin-steroid conjugates : new angiogenesis inhibitors with antitumor activity in mice . NULL NULL NULL 
18 NULL NULL heparin-steroid conjugates : new angiogenesis inhibitors with antitumor activity in mice . NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL inhibitors of angiogenesis hold potential in the treatment of cancer and other diseases 
0 NULL NULL NULL NULL NULL NULL inhibitors of angiogenesis hold potential in the treatment of cancer and other diseases where the 
19 NULL NULL NULL inhibitors of angiogenesis hold potential in the treatment of cancer and other diseases where the disease is caused 
0 treatment of cancer and other diseases where the disease is caused or maintained by the inappropriate growth of blood vessels . 
0 cancer and other diseases where the disease is caused or maintained by the inappropriate growth of blood vessels . NULL NULL 
4 where the disease is caused or maintained by the inappropriate growth of blood vessels . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL in the present study , a novel inhibitor of angiogenesis was synthesized by 
0 NULL NULL NULL in the present study , a novel inhibitor of angiogenesis was synthesized by covalently linking a nonanticoagulating derivative 
3 NULL in the present study , a novel inhibitor of angiogenesis was synthesized by covalently linking a nonanticoagulating derivative of heparin 
0 the present study , a novel inhibitor of angiogenesis was synthesized by covalently linking a nonanticoagulating derivative of heparin , heparin 
3 ( hah ) , by an acid-labile bond to the angiogenic steroid , cortisol . NULL NULL NULL NULL NULL NULL 
15 NULL the rationale was that the heparin derivative , which binds to sulfated polyanion receptors on endothelial cells , should concentrate 
0 linkage inside lysosomes and other acidic intracellular compartments should then lead to release of the cortisol and expression of its antiproliferative 
14 lysosomes and other acidic intracellular compartments should then lead to release of the cortisol and expression of its antiproliferative activity . 
0 compartments should then lead to release of the cortisol and expression of its antiproliferative activity . NULL NULL NULL NULL NULL 
0 to release of the cortisol and expression of its antiproliferative activity . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL analysis of the stability of hah-cortisol showed that it was stable at ph 7.4 and broke down 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL treatment of murine pulmonary capillary endothelial cells with hah-cortisol at 10 
0 ( -5 ) m ( with respect to cortisol ) suppressed their dna synthesis by 50 % and inhibited their migration 
0 m ( with respect to cortisol ) suppressed their dna synthesis by 50 % and inhibited their migration into wounded areas 
18 cortisol ) suppressed their dna synthesis by 50 % and inhibited their migration into wounded areas of confluent monolayers . NULL 
14 suppressed their dna synthesis by 50 % and inhibited their migration into wounded areas of confluent monolayers . NULL NULL NULL 
0 ) m ( with respect to cortisol ) did not suppress the dna synthesis of lewis lung carcinoma cells . NULL 
0 with respect to cortisol ) did not suppress the dna synthesis of lewis lung carcinoma cells . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL sponge implants retarded vascularization of the sponge , and injections directly into the sponge 
18 of the sponge , and injections directly into the sponge abolished vascularization for as long as the injections were continued . 
3 the sponge , and injections directly into the sponge abolished vascularization for as long as the injections were continued . NULL 
4 of hah-cortisol at doses causing no apparent toxicity retarded the growth of solid s.c . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL in all of these assays , equivalent treatments with a mixture of the hah plus cortisol was significantly 
0 a mixture of the hah plus cortisol was significantly less effective . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL the antiproliferative effect of hah-cortisol on endothelial cells appeared independent of the glucocorticoid 
0 NULL the antiproliferative effect of hah-cortisol on endothelial cells appeared independent of the glucocorticoid activity of the steroid since hah conjugated 
0 of hah-cortisol on endothelial cells appeared independent of the glucocorticoid activity of the steroid since hah conjugated to 5 beta-pregnane-3 alpha 
0 alpha , 21-triol-20-one , a steroid lacking glucocorticoid or mineralocorticoid activity , was even more effective at inhibiting dna synthesis by 
0 steroid lacking glucocorticoid or mineralocorticoid activity , was even more effective at inhibiting dna synthesis by murine pulmonary capillary endothelial cells 
0 glucocorticoid or mineralocorticoid activity , was even more effective at inhibiting dna synthesis by murine pulmonary capillary endothelial cells than was 
0 mineralocorticoid activity , was even more effective at inhibiting dna synthesis by murine pulmonary capillary endothelial cells than was hah-cortisol . 
3 , hah-cortisol represents the prototype of a new class of angiogenesis inhibitors for the treatment of cancer and other angiogenic diseases 
19 prototype of a new class of angiogenesis inhibitors for the treatment of cancer and other angiogenic diseases . NULL NULL NULL 
3 of angiogenesis inhibitors for the treatment of cancer and other angiogenic diseases . NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL NULL NULL [ treatment of the diabetic foot by hyperbaric oxygen ] NULL NULL 
0 at the cellular level , the result is hypoxia which impairs wound healing . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL it leads to enhanced oxygenation of the affected tissues , has an 
0 NULL NULL NULL NULL NULL NULL NULL it leads to enhanced oxygenation of the affected tissues , has an antiseptic effect 
16 NULL NULL NULL it leads to enhanced oxygenation of the affected tissues , has an antiseptic effect , reduces edema , 
0 enhanced oxygenation of the affected tissues , has an antiseptic effect , reduces edema , and accelerates collagen production and angiogenesis 
18 of the affected tissues , has an antiseptic effect , reduces edema , and accelerates collagen production and angiogenesis , thus 
9 an antiseptic effect , reduces edema , and accelerates collagen production and angiogenesis , thus enhancing tissue repair . NULL NULL 
3 effect , reduces edema , and accelerates collagen production and angiogenesis , thus enhancing tissue repair . NULL NULL NULL NULL 
17 edema , and accelerates collagen production and angiogenesis , thus enhancing tissue repair . NULL NULL NULL NULL NULL NULL NULL 
2 and accelerates collagen production and angiogenesis , thus enhancing tissue repair . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL 14 diabetics with chronic nonhealing wounds which did not respond to treatment for at least 3 months were treated by 
0 diabetics with chronic nonhealing wounds which did not respond to treatment for at least 3 months were treated by hbo . 
0 not respond to treatment for at least 3 months were treated by hbo . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL transcutaneous measurements of tissue po2 showed elevation from 20 +/- 10 mm hg during air breathing 
0 NULL NULL NULL NULL transcutaneous measurements of tissue po2 showed elevation from 20 +/- 10 mm hg during air breathing to 
0 NULL NULL NULL NULL NULL NULL NULL NULL they were treated with hbo in 56 +/- 10 consecutive hbo sessions . 
0 complete wound healing , while in 1 there was partial response , in 1 minimal response , and in 1 a 
0 in 1 there was partial response , in 1 minimal response , and in 1 a transient response . NULL NULL 
0 in 1 minimal response , and in 1 a transient response . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL it is a safe mode of therapy , but further studies are required to establish its efficacy 
0 a safe mode of therapy , but further studies are required to establish its efficacy and to ascertain which diabetic patients 
0 therapy , but further studies are required to establish its efficacy and to ascertain which diabetic patients and wounds will benefit 
0 NULL NULL the purpose of the immune system is to protect cells from invasion by microorganisms . NULL NULL NULL NULL 
0 purpose of the immune system is to protect cells from invasion by microorganisms . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL the body has three equally important interactive immune defense systems , all of which are profoundly 
0 NULL NULL the body has three equally important interactive immune defense systems , all of which are profoundly disrupted with major 
0 interactive immune defense systems , all of which are profoundly disrupted with major burn injury . NULL NULL NULL NULL NULL 
0 defense systems , all of which are profoundly disrupted with major burn injury . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL the immune response to burn injury is immediate , prolonged , and severe 
0 NULL the immune response to burn injury is immediate , prolonged , and severe . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL the end result in individuals surviving burn shock is immunosuppression , with increased susceptibility to potentially 
0 result in individuals surviving burn shock is immunosuppression , with increased susceptibility to potentially fatal systemic burn wound or pulmonary sepsis 
0 NULL NULL NULL NULL NULL NULL NULL nursing actions to support the humoral and cell-mediated immune system of the burned patient 
0 NULL NULL NULL nursing actions to support the humoral and mediated immune system of the burned patient include providing nutritional support 
0 cell-mediated immune system of the burned patient include providing nutritional support to maintain serum protein levels at optimal levels ; measures 
0 the burned patient include providing nutritional support to maintain serum protein levels at optimal levels ; measures to decrease edema and 
0 burned patient include providing nutritional support to maintain serum protein levels at optimal levels ; measures to decrease edema and promote 
0 providing nutritional support to maintain serum protein levels at optimal levels ; measures to decrease edema and promote angiogenesis in areas 
18 maintain serum protein levels at optimal levels ; measures to decrease edema and promote angiogenesis in areas of partial-thickness injury ; 
17 levels at optimal levels ; measures to decrease edema and promote angiogenesis in areas of partial-thickness injury ; meticulous treatment of 
3 at optimal levels ; measures to decrease edema and promote angiogenesis in areas of partial-thickness injury ; meticulous treatment of the 
0 and promote angiogenesis in areas of partial-thickness injury ; meticulous treatment of the wound to prevent infection and promote healing ; 
0 of partial-thickness injury ; meticulous treatment of the wound to prevent infection and promote healing ; monitoring of antibiotic use ; 
0 partial-thickness injury ; meticulous treatment of the wound to prevent infection and promote healing ; monitoring of antibiotic use ; conservative 
0 ; meticulous treatment of the wound to prevent infection and promote healing ; monitoring of antibiotic use ; conservative use of 
0 to prevent infection and promote healing ; monitoring of antibiotic use ; conservative use of invasive techniques , including intubation and 
0 and promote healing ; monitoring of antibiotic use ; conservative use of invasive techniques , including intubation and vascular access devices 
0 invasive techniques , including intubation and vascular access devices ; maintenance of fluid and electrolyte balance and body temperature ; and 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL autocrine angiogenic vascular prosthesis with bone marrow transplantation . NULL NULL NULL 
19 NULL NULL NULL autocrine angiogenic vascular prosthesis with bone marrow transplantation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL a vascular prosthesis needs angiogenesis for endothelialization of the luminal surface , as endothelial cells 
0 surface , as endothelial cells have natural and permanent antithrombogenic properties . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL to induce capillary growth into the graft , we developed a method 
4 NULL NULL NULL NULL NULL NULL NULL to induce capillary growth into the graft , we developed a method of transplanting 
0 NULL to induce capillary growth into the graft , we developed a method of transplanting bone marrow cells , which are 
0 marrow cells , which are primitive , strong enough to survive , and create blood cells , resulting in the inducement 
17 strong enough to survive , and create blood cells , resulting in the inducement of capillary growth . NULL NULL NULL 
4 create blood cells , resulting in the inducement of capillary growth . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL the grafts were implanted in the abdominal aortic position of 24 dogs autologously . 
5 NULL NULL NULL NULL NULL NULL NULL NULL marrow cells survived and continued exogenous hemopoiesis for up to six months and 
0 to six months and were immunohistochemically reactive to basic fibroblast growth factor ( bfgf ) . NULL NULL NULL NULL NULL 
0 the grafts older than three weeks had complete endothelialization and maintained their patency . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL twenty grafts without bone marrow were implanted as controls . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL twenty grafts without bone marrow were implanted as controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL endothelialization was present at anastomotic sites , but other areas were covered with 
0 NULL NULL NULL NULL NULL NULL four out of seven control grafts were patent with endothelial cell lining at six months 
0 NULL NULL NULL NULL bone marrow with its unique native properties produced autocrine angiogenicity in the graft . NULL NULL NULL 
0 NULL NULL NULL bone marrow with its unique native properties produced autocrine angiogenicity in the graft . NULL NULL NULL NULL 
3 NULL bone marrow with its unique native properties produced autocrine angiogenic in the graft . NULL NULL NULL NULL NULL NULL 
16 NULL NULL NULL NULL NULL NULL NULL NULL NULL the effects of radiation on neovascularization in a rat model . NULL 
0 NULL NULL NULL NULL NULL NULL NULL the effects of radiation on neovascularization in a rat model . NULL NULL NULL 
3 NULL NULL NULL NULL NULL the effects of radiation on neovascularization in a rat model . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL it is thought that radiation treatment inhibits neovascularization of recipient and/or graft tissues , and 
0 NULL NULL NULL NULL NULL it is thought that radiation treatment inhibits neovascularization of recipient and/or graft tissues , and this 
18 NULL NULL NULL NULL it is thought that radiation treatment inhibits neovascularization of recipient and/or graft tissues , and this may 
3 NULL NULL NULL it is thought that radiation treatment inhibits neovascularization of recipient and/or graft tissues , and this may account 
0 this may account in part for abnormalities in wound healing associated with radiation therapy . NULL NULL NULL NULL NULL NULL 
0 account in part for abnormalities in wound healing associated with radiation therapy . NULL NULL NULL NULL NULL NULL NULL NULL 
0 in part for abnormalities in wound healing associated with radiation therapy . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 have examined this hypothesis using a model that measures the neovascularization of an implanted foreign material . NULL NULL NULL NULL 
0 hypothesis using a model that measures the neovascularization of an implanted foreign material . NULL NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL expanded polytetrafluoroethylene ( ptfe ) sheets were implanted adjacent to both superficial epigastric vascular pedicles of 63 rats 
0 NULL NULL NULL zero to 10 daily fractions of electron-beam radiation ( 300 cgy each ) were delivered to the implant 
0 fractions of electron-beam radiation ( 300 cgy each ) were delivered to the implant in the right groin , while the 
0 implant in the left groin served as a nonirradiated internal control . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL unirradiated animals showed equal neovascularization of both implants . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL unirradiated animals showed equal neovascularization of both implants . NULL NULL NULL NULL NULL NULL 
19 NULL NULL NULL NULL NULL NULL NULL rats that were irradiated twice ( single fractions at 0 and 24 hours after 
0 twice ( single fractions at 0 and 24 hours after implantation ) did not show a significant decrease in the neovascularization 
0 and 24 hours after implantation ) did not show a significant decrease in the neovascularization of the irradiated implant compared with 
18 24 hours after implantation ) did not show a significant decrease in the neovascularization of the irradiated implant compared with the 
3 implantation ) did not show a significant decrease in the neovascularization of the irradiated implant compared with the contralateral control implant 
0 not show a significant decrease in the neovascularization of the irradiated implant compared with the contralateral control implant . NULL NULL 
0 the neovascularization of the irradiated implant compared with the contralateral control implant . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL in contrast , the implants that were irradiated three times ( single fractions at 0 , 24 , 
0 fractions at 0 , 24 , and 48 hours after implantation ) demonstrated significantly diminished ( greater than 25 percent , 
18 24 , and 48 hours after implantation ) demonstrated significantly diminished ( greater than 25 percent , p less than 0.05 
3 greater than 25 percent , p less than 0.05 ) neovascularization beyond day 7 , whereas implants irradiated only at 48 
0 than 0.05 ) neovascularization beyond day 7 , whereas implants irradiated only at 48 hours after implantation did not . NULL 
0 7 , whereas implants irradiated only at 48 hours after implantation did not . NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL interestingly , neovascularization of the implants irradiated with 10 fractions ( 3000 cgy 
0 NULL NULL NULL NULL interestingly , neovascularization of the implants irradiated with 10 fractions ( 3000 cgy ) was not significantly 
18 with 10 fractions ( 3000 cgy ) was not significantly decreased compared with irradiation with three fractions ( 900 cgy ) 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL irradiation delivered before implantation ( 900 cgy ) inhibited neovascularization significantly less 
0 NULL NULL NULL NULL NULL NULL NULL irradiation delivered before implantation ( 900 cgy ) inhibited neovascularization significantly less than the 
18 NULL NULL irradiation delivered before implantation ( 900 cgy ) inhibited neovascularization significantly less than the same dose administered after implantation 
3 NULL irradiation delivered before implantation ( 900 cgy ) inhibited neovascularization significantly less than the same dose administered after implantation . 
0 cgy ) inhibited neovascularization significantly less than the same dose administered after implantation . NULL NULL NULL NULL NULL NULL NULL 
0 inhibited neovascularization significantly less than the same dose administered after implantation . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the results of this study suggest that a subclinical cumulative dose of 
18 subclinical cumulative dose of 900 cgy is the threshold for impaired tissue revascularization provided that treatment is delivered immediately after implantation 
3 dose of 900 cgy is the threshold for impaired tissue revascularization provided that treatment is delivered immediately after implantation over a 
0 cgy is the threshold for impaired tissue revascularization provided that treatment is delivered immediately after implantation over a 48-hour interval . 
0 the threshold for impaired tissue revascularization provided that treatment is delivered immediately after implantation over a 48-hour interval . NULL NULL 
0 impaired tissue revascularization provided that treatment is delivered immediately after implantation over a 48-hour interval . NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL prognostic value of angiogenesis in operable non-small cell lung cancer . NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL tumour angiogenesis is an important factor for tumour growth and metastasis . 
0 NULL NULL NULL NULL NULL NULL tumour angiogenesis is an important factor for tumour growth and metastasis . NULL NULL NULL 
4 NULL NULL tumour angiogenesis is an important factor for tumour growth and metastasis . NULL NULL NULL NULL NULL NULL NULL 
14 tumour angiogenesis is an important factor for tumour growth and metastasis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 cancer are related to a poor disease outcome , the results were not conclusive and were not compared with other molecular 
0 NULL NULL NULL NULL NULL NULL NULL NULL in the present study , the vascular grade was assessed in 107 ( 
0 NULL NULL NULL NULL NULL NULL NULL there was a significant correlation between eye appraisal and chalkley counting ( p less 
0 vascular grade was not related to histology , grade , proliferation index ( ki67 ) , or egfr or p53 expression 
9 proliferation index ( ki67 ) , or egfr or p53 expression . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL tumours from younger patients had a higher grade of angiogenesis ( p = 0.05 ) . NULL NULL NULL NULL 
0 the other factors examined was statistically related to lymph node metastasis ( p less than 0.0001 ) . NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL a univariate analysis of survival showed that vascular grade was the most significant prognostic factor 
0 NULL NULL NULL NULL NULL a univariate analysis of survival showed that vascular grade was the most significant prognostic factor ( 
0 analysis of survival showed that vascular grade was the most significant prognostic factor ( p = 0.0004 ) , followed by 
0 , n-stage and vascular grade were not found to be independent prognostic factors , since they were strongly related to each 
0 NULL NULL excluding n-stage , vascular grade was the only independent prognostic factor ( p = 0.007 ) . NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL kaplan-meier survival curves showed a statistically significant worse prognosis for patients with 
0 NULL NULL NULL NULL NULL NULL NULL kaplan-meier survival curves showed a statistically significant worse prognosis for patients with high vascular 
0 NULL NULL NULL NULL kaplan-meier survival curves showed a statistically significant worse prognosis for patients with high vascular grade , but 
0 patients with high vascular grade , but no difference was observed between low and medium vascular grade . NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL these data suggest that angiogenesis in operable non-small cell lung cancer is a major prognostic 
0 that angiogenesis in operable non-small cell lung cancer is a major prognostic factor for survival and , among the parameters tested 
0 non-small cell lung cancer is a major prognostic factor for survival and , among the parameters tested , is the only 
14 tested , is the only factor related to cancer cell migration to lymph nodes . NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL the integration of vascular grading in clinical trials on adjuvant chemotherapy and/or radiotherapy could substantially contribute in 
0 NULL NULL NULL the integration of vascular grading in clinical trials on adjuvant chemotherapy and/or radiotherapy could substantially contribute in defining 
19 the integration of vascular grading in clinical trials on adjuvant chemotherapy and/or radiotherapy could substantially contribute in defining groups of operable 
19 of vascular grading in clinical trials on adjuvant chemotherapy and/or radiotherapy could substantially contribute in defining groups of operable patients who 
0 in clinical trials on adjuvant chemotherapy and/or radiotherapy could substantially contribute in defining groups of operable patients who might benefit from 
0 defining groups of operable patients who might benefit from cytotoxic treatment . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL integrin alphavbeta3 requirement for sustained activated protein kinase activity during angiogenesis . NULL NULL NULL NULL 
0 NULL NULL NULL NULL integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis . NULL NULL NULL NULL NULL 
0 NULL NULL integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis . NULL NULL NULL NULL NULL NULL NULL 
3 integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis depends on growth factors and vascular cell adhesion events . 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL angiogenesis depends on growth factors and vascular cell adhesion events . NULL 
0 NULL NULL NULL NULL NULL NULL NULL angiogenesis depends on growth factors and vascular cell adhesion events . NULL NULL NULL 
15 NULL NULL angiogenesis depends on growth factors and vascular cell adhesion events . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL integrins and growth factors are capable of activating the ras/map kinase pathway in 
17 NULL NULL NULL integrins and growth factors are capable of activating the ras/map kinase pathway in vitro , yet how these 
0 the ras/map kinase pathway in vitro , yet how these signals influence endothelial cells during angiogenesis is unknown . NULL NULL 
16 ras/map kinase pathway in vitro , yet how these signals influence endothelial cells during angiogenesis is unknown . NULL NULL NULL 
3 vitro , yet how these signals influence endothelial cells during angiogenesis is unknown . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL NULL NULL upon initiation of angiogenesis with basic fibroblast growth factor ( bfgf ) 
3 NULL NULL NULL NULL NULL NULL NULL upon initiation of angiogenesis with basic fibroblast growth factor ( bfgf ) on the 
0 NULL NULL NULL upon initiation of angiogenesis with basic fibroblast growth factor ( bfgf ) on the chick chorioallantoic membrane ( 
0 the chick chorioallantoic membrane ( cam ) , endothelial cell activated protein ( map ) kinase ( erk ) activity was 
0 chick chorioallantoic membrane ( cam ) , endothelial cell mitogen-activated protein ( map ) kinase ( erk ) activity was detected 
0 cell mitogen-activated protein ( map ) kinase ( erk ) activity was detected as early as 5 min yet was sustained 
0 protein ( map ) kinase ( erk ) activity was detected as early as 5 min yet was sustained for at 
0 NULL NULL NULL NULL NULL the initial wave of erk activity ( 5-120 min ) was refractory to integrin antagonists , 
0 ) was refractory to integrin antagonists , whereas the sustained activity ( 4-20 h ) depended on integrin alphavbeta3 , but 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of map kinase kinase ( mek ) during this sustained 
17 of map kinase kinase ( mek ) during this sustained dependent erk signal blocked the formation of new blood vessels while 
18 kinase ( mek ) during this sustained alphavbeta3-dependent erk signal blocked the formation of new blood vessels while not influencing preexisting 
2 mek ) during this sustained alphavbeta3-dependent erk signal blocked the formation of new blood vessels while not influencing preexisting blood vessels 
16 signal blocked the formation of new blood vessels while not influencing preexisting blood vessels on the cam . NULL NULL NULL 
18 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL inhibition of mek also blocked growth factor induced migration but not 
0 NULL NULL NULL NULL NULL NULL inhibition of mek also blocked growth factor induced migration but not adhesion of endothelial cells 
0 NULL NULL NULL NULL NULL inhibition of mek also blocked growth factor induced migration but not adhesion of endothelial cells in 
17 NULL NULL NULL inhibition of mek also blocked growth factor induced migration but not adhesion of endothelial cells in vitro . 
14 NULL NULL inhibition of mek also blocked growth factor induced migration but not adhesion of endothelial cells in vitro . NULL 
15 of mek also blocked growth factor induced migration but not adhesion of endothelial cells in vitro . NULL NULL NULL NULL 
3 NULL NULL NULL NULL NULL NULL NULL NULL therefore , angiogenesis depends on sustained erk activity regulated by the ligation state 
17 NULL NULL NULL NULL NULL NULL NULL therefore , angiogenesis depends on sustained erk activity regulated by the ligation state of 
0 NULL NULL NULL therefore , angiogenesis depends on sustained erk activity regulated by the ligation state of both a growth factor 
16 NULL NULL therefore , angiogenesis depends on sustained erk activity regulated by the ligation state of both a growth factor receptor 
0 , angiogenesis depends on sustained erk activity regulated by the ligation state of both a growth factor receptor and integrin alphavbeta3 
0 erk activity regulated by the ligation state of both a growth factor receptor and integrin alphavbeta3 . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL basic fibroblast growth factor : a missing link between collagen vii , increased 
17 growth factor : a missing link between collagen vii , increased collagenase , and squamous cell carcinoma in recessive dystrophic epidermolysis 
17 rdeb ) have deficiencies of collagen type vii and have elevated levels of fibroblast collagenase , and a greatly increased risk 
0 ) have deficiencies of collagen type vii and have elevated levels of fibroblast collagenase , and a greatly increased risk of 
0 have elevated levels of fibroblast collagenase , and a greatly increased risk of cutaneous squamous cell carcinoma . NULL NULL NULL 
17 NULL patients with other genetic blistering disorders do not have elevated collagenase or an increased risk of squamous cell carcinoma , 
0 genetic blistering disorders do not have elevated collagenase or an increased risk of squamous cell carcinoma , despite chronic wounding . 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the connection between collagen type vii deficiency , increased collagenase , and 
0 NULL NULL NULL NULL the connection between collagen type vii deficiency , increased collagenase , and squamous cell carcinoma is not 
17 NULL NULL the connection between collagen type vii deficiency , increased collagenase , and squamous cell carcinoma is not understood . 
0 ( ebs ; 30 patients ) , as well as unaffected family members of rdeb patients ( 33 patients ) , 
14 patients ( 33 patients ) , was tested for the presence of basic fibroblast growth factor ( bfgf ) using a 
0 ) , was tested for the presence of basic fibroblast growth factor ( bfgf ) using a sensitive radioimmunoassay . NULL 
0 of basic fibroblast growth factor ( bfgf ) using a sensitive radioimmunoassay . NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL results : fifty-one percent of patients with rdeb had elevated levels 
17 NULL results : fifty-one percent of patients with rdeb had elevated levels ( greater than 5000 pg/g ) of urinary bfgf 
0 results : fifty-one percent of patients with rdeb had elevated levels ( greater than 5000 pg/g ) of urinary bfgf . 
17 in contrast , none of the patients with jeb had elevated levels of bfgf . NULL NULL NULL NULL NULL NULL 
0 contrast , none of the patients with jeb had elevated levels of bfgf . NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL twenty-one percent of clinically unaffected family members had elevated levels of bfgf , and 13 
17 NULL NULL twenty-one percent of clinically unaffected family members had elevated levels of bfgf , and 13 % of patients with 
0 NULL twenty-one percent of clinically unaffected family members had elevated levels of bfgf , and 13 % of patients with ebs 
17 bfgf , and 13 % of patients with ebs had elevated levels of bfgf . NULL NULL NULL NULL NULL NULL 
0 , and 13 % of patients with ebs had elevated levels of bfgf . NULL NULL NULL NULL NULL NULL NULL 
17 NULL NULL NULL NULL NULL NULL NULL the frequency of elevated bfgf values among all groups was statistically significant ( p 
0 frequency of elevated bfgf values among all groups was statistically significant ( p = 0.002 ) , and the levels of 
0 statistically significant ( p = 0.002 ) , and the levels of bfgf in rdeb patients were significantly elevated compared with 
17 and the levels of bfgf in rdeb patients were significantly elevated compared with those of other groups ( p less than 
17 conclusions : we have found that patients with rdeb have elevated levels of bfgf , which may contribute to increased fibroblast 
0 : we have found that patients with rdeb have elevated levels of bfgf , which may contribute to increased fibroblast collagenase 
0 with rdeb have elevated levels of bfgf , which may contribute to increased fibroblast collagenase and the development of squamous cell 
17 have elevated levels of bfgf , which may contribute to increased fibroblast collagenase and the development of squamous cell carcinoma . 
2 , which may contribute to increased fibroblast collagenase and the development of squamous cell carcinoma . NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL these results suggest a novel treatment for rdeb , namely , angiogenesis 
0 NULL NULL NULL NULL NULL these results suggest a novel treatment for rdeb , namely , angiogenesis inhibitors , which may 
3 results suggest a novel treatment for rdeb , namely , angiogenesis inhibitors , which may antagonize the effects of bfgf in 
18 for rdeb , namely , angiogenesis inhibitors , which may antagonize the effects of bfgf in this disorder . NULL NULL 
18 , namely , angiogenesis inhibitors , which may antagonize the effects of bfgf in this disorder . NULL NULL NULL NULL 
0 NULL NULL NULL there are currently no other means of treatment for this disorder , which has a high morbidity and 
0 side , with the contralateral fat pad serving as a control . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 3 weeks , the endogenous blood supply of both the control and the experimental fat pads was isolated and ligated , 
0 of both the control and the experimental fat pads was isolated and ligated , and the composite fat/muscle flap was transferred 
0 , width , and weight ; perfused with fluorescein or lead oxide ; and examined histologically . NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL NULL significant differences were found between the control and experimental fat pads 
0 NULL NULL NULL NULL significant differences were found between the control and experimental fat pads with regard to weight and length 
0 flaps were found to be perfused fully with fluorescein and lead oxide ; control fat pads were found not to be 
0 to be perfused fully with fluorescein and lead oxide ; control fat pads were found not to be perfused . NULL 
0 NULL NULL NULL NULL NULL NULL NULL NULL NULL the lead oxide group revealed extensive growth of blood vessels from the 
4 NULL NULL NULL NULL the lead oxide group revealed extensive growth of blood vessels from the latissimus graft into the experimental 
0 NULL NULL NULL NULL no vessels were visualized in the controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 NULL NULL NULL NULL NULL finally , sections of the control and experimental flaps were analyzed histologically . NULL NULL NULL 
3 NULL a preponderance of viable fat , with evidence of neovascularization , was found in experimental flaps , compared with the 
0 flaps , compared with the necrotic fat that characterized the controls . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
0 of a fat flap is possible and may have extensive application in various areas of plastic surgery . NULL NULL NULL 
0 and may have extensive application in various areas of plastic surgery . NULL NULL NULL NULL NULL NULL NULL NULL NULL 
